Identification of Novel Modifiers of RAN Translation at FMR1 and C9ORF72 by Linsalata, Alexander
Identification of Novel Modifiers of RAN Translation at FMR1 and C9ORF72 
by 
Alexander Linsalata 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Cellular and Molecular Biology) 
in the University of Michigan 
2020 
Doctoral Committee: 
Associate Professor Peter K. Todd, Chair 
Associate Professor David Turner 
Professor Nils Walter 
Associate Professor Bing Ye 
Alexander Edward Linsalata 
linsalex@med.umich.edu 
ORCID iD: 0000-0001-9961-4181 
© Alexander Edward Linsalata 2020 
ii 
Acknowledgements 
I write these acknowledgements with the benefit of almost exactly one year spent 
in medical school and away from my doctoral research, as well as 2 weeks of all the 
simultaneous comforts and miseries of sheltering in place due to COVID-19. I like to 
think this has given me some added perspective on my experience in graduate school. 
First, to Peter Todd—thank you for your patience, your guidance, and your 
generosity. I am as stubborn as they come (about as stubborn as I am frequently 
wrong), and you still allowed me the freedom to conduct, design, and prioritize 
experiments as I thought best. Our weekly discussions nudged (occasionally dragged) 
me in the direction I needed to go. I would not be the scientist I am today without the 
tangible and intangible resources you have invested in my growth since my first nervous 
day in lab. I think of you as family. 
To the members of the Todd lab, past and present—you are an outrageously 
intelligent, talented bunch, and I still cannot believe I was fortunate enough to share in 
your creativity, insight, mettle, and community. There’s not one piece of data I’ve 
generated that does not have your collective fingerprints on it in some way. In particular, 
thank you to Caitlin Rodriguez, Katelyn Green, and Shannon Wright for your collective 
wisdom and understanding as we all moved through PhD life together; to Mike Kearse, 
my first mentor in Peter’s Lab, for your infinite patience and desire to teach; and to Yi-Ju 
(Lulu) Tseng for your endless enthusiasm, tireless labor, and readiness to tackle our 
genome-wide screens head-on. 
To the administration at the Cell and Molecular Biology Graduate Program and 
the Medical Scientist Training Program (MSTP)—thank you for smoothing out all the 
wrinkles that have popped up over the past 7 years. I’m very confident that if it were not 
for your dedication to the students here, I literally would have starved many winters ago. 
To my co-fellows of the MSTP—I feel like the luckiest idiot in the world to have
joined this program and met each of you. Graduate school can be an oddly atomizing 
iii 
experience, but we’ve stuck together and stuck through. I love you all like siblings, and I 
can’t wait to see the brilliant directions your lives will take. 
To the members of Funkytown Monkeypants, new and old, near and far—thank 
you for every single adventure. Thank you for every single pizza, taco, margarita, Ale 8, 
bourbon, belay, soft-catch, goat, jackfruit, debris fire, and near-death experience. Thank 
you for bringing me back to life when I needed it. It pains me to know that so many will 
soon leave Michigan, and that I have spent so much of this past year studying for 
medical school instead of in your company. Please know I’m already looking forward to 
a reunion. 
To my mother, Marilyn Linsalata—you’re the one who taught me by your own 
example how to think, how to be creative, how to be resourceful, and how to work hard. 
It’s from you that I learned how to be a scientist without even realizing it, even before I 
knew I wanted to be one. Every day that we talk, and every day we don’t, I become a bit 
more aware of how much everything I am and everything I have comes from you. Thank 
you for starting me on this path. 
To my father, Nicholas Linsalata—it still baffles me that I cannot express to you, 
right now, how much I am covered in your fingerprints. But you always knew. It’s from 
you I get my sense of humor, my sense of adventure, my patience (or, what little I 
have). You’re in everything I do, big or small. And though you could not be there at my 
defense, that feeling, that knowledge, is always with me. Thank you, Dad. 
 iv 
Table of Contents 
 
Acknowledgements...........................................................................................................ii 
List of Figures...................................................................................................................vi 
List of Tables....................................................................................................................ix 
List of Appendices.............................................................................................................x 
List of Abbreviations.........................................................................................................xi 
Abstract..........................................................................................................................xiii 
Chapter 1: Introduction...................................................................................................1 
Abstract..................................................................................................................1 
Translation Initiation, Classically............................................................................3 
 The Role of Secondary Structure in Translation Initiation.......................................8 
 RAN Translation: an Unexpected Finding at NREs.................................................9 
 FXTAS and RNA-Mediated Neurodegeneration...................................................11 
 FXTAS and RAN Translation................................................................................12 
 RAN Translation at G4C2/G2C4 Repeats in C9 ALS and FTD................................15 
 DPRs in Patients and Model Systems...................................................................16 
 The Mechanism of RAN Translation at G4C2/G2C4 Repeats.................................18 
 RAN translation and the Integrated Stress Response...........................................20 
 Hypotheses and Addressable Questions..............................................................21 






Materials and Methods.........................................................................................56 
Acknowledgements..............................................................................................69 
Chapter 3: A High-Throughput, Genome-Wide Screen Identifies Modifiers of





 Materials and Methods.......................................................................................114 
 Acknowledgements............................................................................................118 
 v 
Chapter 4: Conclusions and Future Directions.........................................................119 






List of Figures 
 
Figure 1.1: Canonical Scanning Model of Translation Initiation, Part I...............................4 
Figure 1.2: Canonical Scanning Model of Translation Initiation, Part II..............................7 
Figure 1.3: Production of RAN-Translated Proteins Across Different Sequence 
Contexts...............................................................................................................14 
Figure 2.1: A Candidate-Based Screen Identifies Modifiers of Repeat-Elicited 
Toxicity in Drosophila Melanogaster.....................................................................29 
Figure 2.2: Knockdown of Belle (Bel) Mitigates Repeat-Elicited Toxicity in 
Drosophila............................................................................................................31 
Figure 2.3: Knockdown of Bel Specifically Inhibits RAN Translation in 
Drosophila............................................................................................................33 
Figure 2.4: Knockdown of DDX3X Inhibits RAN Translation in Cultured Human 
Cells.....................................................................................................................35 
Figure 2.5: DDX3X Facilitates Expression of RAN Products at the Level of 
Translation...........................................................................................................38 
Figure 2.6: In Cultured Human Cells, Near-AUG Start Codons Are Sufficient but 
Not Necessary to Confer Dependency on DDX3X................................................41 
Figure 2.7: eIF4B and eIF4H Modulate NRE-Elicited Toxicity in Drosophila....................43 
Figure 2.8: In Cultured Human Cells, EIF4B and EIF4H Modulate Both RAN and 
Canonical Translation...........................................................................................45 
Figure 2.9: EIF1 and EIF5 Modulate RAN Translation by Determining AUG Start- 
Codon Specificity..................................................................................................47 
Figure 2.10: Knockdown of DDX3X Mitigates (CGG)100 Toxicity in Primary 
Rodent Neurons...................................................................................................49 
Figure 2.11: Knockdown of DDX3X Inhibits RAN Translation of Expanded G4C2  
Repeats in C9ORF72...........................................................................................51 
Figure 3.1: Design of High-Throughput siRNA Screens for Modifiers of C9ORF72 
and FMR1 RAN Translation..................................................................................74 
Figure 3.2: Schematic of the Algorithm by Which RAN-Specific Suppressors and 
Enhancers of GA70 NL-3xF Were Determined During the Primary Screen............75 
Figure 3.3: Serial Screens Identify RAN-Specific Modifiers of C9ORF72 and 
FMR1 RAN Translation........................................................................................77 
Figure 3.4: Identification of a Subset of Genes that Modifies Both C9ORF72 and 
FMR1 RAN Translation........................................................................................81 
Figure 3.5: Knockdown of HNRNPA2B1 Selectively Inhibits RAN Translation of
 vii 
G4C2-Expanded C9ORF72 and CGG-Expanded FMR1, Part 1............................89 
Figure 3.6: Knockdown of HNRNPA2B1 Selectively Inhibits RAN Translation of 
G4C2-Expanded C9ORF72 and CGG-Expanded FMR1, Part 2............................91 
Figure 3.7: Knockdown of HNRNPA2B1 Does Not Change the Subcellular 
Localization of +1 (CGG)100 NL-3xF RNA.............................................................93 
Figure 3.8: Modulation of HNRNPA2B1 and its Homologs Bidirectionally Modifies 
(CGG)90 Toxicity in Drosophila.............................................................................94 
Figure 3.9: Modulation of HNRNPA2B1 and Its Homologs Has Inconsistent 
Effects on FMRpolyG Expression in Drosophila, Part 1........................................95 
Figure 3.10: Modulation of HNRNPA2B1 and Its Homologs Has Inconsistent 
Effects on FMRpolyG Expression in Drosophila, Part 2........................................96 
Figure 3.11: Knockdown of HNRNPA2B1 in C9 iPSCs Does Not Affect GP 
Expression...........................................................................................................98 
Figure 3.12: PSMB5 Knockdown with Pooled and Individual siRNAs Have 
Differential Effects on Expression of C9ORF72 RAN Products, FMR1 RAN 
Products, and PSMB5..........................................................................................99 
Figure 3.13: Knockdown of PSMB5 Selectively Suppresses Expression of 
C9ORF72 and FMR1 RAN Products at Expanded Repeat Sizes........................101 
Figure 3.14: Inhibition of PSMB5 by Bortezomib Increases the Expression of 
FMRpolyG Reporters.........................................................................................103 
Figure A.1: Supplement to Figure 2.2............................................................................130 
Figure A.2: NL-3xF and FF Reporter Constructs Used in This Study.............................131 
Figure A.3: Supplement to Figure 2.4............................................................................132 
Figure A.4: Supplement to Figures 2.4 and 2.5. ............................................................133 
Figure A.5: Knockdown of DDX3X Does Not Inhibit Global Translation.........................135 
Figure A.6: Reporter Expression in In Vitro Translation Assays is Consistent 
Across Independently Prepared, Replicate Extracts...........................................136 
Figure A.7: Anti-DDX3X RIP Co-Precipitates +1 (CGG)100 NL-3xF RNA 
Independently of the NL-3xF Tag or NRE Size...................................................138 
Figure A.8: Sequence Maps of the +1 and +2 (CGG)100 NL-3xF Reporter 
Constructs, With and Without an AUG Inserted 5’ to the CGG NRE....................139 
Figure A.9: Supplement to Figures 2.7 and 2.8..............................................................140 
Figure A.10: Supplement to Figure 2.9..........................................................................142 
Figure A.11: Supplement to Figure 2.10........................................................................143 
Figure B.1: Primary Screen Identifies Candidate Suppressors and Enhancers 
of C9ORF72 RAN Translation............................................................................149 
Figure B.2: Serial Validation and Refinement of RAN-Specific C9ORF72 
Candidate Modifiers...........................................................................................150 
Figure B.3: The Failure of Some Candidate C9ORF72 Modifiers to Validate 
Was Driven by Inconsistencies in Effects on AUG-FF Expression, not 
 viii 
GA70 NL-3xF Expression....................................................................................152 
Figure B.4: The AUG Counter Screen Eliminates Several Hits That Modified Both 
C9ORF72 and FMR1 Reporters.........................................................................154 
Figure B.5: An Independent Primary Screen Identifies Candidate Suppressors 
and Enhancers of FMR1 RAN Translation..........................................................156 
Figure B.6: Serial Validation and Refinement of RAN-Specific FMR1 Candidate 
Modifiers............................................................................................................157 
Figure B.7: Gene Ontology (GO) Analysis of Validated, RAN-Specific 
Modifiers of C9ORF72........................................................................................159 
Figure B.8: GO Analysis of Validated, RAN-Specific Modifiers of FMR1........................161 
Figure B.9: The Relationship Between Multiple Modifiers of C9ORF72 RAN 













List of Tables 
 
Table 3.1: Validation of RAN-Translation Modifiers Using the ON-TARGETplus 
siRNA Library.......................................................................................................83 
Table 3.2: RNA Sequencing (RNA-Seq) Libraries Used to Construct the Off- 
Target Filter..........................................................................................................85 
Table 3.3: Off-Target Filtration of Candidate Modifiers by Modifier Class........................86 
Table A.1: Summary of the Candidate-Based Screen for Modifiers of (CGG)90- 
 Elicited Toxicity...................................................................................................144 
Table A.2: Fly Stocks Used in This Study and Their Sources.........................................146 
Table A.3: Primers Used in This Study for qRT-PCR.....................................................147 
Table B.1: Modulation of GA70 NL-3xF by Knockdown of eIFs, Part I.............................164 
Table B.2: Modulation of GA70 NL-3xF by Knockdown of eIFs, Part II............................166 
Table B.3: Modulation of GA70 NL-3xF by Components of the Proteasome, 
Part I...................................................................................................................167 
Table B.4: Modulation of GA70 NL-3xF by Components of the Proteasome, 
Part II..................................................................................................................168 
Table B.5: Modulation of +1 CGG100 NL-3xF by Knockdown of eIFs, Part I....................169 
Table B.6: Modulation of +1 CGG100 NL-3xF by Knockdown of eIFs, Part II...................171 
Table B.7: Modulation of +1 CGG100 NL-3xF by Components of the Proteasome..........172 
Table B.8: Comparison of the Number of Genes Beneath Expression Threshold 
Across RNA-Seq Libraries..................................................................................173 
Table B.9: Most Efficacious C9ORF72-Validated, RAN-Specific Suppressors..............174 
Table B.10: Most Efficacious C9ORF72-Validated, RAN-Specific Enhancers...............176 
Table B.11: Most Efficacious C9ORF72-Validated, RAN-Specific, FMR1- 
Validated Suppressors.......................................................................................177 
Table B.12: Most Efficacious C9ORF72-Validated, RAN-Specific, FMR1- 
Validated Enhancers..........................................................................................179 
Table B.13: Most Efficacious FMR1-Validated, RAN-Specific Suppressors..................180 
Table B.14: Primers Used in This Study........................................................................182 
Table B.15: Fly Lines Used in This Study and Their Sources.........................................183 
  
 x 
List of Appendices 
 
Appendix A: Supplement to Chapter 2......................................................................129 
Appendix B: Supplement to Chapter 3......................................................................148 
 
 xi 
List of Abbreviations 
 
3xF—  3x FLAG 
ALS—  amyotrophic lateral sclerosis 
AuC—  area under the curve 
Bel—  belle 
BDSC—  Bloomington Drosophila Stock Center 
CCDS—  consensus coding sequence 
CHX—  cycloheximide 
CNS—  central nervous system 
DMEM—  Dulbecco’s Modified Eagle Medium 
DPR—  dipeptide repeat 
eIF—  eukaryotic initiation factor 
FF—  firefly luciferase 
FMRpolyA—  FMR1 polyalanine RAN product 
FMRpolyG—  FMR1 polyglycine RAN product 
FTD—  frontotemporal dementia 
FXPOI—  Fragile X-associated premature ovarian insufficiency 
FXTAS—  Fragile X-associated tremor/ataxia syndrome 
GA—  glycine-alanine C9ORF72 RAN product 
GAP—  GTPase-activating protein 
GO—  gene ontology 
GP—  glycine-proline C9ORF72 RAN product 
GR—  glycine-arginine C9ORF72 RAN product 
HCR—  hybridization chain reaction 
ICC—  immunocytochemistry  
IHC—  immunohistochemistry
iPSC—  induced pluripotent stem cell 
IRES—  internal ribosome entry site 
ISR—  integrated stress response 
LCD—  low-complexity domain 
LNA—  locked nucleic acids 
m6A—  N6-methyladenosine 
m7G—  methyl-7-guanosine 
MBNL—  muscleblind 
NL—  nanoluciferase 
 xii 
NLS—  nuclear localization signal 
NPC—  nuclear pore complex 
NRE—  nucleotide-repeat expansion 
O/E—  overexpression  
ORF—  open reading frame 
P bodies—  processing bodies 
PA—  proline-alanine C9ORF72 RAN product 
PABP—  polyA-binding protein 
PIC—  pre-initiation complex 
PR—  proline-arginine C9ORF72 RAN product  
RAN—  repeat-associated, non-AUG 
RIP—   RNA immunoprecipitation 
RIPA—  radioimmunoprecipitation assay 
RNA-Seq—  RNA sequencing 
RNP—  ribonucleoprotein 
SCA—  spinocerebellar ataxia 
shRNA—  small hairpin RNA 
siNL—  anti-nanoluciferase siRNA 
siNT—  non-targeting siRNA 
siRNA—  small interfering RNA 
sgRNA—  single guide RNA 
TPM—  transcripts per million 
tRNAiMet—  methionine-conjugated initiator tRNA 
UAS—  upstream activating sequence 
uORF—  upstream open reading frame 






 Microsatellites are tracts of short (2-6 nucleotides) DNA units repeated in 
tandem. These occur throughout eukaryotic genomes and are prone to inter-
generational expansion and contraction. Microsatellite expansions, also known as 
nucleotide-repeat expansions (NREs), underlie a diverse set of clinical disorders, many 
of them neurodegenerative. Historically, researchers hypothesized that NREs could 
elicit toxicity through a variety of pathogenic mechanisms, including protein-mediated 
gain- and loss-of-function, RNA-mediated gain- and loss-of-function, induction of 
mitochondrial stress, and DNA damage. More recently, investigators recognized that 
transcribed NREs can trigger initiation of translation and protein synthesis in the 
absence of an AUG codon, violating a widely-held assumption of protein synthesis. This 
process, known as repeat-associated, non-AUG (RAN) translation, yields aberrant 
protein products that are detected in patient tissue. Expression of RAN products is 
sufficient and in certain contexts necessary for those NREs outside of annotated open-
reading frames (ORFs) to elicit toxicity in animal and cellular models. Despite its 
significance to multiple neurodegenerative disorders, the mechanism by which RAN 
translation occurs remains enigmatic. The goal of this thesis is to identify modulators of 
RAN translation at two different NREs—CGG repeats in FMR1, associated with Fragile 
X-associated tremor/ataxia syndrome (FXTAS), and G4C2 repeats in C9ORF72, 
associated with C9 amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 
(FTD)—as a means of defining the mechanics of RAN translation and identifying 
potential targets for therapeutic intervention. 
To identify proteins and pathways that regulate RAN translation, I conducted two 
screens. First, I performed a candidate-based screen of eukaryotic initiation factors 
(eIFs), RNA helicases, and known translational regulators in a Drosophila melanogaster 
model of FXTAS. This screen identified and subsequent experiments validated five
 xiv 
factors as modifiers of RAN translation: the RNA helicase belle (bel)/DDX3X, eIF4B, 
eIF4H, eIF1, and eIF5. Knockdown of bel/DDX3X suppressed the expression of FMR1- 
and C9ORF72-associated RAN products in flies, heterologous human cells, primary 
rodent neurons, and patient-derived induced pluripotent stem cells (iPSCs), while also 
mitigating FMR1 (CGG)n-elicited toxicity in flies and rodent neurons. Identification of 
these specific factors is suggestive of the roles that RNA secondary structure and start-
codon fidelity play in RAN translation. 
Second, I performed a high-throughput, genome-wide, small-interfering RNA 
(siRNA) screen in HEK293 cells that expressed a reporter for RAN translation of the 
G4C2 NRE in C9ORF72, with additional screening for modifiers of FMR1-based RAN 
translation in a subset of the genome. This identified 561 and 75 high-confidence, RAN 
translation-selective candidate modifiers of C9ORF72 and FMR1 RAN translation, 
respectively. In subsequent experiments depletion of two candidates, the RNA-binding 
protein hnRNPA2/B1 and the proteasomal subunit PSMB5, significantly and selectively 
suppressed the expression of multiple FMR1- and C9ORF72-associated RAN products 
tested in reporter assays. These studies provide insight into the shared factors and 
pathways required for RAN translation at two independent NREs, while providing a 
mechanistic framework for developing new therapeutic strategies for FXTAS, C9 






Nucleotide-repeat expansions (NREs) underlie a heterogeneous group of 
neurodegenerative and neuromuscular disorders for which there are currently no 
effective therapies. Recently, it was discovered that NREs in mRNA can support 
translation initiation in the absence of an AUG start codon across a wide variety of 
sequence contexts, and that the products of these atypical translation initiation events 
contribute to neuronal toxicity. The mechanism of this process, known as repeat-
associated, non-AUG (RAN) translation, remains unclear. RAN translation at two loci at 
least—CGG repeats in FMR1 [(associated with Fragile X-associated tremor/ataxia 
syndrome (FXTAS)] and G4C2 repeats in C9ORF72 [(associated with amyotrophic 
lateral sclerosis (ALS)/frontotemporal dementia (FTD)]—generates homopolymeric and 
dipeptide-repeat (DPR) proteins that elicit toxicity through a variety of mechanisms. 
Additional research into which protein factors [particularly eukaryotic initiation factors 
(eIFs) and other known regulators of translation] mediate or modulate RAN translation 
would prove advantageous, both in understanding this odd biological phenomenon and 
identifying potential targets for therapeutic intervention. 
 
1 Parts of this chapter were originally published as Green KM, Linsalata AE, Todd PK. RAN translation—What makes 
it run? Brain Research 1647, 30-42 (2016). 
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Nucleotide-repeat expansions (NREs) underlie a heterogeneous group of 
primarily neurological diseases that, in aggregate, impact a significant number of 
patients1,2. They elicit toxicity through a variety of mechanisms delineated over the past 
25 years. When located within protein-coding open reading frames (ORFs), NREs lead 
to cellular toxicity via the synthesis of homopolymeric (frequently polyglutamine) 
proteins3-6. Toxicity results from both disruption of the native functions of the proteins in 
which the repeats reside (loss-of-function), as well as perturbations in cellular 
proteostasis independent of protein context (gain-of-function). By contrast, NREs 
located outside of known protein-coding ORFs can elicit changes in the expression of 
the gene in which they reside, leading to reduced or enhanced expression at the 
transcript and protein level7. Non-coding NREs can also elicit toxicity as RNA by binding 
to and sequestering specific RNA-binding proteins via presentation of a repetitive 
sequence or structural motif8-10, or more novelly, forming phase-separated gels11. 
 The discovery of repeat-associated, non-AUG (RAN) translation blurred the line 
that defines which NREs elicit toxicity via protein gain-of-function/loss-of-function and 
which act through RNA-mediated gain-of-function12,13. This non-canonical process of 
translation initiation, which occurs in the absence of an AUG initiation codon and in 
multiple reading frames, enables elongation through NREs in mRNA, producing multiple 
homopolymeric or polypeptide repeat-containing proteins. Originally described in 
association with CAG NREs causative for spinocerebellar ataxia type 8 (SCA8), this 
process also occurs in association with expansions of CAG, CUG, G4C2, G2C4, CCUG, 
CAGG, UGGAA, CGG, and CCG14-26. The recognition of these initiation events has led 
to a flurry of activity within the scientific and medical communities, with a significant 
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body of work now demonstrating 1) the presence of RAN-translated peptides in patient 
and animal-model tissue across a wide spectrum of neurodegenerative disorders, and 
2) a link between these peptides and cellular toxicity. Despite this interest, the 
mechanism or mechanisms by which RAN translation initiates—and the ways in which it 
departs from general, AUG-initiated translation—remains unclear. 
 
Translation Initiation, Classically 
 
 Translation initiation is the step-wise assembly of elongation-competent 80S 
ribosomes at start codons of mRNA. It is a highly complex process, entailing the 
concerted activity of at least nine eukaryotic initiation factors (eIFs)27. In most cases, 
initiation begins with recognition of the 5’ methyl-7-guanosine (m7G) cap on mRNA by 
the eIF4F complex (Figure 1.1, Step 1)28-30. The eIF4F complex is composed of eIF4E 
(the direct cap-binding subunit), eIF4G (a scaffolding subunit), and eIF4A (a DEAD-box 
RNA helicase). eIF4G also recognizes the polyA-binding protein (PABP)31,32, which in 
turn binds to the 3’ polyA tail on mRNAs. This is thought to result in circularization of the 
mRNA and greater initiation efficiency33,34. 
 The eIF4F complex, still bound to the m7G cap, is joined by the 43S pre-initiation 
–––––––––––––––––––––––––––––––– 
Figure 1.1: Canonical Scanning Model of Translation Initiation, Part I. 
Step 1: The eIF4F complex, composed of eukaryotic initiation factors (eIFs) eIF4E, eIF4G, and 
eIF4A, binds to the 5’ methyl-7-guanosine (m7G) cap with eIF4B and eIF4H. PolyA-binding protein 
(PABP) associates with eIF4G to circularize the mRNA. 
Step 2: The eIF4F complex recruits the 43S pre-initiation complex (PIC), composed of the 40S 
ribosomal subunit, eIF1, eIF1A, eIF3, eIF5, and the ternary complex, itself consisting of the initiator 
methionine-tRNA (tRNAiMet), eIF2, and GTP. 
Step 3-4: The PIC and components of the eIF4F complex scan through the 5’ untranslated region 




complex (PIC), composed of the 40S ribosomal subunit, eIF1, eIF1A, eIF3, eIF5, and 
the ternary complex [in turn composed of methionine-conjugated tRNA (tRNAiMet) and 
eIF2-GTP; Figure 1.1, Step 2]. This joining of the 43S PIC to the eIF4F complex is 
mediated by an eIF4G-eIF3 interaction35. Successful translation of most eukaryotic 
mRNAs is thought to require the RNA helicase activity of eIF4A in order to resolve RNA- 
RNA secondary structures adjacent to the m7G cap and prepare a “landing pad” for the 
43S PIC36. 
According to the scanning model of translation initiation37,38, the 43S PIC and 
components of the eIF4F complex scan through the 5’ untranslated region (UTR) in the 
5’ to 3’ direction (Figure 1.1, Step 3). This stage is also known to require eIF4A in order 
to resolve weaker internal secondary structures39,40, though additional helicases such as 
DHX29 and DHX3341-43 assist in melting stronger structures. eIF4A is also joined by two 
co-stimulatory factors, eIF4B and eIF4H, both of which are required to achieve maximal 
eIF4A-mRNA binding, helicase catalytic efficiency, and translational efficiency44-46. 
A related RNA helicase, the DEAD-box protein DDX3X [Ded1 in yeast, belle (bel) 
in Drosophila melanogaster], has received particular attention for its function in 43S PIC 
scanning. DDX3X/Ded1 exhibits efficient, interdependent ATPase and RNA helicase 
activities in vitro47-51 and acts by binding to single-stranded RNA and destabilizing local 
RNA-RNA helices52-55. Like most DEAD-box helicases, DDX3X/Ded1 exhibits no 
specificity or preference for RNA sequences. In vivo, DDX3X/Ded1 directly interacts 
with eIF4E and PABP56,57, eIF4G58, and the 40S ribosomal subunit itself59. It has been 
shown to be a component of 43S PICs60,61 with functions distinct from and 
complementary to those of eIF4A and its cofactors46,50,62-64. On both individual-transcript 
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and translatome-wide levels, DDX3X/Ded1/bel has been demonstrated to be required 
for ribosomal scanning and translation initiation of transcripts bearing long, GC-rich (and 
putatively secondary-/tertiary-structured) 5’ UTRs46,59,61-68. DDX3X/Ded1 has also been 
identified as a component of stress granules and processing (P)-bodies—membrane-
less organelles with roles in mRNA triage, mRNA degradation, and translational 
suppression—and can, under certain circumstances, inhibit translation56,58,69-73. Thus, 
DDX3X/Ded1/bel is a multifunctional RNA helicase positioned at the nexus of multiple 
translational regulatory pathways, with demonstrated functions and binding partners 
consistent with roles in both facilitation and inhibition of mRNA translation. 
Having unwound any secondary structures, the 43S PIC scans until encountering 
an AUG codon in good Kozak context, (A/G)NNAUGG (Figure 1.1, Step 4)74,75. At this 
point, base-pairing between the AUG codon and CAU anti-codon loop on tRNAiMet 
results in the ejection of eIF1, a factor which, along with eIF1A, increases the stringency 
of AUG start-codon selection76-82. eIF2 hydrolyzes its bound GTP with the assistance of 
eIF5, its associated GTPase-activating protein (GAP; Figure 1.2, Step 5). Regulating 
the abundance and availability of eIF5 is one mechanism through which cells can “tune” 
start-codon fidelity in response to stimuli83-86. At this point, the 40S ribosome is 
committed to its selection of start codon, and forms a tighter interaction with the 
substrate mRNA, collectively known as the 48S PIC. In the final stages of initiation, the 
40S subunit is joined by the 60S ribosomal subunit (Figure 1.2, Step 6), the majority of 
remaining eIFs are ejected, eIF5B hydrolyzes its bound GTP (Figure 1.2, Step 7), and 





Figure 1.2: Canonical Scanning Model of Translation Initiation, Part II. 
Step 5: eIF1 dissociates from the PIC, and eIF2 hydrolyzes GTP with the assistance of eIF5. This 
commits the 40S ribosome to translation initiation at the present AUG codon. 
Step 6: eIF5B-GTP promotes the recruitment of the 60S subunit and displacement of most 
remaining eIFs. 
Step 7: eIF5B hydrolyzes its bound GTP and dissociates with eIF1A, establishing the elongation-
competent 80S ribosome. 
–––––––––––––––––––––––––––––––– 
The Role of Secondary Structure in Translation Initiation 
 
 Secondary and tertiary structures in 5’ UTRs impact translation initiation both 
positively and negatively, depending on the structure’s location. When placed upstream 
of an AUG start codon, they inhibit initiation, either by blocking the eIF4E-m7G 
interaction when located adjacent to the cap or by impeding 5’-to-3’ translocation of the 
43S PIC when located internally in the 5’ UTR75,88-91. In contrast, secondary structures 
downstream of start codons facilitate initiation at imperfect start codons (i.e., those with 
poor Kozak context and even non-AUG codons90,92). Initiation at non-AUG codons 
occurs at reduced efficiency relative to AUG codons in in vitro translation systems93,94, 
but the presence of secondary structures downstream markedly increases initiation 
efficiency90-92,95.  
Recent advances in ribosomal footprinting methodologies suggest that these in 
vitro findings may reflect a common but heretofore unrecognized set of initiation events 
in vivo. Ribosome profiling combines the traditional aspects of an RNase-protection 
assay with next-generation sequencing to identify the positions of initiating and 
elongating ribosomes on mRNAs on a transcriptome-wide scale96. This technique has 
generated evidence for thousands of unpredicted translation initiation events, many of 
which occur at non-AUG codons96-99. This is especially true for upstream open reading 
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frames (uORFs): short ORFs upstream of canonical, annotated ORFs in the same 
mRNA transcript. Many uORFs appear to play regulatory roles in translation that are 
dependent on metabolic conditions and cell-cycle stage100. These findings are also 
supported by a variety of studies utilizing mass spectroscopy to confirm the presence of 
uORF-encoded peptides in vitro and in vivo, many of which possess functional roles101-
107. Thus, initiation at non-AUG codons occurs in vivo, is regulated in part by mRNA-
specific cis factors, might be regulated in part by trans-acting eIFs as well, and appears 
to play important regulatory roles in protein synthesis. 
 
RAN Translation: an Unexpected Finding at NREs 
 
 Above, mRNA secondary structure encodes “instructions” for how a given 
transcript is to be translated. Laura Ranum and colleagues’ discovery of RAN 
translation introduced a novel mode of translation to this mechanistic multitude14. 
Expansions of protein-coding CAG repeats in ATXN8 cause the neurodegenerative 
disorder SCA8. Unexpectedly, Zu et al.14 demonstrated that mutation of the only AUG 
codon upstream of expanded (CAG)n does not abrogate protein synthesis. In fact, 
translation initiated in multiple reading frames, generating homopolymeric proteins with 
glutamine, serine, or alanine repeats depending on the reading frame. RAN translation 
products from all three reading frames accumulated in cells transfected with expanded 
(CAG)n reporters, occasionally even within the same transfected cell. Antisense ATXN8 
transcripts bearing expanded CUG repeats also supported RAN translation. Antibodies 
generated against the predicted polyalanine product of ATXN8 sense mRNA recognized 
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a protein in the cerebellums of SCA8 human patients and mouse models. Finally, a 
similar approach provided in vivo evidence of a polyglutamine RAN product from DMPK 
antisense RNAs bearing expanded CAG repeats, causative for myotonic dystrophy type 
I. 
In silico modeling predicts and in vitro analysis suggests that consecutive GC-
rich repeats form hairpin structures108-110 sufficiently stable to impede 43S PICs75,88-
91,111. In parallel, Zu et al.14 demonstrated that RAN translation of ATXN8 mRNAs is 
dependent on the GC content and length of these repeats—factors that directly 
correlate with the stability of secondary structure. These results support the hypothesis 
that secondary-structured elements within mRNA are critical for RAN translation to 
initiate. Kozak’s work90,92,95 could explain how: downstream secondary structures 
enhance initiation at upstream non-AUG codons. Specifically, the increase in non-AUG 
initiation is maximal when a hairpin falls 14 nucleotides downstream of the initiator 
codon. Based on the known size of ribosomes, this orientation would place the start 
codon within the P site of the 40S ribosome, opposite the anti-codon loop of tRNAiMet 92. 
These observations have led to our current working model of RAN translation, in which 
secondary structures formed by GC-rich NREs cause 43S PICs to stall, increasing 
initiation at optimally positioned non-AUG codons. The link between 43S PIC stalling 
and non-AUG initiation could be explained by several possible mechanisms: increased 
dwell time of the 40S subunit over an imperfect codon-anticodon match, congestion of 
mRNA-bound 43S PICs upstream of the NRE90,92,95, dissociation of key eIFs that help 
determine AUG start codon fidelity (e.g., eIF1112,113), or even alternative ribosomal 
conformations114,115. 
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Fragile X-Associated Tremor/Ataxia Syndrome and RNA-Mediated 
Neurodegeneration 
 
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset 
neurodegenerative disorder caused by a CGG NRE in the 5’ UTR of FMR1. In 
unaffected individuals, repeats number less than 45. Individuals with FXTAS carry 
between 55 and 200 repeats, known as the “premutation” range116-119. Premutation 
NREs result in enhanced transcription of FMR1 mRNA120-123. In contrast, expansion to 
>200 repeats triggers transcriptional silencing of the FMR1 locus, leading to loss of 
FMR1 mRNA and the Fragile X protein, FMRP. Transcriptional silencing manifests in 
Fragile X syndrome, a clinically distinct neurodevelopmental disorder characterized by 
intellectual disability and features of autism-spectrum disorder124,125. Approximately 40% 
of male premutation carriers develop FXTAS (approximately 1:3,000 of the total 
population), with increased penetrance at older ages and larger repeat sizes126-128. 
FXTAS is characterized clinically by action tremors, ataxia, parkinsonism, and cognitive 
decline, and pathologically by both neuronal and non-neuronal ubiquitinated inclusions 
throughout the cerebral cortex, brainstem, and cerebellum129. Premutation carrier 
women are also at increased risk of Fragile X-associated premature ovarian 
insufficiency (FXPOI)130,131. 
Before the discovery of RAN translation, the dominant hypothesis of FXTAS 
pathogenesis explained NRE-elicited toxicity by invoking an RNA gain-of-function 
mechanism132, in which expanded (CGG)n RNAs sequester essential RNA-binding 
proteins10. This model is not without supporting evidence. CGG-expanded FMR1 
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mRNAs are more abundant than non-expanded FMR1120-123. Expanded (CGG)n in 
heterologous mRNAs is sufficient to drive toxicity in Purkinje neurons133, which hints at 
an RNA-mediated gain-of-function mechanism. In addition, RNA pathology is 
observed—in at least one patient, (CGG)113 FMR1 mRNAs formed nuclear foci134, which 
can be recapitulated in cultured COS7 cells135. (CGG)n RNAs could perturb the 
functions of clinically relevant RNA-binding proteins, since ubiquitinated inclusions 
purified from FXTAS-patient frontal cortex were found to contain both muscleblind 
(MBNL)136—an RNA splicing regulator whose sequestration by expanded CUG repeats 
is a key event in myotonic dystrophy pathogenesis8,9—and hnRNPA2/B1—an RNA-
binding protein which binds to the FMR1 5’ UTR137-139 and mutations in which are 
associated with other neurodegenenrative disorders140. In addition, overexpression of 
hnRNPA2/B1 ameliorates (CGG)n-and NRE-elicited toxicity22,139,141, implying that its 
sequestration might have contributed to (CGG)n-elicited toxicity. Expanded (CGG)n 
RNAs also form complexes with the splicing factor Sam68, and Sam68 disruption 
recapitulates some of the splicing changes observed in FXTAS brains135. Expanded 
(CGG)n RNAs form complexes with DGCR8 and DROSHA142, disrupt miRNA 
maturation142, and elicit a change in the distrubution of mRNAs critical for 
proteostasis143. Finally, (CGG)n-elicted DNA damage and mitochondrial stress have also 
been considered as possible pathogenic contributers144. 
 
FXTAS and RAN Translation 
 
It was in this context that our lab demonstrated that the CGG-expanded FMR1 5’ 
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UTR supports RAN translation19. Initiation within the 5’ UTR occurs in at least two 
reading frames in the absence of an AUG start codon: the GGC (+1) frame yields a 
polyglycine product (FMRpolyG), and the GCG (+2) frame yields a polyalanine product 
(FMRpolyA; Figure 1.3A). FMRpolyG accumulates in ubiquitinated inclusions in patient 
tissue and cellular and animal disease models, is necessary to elicit toxicity in 
Drosophila and mouse models of disease145, induces proteasome perturbations in 
Drosophila and HeLa cells19,146,147, and might be responsible for laminopathy in 
transgenic mice and FXTAS patient induced pluripotent stem cell (iPSC)-derived 
neurons145. Antisense FMR1 transcripts bearing expanded (CCG)n repeats also 
undergo RAN translation in transfected cells and FXTAS patient tissue21. In an inducible 
mouse model of FXTAS that expresses the FMR1 5'UTR with 90 CGG repeats, turning 
off transgene expression reversed the formation of neuronal FMRpolyG-positive 
inclusions and repeat-elicited behavioral deficits148. Finally, FMRpolyG-positive 
inclusions are observed in ovarian stromal cells in FXTAS mouse models and a FXPOI 
patient, suggesting FMRpolyG expression could be linked to other Fragile X-related 
clinical phenotypes149. 
In experiments using transfectable reporters for FMRpolyG and FMRpolyA in 
cultured human cells, we detected synthesis of FMRpolyG constructs bearing 0-100 
CGG repeats, with expression strongly correlating with repeat number19,150. Using a 
combination of point mutagenesis and stop-codon insertion, we also identified the start 
codons used for FMRpolyG synthesis: an ACG and a GUG 5’ to the NRE. In contrast, 
synthesis of FMRpolyA reporters was more stringently repeat-dependent. Moreover, 
inserting a stop codon immediately 5’ to the NRE did not preclude FMRpolyA 
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Figure 1.3: Production of RAN-Translated Proteins Across Different Sequence Contexts.  
A When located in the 5′ UTR, as in FMR1, expanded GC-rich repeats trigger initiation of 
repeat-associated, non-AUG (RAN) translation upstream of the canonical AUG start codon, leading 
to the production of FMRpolyG (1) and FMRpolyA (2).  
B When located in an intron, as in C9ORF72, it is unclear what RNA species is the substrate 
for RAN translation: a spliced lariat, an aberrantly spliced transcript in which the intron is retained, or 
a 3′ truncated RNA resulting from stalled transcription. The translated RNA species yields GA, GR, 
and GP dipeptide repeat (DPR)-containing RAN-translation products. In both panels, generation of 
RAN products from antisense transcripts has been excluded for clarity. 
–––––––––––––––––––––––––––––––– 
expression, suggesting that RAN translation can initiate within the NRE in the GCG 
frame. These results raise the intriguing possibility that RAN translation of the same 
sequence can differ mechanistically in different reading frames. Additional experiments 
demonstrated that FMRpolyG and FMRpolyA synthesis is dependent on the initial 
eIF4E-m7G interaction and the helicase activity of eIF4A150, all of which suggest that the 
initial stages of RAN translation closely resemble canonical AUG-initiated translation. 




RAN Translation at G4C2/G2C4 Repeats in C9 Amyotrophic Lateral Sclerosis and 
Frontotemporal Dementia 
 
The C9ORF72 G4C2/G2C4 NRE was identified by two groups in 2011 as the most 
common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD)151,152. ALS is the most frequently occurring form of motor neuron 
disease, affecting approximately 2-4/100,000 individuals153, and is characterized by 
progressive paralysis typically leading to death within two to three years after onset. 
FTD is the second most common form of presenile dementia and affects approximately 
20/100,000 individuals between the ages of 45 and 65154. Although ALS and FTD each 
manifest with a unique set of symptoms and pathology, they are believed to constitute 
two ends of a single disease spectrum. Approximately 50% of ALS patients develop 
FTD-like cognitive and behavioral impairment155,156, while up to 50% of FTD patients 
develop motor dysfunction157. Additionally, TDP-43-positive inclusions are present 
within the neurons and glia of a majority of ALS patients, as well as in the most common 
familial variants of FTD158. 
The G4C2/G2C4 NRE, located within the first intron of transcript isoforms 1 and 3 
and the promoter region of isoform 2, is expanded from 2-25 repeats in healthy 
individuals to >1,000 repeats in C9-associated ALS/FTD patients151,152,159. Both sense 
and antisense strands of C9ORF72 are transcribed in mutation carriers, resulting in the 
production of G4C2/G2C4-repeat containing RNAs17,18,26. These expanded repeats are 
both predicted to form highly stable RNA secondary structures, with the sense RNA 
repeat generating G-quadruplexes and hairpins in vitro160-163 and the antisense RNA 
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repeat shown to assume A form-like double helices in vitro116. 
 
Dipeptide Repeat Proteins in Patients and Model Systems 
 
 In addition to TDP-43-positive inclusions within both neurons and glia158, 
neuronal TDP-43-negative inclusions that co-stain for ubiquitin and ubiquitin-binding 
proteins are found throughout the central nervous system (CNS) of C9 ALS/FTD 
patients164,165. Immunohistochemical (IHC) analysis by multiple laboratories indicates 
that RAN translation-derived proteins constitute these TDP43-negative inclusions15-18,26. 
A total of six different dipeptide repeat (DPR) proteins are generated from G4C2/G2C4 
transcripts (Figure 1.3B). Specifically, glycine-alanine (GA) and glycine-arginine (GR) 
DPRs are generated from the sense strand, proline-alanine (PA) and proline-arginine 
(PR) arise from the antisense strand, and two glycine-proline (GP)-containing proteins 
arise from RAN translation of both strands. 
DPRs form cytoplasmic and intranuclear inclusions throughout neurons in the 
CNS. The distribution of DPRs throughout the brain is highly variable, however, with the 
highest burden occurring in the hippocampus, cerebellum, neocortex, and 
thalamus15,166,167. Although limited by potential differences in antibody affinities, IHC 
studies also suggest that the different DPRs are not present in equal abundance. In 
several brain regions assessed with multiple independently-generated antibodies for 
each DPR, GA appears to be the most abundant, followed by GP and GR, while the 
DPRs derived exclusively from antisense transcripts (PA and PR) appear to be least 
abundant16,17,168. Expression of (G4C2)n reporters in in vitro expression systems, 
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transfected HEK293 cells, and transfected rodent neurons recapitulates this differential 
abundance169,170. 
 Although their distribution throughout the brain raises questions about their exact 
role in disease, it is clear from studies in vitro and in vivo that DPR expression in 
isolation can induce neurodegeneration. From yeast171, to Drosophila172-176, cultured 
cells18,167,177,178, and primary mammalian neurons167,175,179, DPR expression leads to cell 
death and/or reduced survival. In many of these studies, DPR expression was sufficient 
to trigger toxicity, as demonstrated by the use of alternative codons in place of a G4C2 
NRE that allow for DPR production in the absence of the potentially toxic repeat-
containing RNA species167,171,173,175-179. Furthermore, transgenic flies expressing G4C2 
repeats of various lengths with stop codons in all three reading frames formed RNA foci, 
but only flies containing pure repeats produced GR and GP DPRs and exhibited 
significant cell death173. 
 Of the myriad possible pathogenic effects of DPR expression, disruption of 
nuclear-cytoplasmic transport received the most attention initially. Multiple components 
of the nuclear pore complex (NPC), m7G cap-binding proteins, and factors that mediate 
and regulate nuclear import/export interact genetically with G4C2 repeats in Drosophila 
and yeast171,172,180. This interaction is mediated at least in part by the GA and PR RAN 
products171,180,181, though G4C2-containing RNAs might also contribute182. G4C2-
expressing flies in vivo and S2 cells in vitro, and GA50-expressing murine cortical 
neurons in vivo, exhibit nuclear envelope abnormalities172, mislocalization of key NPC 
components181,182, and defects in nuclear-cytoplasmic transport171,172,180,182, much of 
which is also observed in C9 ALS/FTD patient tissue and iPSC-derived neurons172,182. 
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The hypothesis that the G4C2 NRE drives toxicity by impairing nuclear-cytoplasmic 
transport is particularly intriguing because it conceptually links the NRE to the 
mislocalization of TDP43, a pathognomonic hallmark of ALS. 
 Further investigation has focused on the propensity of DPRs to phase-
separate183-187 and their inclusion in membraneless organelles11. Several ALS/FTD-
associated proteins, including FUS, TIA1, hnRNPA1, and hnRNPA2/B1, undergo liquid-
liquid phase separation, a process in which proteins containing low-complexity domains 
(LCDs), sometimes along with RNA188, form “droplets” in vitro and “granules” in vivo189-
193. Under normal, physiological conditions these membraneless organelles—nucleoli, 
nuclear speckles, Cajal bodies, P-bodies, stress granules, and others—are thought to 
play various roles in RNA metabolism. However, disease-associated mutations in LCD-
containing proteins frequently alter the dynamics of these structures, either accelerating 
their formation, inhibiting the diffusion of molecules within them, or preventing their 
disassembly189-193. In rapid succession, multiple groups demonstrated that arginine-rich 
DPRs (GR and PR) interact with LCD-containing proteins and alter the dynamics of 
liquid-liquid droplets in vitro and in vivo180,194-196, leading to toxicity and cell death by 
disrupting nucleoli, inhibiting synthesis of rRNA, impairing pre-mRNA splicing, and 
suppressing mRNA translation175,177,178,194,195,197. It is worth noting that (G4C2)n-
containing RNAs can also promote phase-separation of LCD-containing proteins198. 
Nevertheless, neutralizing the numerous possible toxic effects of DPRs must remain a 
high priority for any therapeutic intervention for C9 ALS/FTD. 
 
The Mechanism of RAN Translation at G4C2/G2C4 Repeats 
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 Despite compelling evidence that RAN translation and the so-generated DPRs 
are involved in pathogenesis, little is known about the mechanism by which expanded 
G4C2/G2C4 repeats trigger RAN translation. RAN translation at G4C2/G2C4 repeats is 
repeat length-dependent with more robust DPR production occurring with longer 
repeats17,18,163,169,170, consistent with observations at CAG and CGG repeats14,19,150. 
Interestingly, the apparent minimum repeat-length requirements for RAN translation, 
determined using heterologous in vitro G4C2 expression, in the sense reading frames 
correlate indirectly with respective DPR abundance in patient tissue168. While these 
differences in length requirements may reflect artifacts of detection based on antibody 
avidity, differences in DPR solubility, or differential rates of protein degradation, they 
could also indicate an inherent discrepancy in RAN translational efficiency across 
reading frames. For example, different RNA secondary structures might favor initiation 
in certain frames at shorter repeats, while an increase in structural variability or frame-
shifting at larger repeat sizes becomes more prominent170. 
Beyond these initial insights lie a series of unanswered questions regarding the 
mechanism of RAN translation at G4C2/G2C4 repeats. First, it remains unknown exactly 
what C9ORF72 RNA species actually undergo RAN translation in vivo. The G4C2 NRE 
is located within the first intron of C9ORF72. Therefore, in patients, RAN-translated 
G4C2 repeats could conceivably derive from a retained intron, a spliced intron lariat, or 
within aberrant disease-specific transcripts generated by transcriptional stalling (Figure 
1.3B). There is evidence for generation of such aberrant transcripts, at least in vitro161. 
The ratio of exon1a-intron1 (unspliced or abortive) RNA to exon1-exon2 (mature, 
spliced) RNA, however, is not altered in C9 ALS/FTD iPSC-derived neurons and patient 
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brain tissue relative to controls, arguing against significant production of truncated 
transcripts or increased intron retention174. However, a recent study suggests that intron 
retention occurs with some frequency in both control and C9 patient cells199, and this 
may only have pathological consequences when the expanded repeat is present. 
Therefore, the lack of increased retention does not rule out the possibility that such 
transcripts undergo RAN translation in C9 patients. 
In our and others’ hands, m7G-capped reporters bearing expanded G4C2 repeats 
in their 5’ leader sequences were translated more efficiently than A-capped reporters, 
indicating that the G4C2 NRE does not support internal ribosome entry and suggesting 
that spliced G4C2-containing lariats are not as efficiently translated169,170. In earlier 
Drosophila experiments, insertion of the NRE into an efficiently spliced intron 
dramatically reduced both RAN translation and NRE-elicited toxicity compared to 
repeats placed into a 5’ leader174. However, DPR synthesis from intronic G4C2 repeats 
was still sufficient to elicit toxicity when Drosophila are grown at elevated temperatures, 
indicating that an intronic context is able to support RAN translation under certain 
conditions. Whether the limited amount of DPRs observed was produced from a spliced 
or retained intronic repeat in this experiment is unclear. If a lariat is the RNA species 
translated, then some mechanism must exist for it to escape normal nuclear 
degradation mechanisms, translocate to the cytoplasm, and engage with translational 
machinery. 
 
RAN Translation and The Integrated Stress Response 
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Initiation at non-AUG codons is a defining feature of RAN translation. In 
canonical translation, start-codon fidelity is regulated by several eIFs—including eIF1, 
eIF1A, and eIF5—as well as multiple upstream pathways, each responsive to a 
particular insult to cellular homeostasis36,76-81,85,100,200,201. In brief, viral infection and 
oxidative, starvation, and proteostatic stress converge to simultaneously inhibit AUG-
initiated translation and promote non-AUG-initiated translation via the integrated stress 
response (ISR), culminating in phosphorylation of eIF2α and subsequent limited 
bioavailability of ternary complexes201. Such stressors also lead to a selective increase 
in RAN translation of CGG-expanded FMR1 and G4C2-expanded C9ORF72 reporters in 
a phospho-eIF2α-dependent manner169,202-204. These results indicate that RAN 
translation is subject to some of the same regulatory mechanisms as AUG-initiated 
translation, though the outcomes of that regulation can differ. 
 
Hypotheses and Addressable Questions 
 
RAN translation represents a new and provocative mechanism by which protein 
translation can occur in the setting of NREs to produce a novel set of toxic proteins. The 
novelty of RAN translation may well prove to be its greatest value, both in revealing 
interesting biology and in providing a particularly good target for therapy development. If 
RAN translation drives neurodegeneration, as current data supports, then factors 
that are selectively required for RAN translation, but not canonical transition, 
offer a major opportunity for therapeutic intervention. 
Nevertheless, it is important to recognize that RAN translation might be one sliver 
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of a greater scheme regulating protein synthesis205,206. Initiation in the absence of an 
AUG start codon is not as uncommon as once thought; data from ribosome profiling 
datasets suggest significant non- and near-AUG initiated translation throughout the 
transcriptome207. Thus, RAN translation may reflect physiological but non-canonical 
initiation processes that, in the setting of NREs, produce toxic proteins but also have 
valuable, adaptive, or necessary functions in other settings. Defining these normal 
functions and their roles in neuronal biology will be critical if RAN translation is to serve 
as a therapeutic target. 
Finally, are the mechanisms underlying RAN translation the same or different 
across repeat types, reading frames, and sequence contexts? Discrepancies do 
suggest that different mechanisms are in play. Thus far, data on FMR1- and C9ORF72-
based RAN translation are most consistent with the scanning model and use of a near-
AUG codon for initiation just 5’ to the repeat19,150,169,170, but this would seem unable to 
explain RAN initiation within an ORF, as apparently occurs in Huntington disease20. And 
though reporters bearing expanded G4C2 repeats are translated most efficiently in a 
m7G-dependent manner169,170, this does not preclude a mechanism in which spliced 
G4C2-containing lariats are translated202. In this fashion, RAN translation may be 
analogous to the diversity of viral internal ribosome entry site (IRES) elements, which 
display significant variance in both eIF requirements and sequence to achieve the same 
goal of bypassing cap-dependent ribosomal loading. Only after careful identification of 
the key factors required for RAN translation can this delineation be made across 
different NREs and disease contexts. 
I hypothesize that RAN translation is modulated by many of the same eIFs 
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that regulate canonical translation. To test this hypothesis, I have taken advantage of 
several models and techniques. A Drosophila model of FXTAS, which expresses an 
EGFP reporter 3’ to the human FMR1 5’ UTR bearing 90 CGG repeats, permits ready 
assessment of NRE-elicited phenotype, as well as quantification of FMRpolyG 
abundance in vivo. HeLa and HEK293 cells, in conjunction with transfectable reporters 
for canonical and FMR1-/C9ORF72-based RAN translation across repeat sizes and 
reading frames, enable rapid (high-throughput, even) quantification of RAN-product 
abundance as well as more thorough, mechanistic investigation of putative modulators 
of RAN translation. Automated longitudinal microscopy of primary rodent neurons 
expressing CGG-expanded FMR1 provides a sensitive measure of cellular toxicity in 
mammalian neurons. Finally, quantification of RAN-product abundance in C9 ALS/FTD 





DDX3X and Specific Initiation Factors Modulate FMR1 RAN Translation2 
 
Abstract 
A CGG trinucleotide repeat expansion in the 5’ UTR of FMR1 causes the 
neurodegenerative disorder Fragile X-associated tremor/ataxia syndrome (FXTAS). 
This repeat supports a non-canonical mode of protein synthesis known as repeat-
associated, non-AUG (RAN) translation. The mechanism underlying RAN translation at 
CGG repeats remains unclear. To identify modifiers of RAN translation and potential 
therapeutic targets, we performed a candidate-based screen of eukaryotic initiation 
factors and RNA helicases using both a Drosophila melanogaster model of FXTAS and 
cell-based assays. We identified multiple modifiers of expanded (CGG)n-elicited toxicity 
and FMR1 RAN translation. These include the DEAD-box RNA helicase belle/DDX3X, 
the helicase accessory factors EIF4B/4H, and the start-codon selectivity factors EIF1 
and EIF5. Disrupting belle/DDX3X selectively inhibited FMR1 RAN translation in 
Drosophila in vivo and cultured human cells, and mitigated repeat-induced toxicity in 
Drosophila and primary rodent neurons. These findings implicate RNA secondary 
structure and start-codon fidelity as critical elements regulating FMR1 RAN translation 




2 The majority of this chapter has been published as: Linsalata, AE, He F, Malik AM, Glineburg MR, Green KM, Natla 
S, Flores BN, Krans A, Archbold HC, Fedak SJ, Barmada SJ, Todd PK. DDX3X and Specific Initiation Factors Modulate 




 Over thirty different NREs cause neurodegeneration in humans1. NREs within 
consensus coding sequences (CCDS) cause disease predominantly via protein-based 
gain-of-function mechanisms that depend on the intrinsic toxicity of homopolymeric 
peptides or dysfunction of the proteins in which they reside3-6. Alternatively, NREs can 
elicit toxicity via mRNA-based mechanisms where expanded repeats sequester 
essential RNA-binding proteins, leading to transcriptome dysregulation (e.g., myotonic 
dystrophy I and II) and gelation of RNA-protein complexes into RNA containing foci8-11. 
More recently, NREs were found to support translational initiation in the absence of an 
AUG start codon through a process known as RAN translation14. Proteins generated 
through RAN translation accumulate in patient tissues14,15,17-19 and are toxic in animal 
and cellular models of disease14,19,145,149,173. Since its discovery, RAN translation has 
been implicated in several NRE-associated neurodegenerative disorders25, including 
FXTAS, C9 ALS/FTD, and Huntington’s disease20. 
FXTAS is an adult-onset neurodegenerative disorder caused by a CGG NRE in 
the 5’ UTR of FMR1 from approximately 30 repeats to 55-200 repeats208. The NRE is 
transcribed into mRNA, which can bind to and sequester specific RNA-binding proteins 
135-139,142. In addition, expanded CGG repeats are translated via RAN translation into 
toxic proteins, which accumulate in ubiquitinated aggregates in tissue of both FXTAS 
patients and animal models of FXTAS19,145,149. Synthesis of RAN products is necessary 
for CGG repeats to elicit toxicity in overexpression systems, including Drosophila 
melanogaster, cultured human cells, and transgenic mice19,145,209. FXTAS shares its 
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causative locus with the neurodevelopmental disorder Fragile X syndrome, but it is 
clinically and mechanistically distinct: Fragile X syndrome results from larger (>200) 
CGG NREs that transcriptionally silence the Fragile X locus, resulting in loss of FMR1 
mRNA, no expression of expanded CGG repeats as RNA, and absence of FMRP210. 
The mechanism of RAN translation, and how it differs from that of canonical 
translation, remains unclear. Early reports demonstrated that, at least under some 
circumstances, RAN translation’s initial stages resemble canonical translation150,169,170: 
the 43S PIC—composed of the 40S ribosomal subunit, tRNAiMet, and a number of 
essential eIFs—binds to the 5’ m7G cap on mRNA and scans through the 5’ UTR27. In 
canonical translation, the 43S PIC scans until it encounters an AUG start codon, which 
triggers a cascade of structural rearrangements that ends with binding of the 60S 
ribosomal subunit and initiation of translation. In RAN translation, initiation occurs at 
non-AUG codons, either upstream of or within the NRE14,150,169,170,203. At CGG repeats 
and possibly G4C2 repeats, this failure of codon fidelity is thought to result from 
impairment of 43S PIC scanning by stable RNA secondary structures formed by the 
expanded repeats, since such structures facilitate initiation at non-AUG sites75,95,111,211. 
At other repeats and cellular contexts, RAN translation may utilize cap-independent 
initiation mechanisms and/or initiator tRNAs other than tRNAiMet 14,202,212. Which 
mechanisms occur in the context of each human disease is unclear and could vary 
based on gene context, repeat content, and cell type25,213,214. 
 Discerning how RAN translation initiates, and how that process diverges from 
canonical translation, might reveal new therapeutic strategies for FXTAS, C9 ALS/FTD, 
and other NRE-associated disorders. Two features distinguish RAN translation from 
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canonical translation: the presence of highly stable RNA secondary structures 
composed of NREs109,110,160 and the use of non-AUG start codons. 43S PIC scanning is 
known to require several RNA helicases in order to resolve mRNA structure within 5’ 
UTRs, including Ded1/bel/DDX3X46,50,58,64,66-68, eIF4A and its cofactors eIF4B and 
eIF4H40,44-46, and DHX2941,215. In addition, start codon fidelity in yeast is regulated by a 
series of eIFs—including eIF1, eIF1A, eIF2, and eIF5—and upstream signaling 
pathways36,76,78-81,200,201. 
With these features in mind, we conducted a candidate-based screen of eIFs, 
RNA helicases, and other RNA-binding proteins to identify regulators of RAN 
translation, using both cell-based assays and a Drosophila melanogaster model of 
FXTAS216. In FXTAS, RAN translation from the sense strand of FMR1 yields at least 
two RAN products from the CGG repeat: a polyglycine peptide (FMRpolyG), reflecting 
initiation in the GGC (+1, relative to the reading frame of the downstream CCDS 
product, FMRP) frame, and a polyalanine peptide (FMRpolyA), reflecting initiation in the 
GCG (+2) frame19,150. Antisense FMR1 transcripts also support RAN translation, 
yielding three distinct RAN products21. In Drosophila, we previously demonstrated that 
CGG repeat-elicited toxicity is largely dependent on RAN translation19,147. Our screen 
identified multiple factors that, when disrupted, suppressed CGG NRE-elicited toxicity in 
Drosophila and were necessary for FMR1 RAN translation. Disruption of one in 
particular, the DEAD-box RNA helicase DDX3X (bel in Drosophila), selectively inhibited 
FMR1 RAN translation in human cell-based systems and suppressed repeat-induced 
neurodegeneration in rodent neurons. Our findings implicate RNA secondary structure 






A Screen for Modifiers of CGG-Repeat Toxicity in Drosophila Melanogaster 
 To identify regulators of FMR1 RAN translation, we conducted a candidate-based 
screen using a Drosophila melanogaster model of FXTAS (Figure 2.1)216. This model 
carries an EGFP transgene 3’ to an upstream activation sequence (UAS) and the 5’ 
UTR of human FMR1 with 90 CGG repeats, with EGFP in the GGC (+1, FMRpolyG) 
reading frame [(CGG)90-EGFP)]. Expression in the eye via a GMR-GAL4 driver 
manifests in a significant rough-eye phenotype observable at eclosion, with ubiquitin-
positive aggregates of the RAN product FMRpolyG-EGFP accumulating in retinal 
neurons19. For the screen, females expressing (CGG)90-EGFP under a GMR-GAL4 
driver were crossed to males carrying germline mutations in, UAS-driven transgenes of, 
and UAS-driven small hairpin RNA (shRNA) constructs targeting 10 canonical eIFs, 4 
RNA helicases, a ribosomal protein associated with non-canonical translation 
initiation217,218, and an RNA-binding protein implicated in ALS/FTD219 (Table A.1). We 
selected these candidates in a hypothesis-driven fashion based on their known 
functions in non-canonical translation initiation and regulation of start-codon fidelity, as 
well their potential to modulate GC-rich secondary structures in RNA. By design, this 
candidate list was non-exhaustive. Because previous work has demonstrated the 
importance of eIF4E-m7G binding and 43S PIC scanning to RAN translation150,169,170 




















Figure 2.1: A Candidate-Based Screen Identifies Modifiers of Repeat-Elicited Toxicity in 
Drosophila Melanogaster. 
Candidate modifiers are categorized here based on their known functions in gene expression. Fly 
genes are listed in the left columns, while their human homologs are listed in the right columns. 
Disruption of genes highlighted in dark blue strongly suppressed (CGG)90-EGFP toxicity. Disruption 
of genes highlighted in light blue weakly suppressed (CGG)90-EGFP toxicity. Disruption of genes 
highlighted in light red enhanced (CGG)90-EGFP toxicity selectively. Disruption of genes highlighted 
in dark red enhanced the toxicity of both (CGG)90-EGFP and GMR-GAL4 (these were toxic 
independent of the repeat.) All other genes are displayed in white. The m7G cap, CGG nucleotide-
repeat expansion (NRE), eIF4F complex, 43S PIC, and ribosomal subunits are indicated. 
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evaluate them in this screen. 
We examined the rough-eye phenotype of F1 flies at eclosion to identify 
suppressors and enhancers of (CGG)90-driven toxicity. Of the 57 candidate lines tested, 
21 acted as suppressors of toxicity, and 17 as enhancers. All lines were subsequently 
crossed to flies carrying GMR-GAL4 alone to control for toxic effects independent of 
(CGG)90-based toxicity (Table A.1). Six of the 17 toxicity-enhancing lines had no effect 
in the absence of (CGG)90-EGFP, suggesting that this enhancement is specific to the 
presence of expanded CGG repeats. We selected 3 suppressors for further analysis—
bel/DDX3X, eIF4B, and eIF4H1—based on their individual functions in translation 
initiation. 
 
Bel/DDX3X Selectively Modulates FMR1 RAN Translation in Drosophila 
 In our candidate-based Drosophila screen, bel disruption by multiple genetic 
means suppressed CGG100-elicited toxicity. Four shRNAs against bel and five 
heterozygous loss-of-function bel mutants significantly suppressed the rough-eye 
phenotype in (CGG)90-EGFP-coexpressing flies (Figure 2.2A, B; Figure A.1A, B). Bel 
mutants tested included nonsense mutations and P[lacW] and P[PZ] element 
insertions220-223. The bel shRNA lines generally suppressed (CGG)90-EGFP toxicity 
more effectively than the heterozygous, loss-of-function bel mutants, potentially 
because the shRNAs had stronger effects on the abundance of functional bel protein. 
None of the bel shRNAs had phenotypic effects in flies expressing an AUG-initiated 
EGFP transgene under a GMR-GAL4 driver (Figure A.1C, D). Modulation of (CGG)90-






















Figure 2.2: Knockdown of Belle (Bel) Mitigates Repeat-Elicited Toxicity in Drosophila. 
A Representative photographs of fly eyes expressing (CGG)90-EGFP under a GMR-GAL4 
driver along with various bel disruptions. 
B Quantitation of GMR-GAL4, (CGG)90-EGFP eye phenotypes with bel disruptions (Mann-
Whitney U test with Bonferonni corrections for multiple comparisons; n=35-77/genotype).  
C, D Longevity assays of (CGG)90-EGFP; Tub5-GS (C; Log-rank Mantel-Cox test with Bonferroni 
corrections for multiple comparisons; n=110-219/genotype) and (CGG)90-EGFP; ElaV-GS (D; n=147-
299/genotype) flies with bel knockdown. 
 
Data Information: For all panels, ns=non-significant, ** P≤0.01, **** P≤0.0001 for the specified 
statistical test. All data in all panels are presented as mean ± SD (compiled from ≥3 replicates).  
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of adult flies expressing (CGG)90-EGFP ubiquitously post-eclosion under an inducible 
Tub5 Geneswitch driver224 (Figure 2.2C). Similarly, four bel shRNAs increased lifespan 
when (CGG)90-EGFP was expressed pan-neuronally in adult flies under an inducible 
Geneswitch ElaV driver (Figure 2.2D). 
 Bel and its homologs in yeast (Ded1) and humans (DDX3X) are important for 
translation of specific mRNAs, particularly those with long or structured 5’ 
UTRs46,50,58,59,64,66-68. Given the role that secondary structure is hypothesized to play in 
the initiation of RAN translation, we asked whether knockdown of bel suppressed the 
(CGG)90-EGFP phenotype by suppressing RAN translation. Knockdown of bel by two 
independent shRNAs reduced the expression of the RAN product FMRpolyG-EGFP in 
(CGG)90-expressing flies (Figure 2.3A, B), supporting the hypothesis that suppression of 
(CGG)90 toxicity is driven by inhibition of RAN translation. In contrast, bel knockdown 
had no effect on the abundance of (CGG)90-EGFP transcripts (Figure 2.3C). Finally, 
knockdown of bel had no effect on expression of an AUG-initiated EGFP reporter 
lacking the FMR1 5’ UTR (Figure 2.3D, E), suggesting that the decrease in FMRpolyG-
EGFP we observed reflects a selective effect on RAN translation rather than a global 
decline in translation. 
 
Bel/DDX3X Selectively Modulates FMR1 RAN Translation in Human Cells 
 We next asked whether DDX3X, the human homolog of bel, might play a similar 
role in facilitating RAN translation of CGG repeats in human cells. We previously 
generated transfectable luciferase-based reporters consisting of a 3xFLAG-tagged 




Figure 2.3: Knockdown of Bel Specifically Inhibits RAN Translation in Drosophila. 
A Western blots of the FMRpolyG-EGFP RAN product from (CGG)90-EGFP; Tub5-GS fly tissue 
with and without bel knockdown by two independent small hairpin RNAs (shRNAs). 
B Quantitation of FMRpolyG-EGFP band density, normalized to β tubulin band density, from 
blots in A (Student’s t test; n=4-5/genotype). 
C Abundance by qRT-PCR of (CGG)90-EGFP mRNA normalized to RPL32 mRNA from 
(CGG)90-EGFP; Tub5-GS fly tissue, following bel knockdown (n=8/genotype). 
D Western blot of AUG-driven EGFP from EGFP; Tub5-GS fly tissue with and without bel 
knockdown. 
E Quantitation of EGFP band density, normalized to β tubulin band density, from blot in D 
(n=4/genotype).  
 
Data Information: For all panels, * P≤0.05, ** P≤0.01 for the specified statistical test. All data in all 
panels are presented as mean + SD (compiled from ≥3 replicates).  
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sizes (0-100 repeats) and with the NL-3xF in both the GGC (+1, FMRpolyG) and GCG 
(+2, FMRpolyA) reading frames (Figure A.2)150. These reporters enable quantitative and 
qualitative detection of RAN-product expression by luminescence assays and western 
blotting, respectively. Knockdown of DDX3X by five independent small interfering RNAs 
(siRNAs) reduced the expression of plasmid-based +1 (CGG)100 NL-3xF reporters in a 
dose-dependent manner (Figure 2.4A; Figure A.3). As in our Drosophila experiments, 
these siRNAs had minimal effect on the expression of an AUG-initiated NL-3xF reporter 
(AUG-NL-3xF). To further test whether DDX3X knockdown inhibits protein synthesis 
across mRNAs, we tested the effects of two DDX3X siRNAs on NL-3xF reporters 
bearing the short, minimally-structured 5’ UTRs of β actin (ACTB) and β globin (HBB). 
siDDX3X #1 had no effect on Actin-NL-3xF and increased the expression of Globin-NL-
3xF but decreased the expression of +1 (CGG)100 NL-3xF (Figure A.4A). Though 
siDDX3X #2 decreased both Actin- and Globin-NL-3xF, it did so significantly less than it 
inhibited +1 (CGG)100 NL-3xF. Finally, to assess the effects of DDX3X knockdown on 
global protein synthesis of endogenous mRNAs, we performed polysome fractionation 
on HeLa cells transfected with siDDX3X or siEGFP (Figure A.5A, B). Consistent with 
our NL-3xF reporter data, knockdown of DDX3X (Figure A.5C) did not result in a 
reproducible shift in the relative monosome and polysome fractions. This indicates that 
DDX3X knockdown does not lead to global inhibition of mRNA translation, again 
highlighting the role of DDX3X in the expression of select genes. This finding is 
consistent with previous work demonstrating that the expression of only a specific 
subset of mRNAs—those with long and/or secondary-structured 5’ UTRs—are reduced 




We next asked whether DDX3X regulates RAN translation of FMR1 transcripts in 
other reading frames. Expression of the +2 (CGG)100 NL-3xF RAN product 
(FMRpolyA100), which likely derives from initiation within the NRE150, was reduced to a 
similar degree as the FMRpolyG100 product in luminescence assays (Figure 2.4B, C; 
Figure A.4B, C). We also observed these effects following detection of the FMRpolyGn 
and FMRpolyAn RAN products by western blotting (Figure 2.4D). These data indicate 
that the function of DDX3X in promoting RAN translation is not limited to a single 
reading frame. 
 DDX3X and its homologs in yeast and Drosophila function in several aspects of 
RNA metabolism. We therefore asked whether DDX3X functions in RAN translation 
directly or whether its effects might instead be mediated by modulating RNA stability or 
transcription. Knockdown of DDX3X reduced expression of +1 and +2 (CGG)100 NL-3xF, 
regardless of whether the reporters were transfected as plasmids or in-vitro transcribed  
–––––––––––––––––––––––––––––––– 
Figure 2.4: Knockdown of DDX3X Inhibits RAN Translation in Cultured Human Cells. 
A Dose-response curves plotting the effects of two independent anti-DDX3X small interfering 
RNAs (siRNAs) on the expression of AUG-NL-3xF (top) and (CGG)100 +1 NL-3xF (bottom) reporters. 
Plasmid-based reporters were transfected into HeLa cells 24 hours after knockdown, and reporter 
expression was quantified by luminescence. Nanoluciferase-3xFLAG (NL-3xF) luminescence has 
been normalized to luminescence from firefly luciferase (FF), which was co-transfected, in order to 
control for transfection variability. Asterisks refer to comparisons between anti-DDX3X siRNAs and 
siRNAs against EGFP (siEGFP; two-way ANOVA with Dunnett’s multiple comparisons test; 
n=12/condition). 
B, C (CGG)n +1 and (CGG)n +2 NL-3xF expression (normalized to FF) with and without DDX3X 
knockdown across a range of CGG repeat sizes. Black asterisks refer to comparisons between 
siDDX3X- and siEGFP-treated cells; orange asterisks refer to comparisons between siDDX3X-
treated cells expressing AUG-NL-3xF and those expressing a different reporter (two-way ANOVA 
with Tukey’s multiple comparisons test; n=17-30/condition). 
D Western blots of FMRpolyG-NL-3xF and FMRpolyA-NL-3xF products with and without 
DDX3X knockdown across a range of repeat sizes. 
 
Data Information: For all panels, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 for the specified 
statistical test. All panels depict data as means ± SD (compiled from ≥3 replicates).  
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RNAs (Figure 2.5A; Figure A.4D, E), suggesting that DDX3X acts post-transcriptionally. 
We next asked whether DDX3X knockdown impacted the abundance of reporter 
mRNAs following plasmid transfection. We observed that the mRNA abundance of both 
AUG-NL-3xF and (CGG)100-NL-3xF in the +1 and +2 frames was not consistently 
affected after transfection with siDDX3X #1 and #2 (Figure 2.5B). In order to isolate 
translational effects per se from other, concurrent effects on gene expression, we 
conducted in vitro translation assays using transcribed reporter RNAs and cytoplasmic 
extracts generated from cells depleted of DDX3X by two independent siRNAs. DDX3X-
depleted extracts yielded reduced translation of +1 (CGG)100 NL-3xF, while having 
either no effect on or increasing the synthesis of an AUG-NL-3xF reporter (Figure 2.5C). 
This effect was consistent across independently prepared in vitro translation extracts 
replicates (4 extracts per siRNA, two anti-DDX3X siRNAs; Figure A.6A, B). These in 
vitro experiments point specifically to a direct translational function of DDX3X, while 
leaving open the possibility that changes in mRNA stability and abundance may further 
impact the expression of RAN products. 
 We next asked how DDX3X regulates FMR1 RAN translation. To determine 
whether DDX3X can directly interact with CGG reporter mRNAs, we performed photo-
crosslinking RNA immunoprecipitation (RIP) assays to probe for an interaction between 
DDX3X and our FMR1 (CGG)100 reporters in cultured cells. As we anticipated, 
significantly more HSPA1A mRNA (translation of which requires DDX3X68) was co-
purified using antibodies against DDX3X than using isotype control IgG (Figure 2.5D). 
Similarly, significantly more +1 (CGG)100 NL-3xF mRNA was co-purified using 























Figure 2.5: DDX3X Facilitates Expression of RAN Products at the Level of Translation. 
A Expression of in vitro transcribed AUG-, +1 (CGG)100-, and +2 (CGG)100-NL-3xF RNAs 
following DDX3X knockdown in HeLa cells, expressed as NL luminescence normalized to FF 
luminescence (Student’s t test with Bonferroni corrections for multiple comparisons; n=21/condition). 
B Abundance of reporter mRNAs following DDX3X knockdown and plasmid-reporter 
transfection, determined by qRT-PCR (n=7/condition). This panel depicts data as means + SEM. 
C Expression of AUG-NL-3xF and +1 (CGG)100 NL-3xF in in vitro translation extracts, collected 
from HeLa cells treated with siRNAs against EGFP or DDX3X (two-way ANOVA with Tukey’s 
multiple comparisons test; n=4/condition). Experiments with independent, replicate lysates are 
presented in Figure A.6A, B. 
D Enrichment of HSPA1A, +1 (CGG)100 NL-3xF, and MALAT RNA following anti-DDX3X RNA 
immunoprecipitation (RIP), relative to incubation with isotype control IgG (Student’s t test, n=3). Data 
from the additional replicate is presented in Figure A.7A. 
 
Data Information: For all panels, ns=non-significant, **** P≤0.0001 for the specified statistical test. All 
panels depict data as means + SD, unless indicated otherwise (compiled from ≥3 replicates). 
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2.5D; Figure A.7A). +1 (CGG)100 NL-3xF mRNA was also enriched by DDX3X RIP in 
comparison to endogenous MALAT RNA, indicating a transcript-selective interaction 
between DDX3X and +1 (CGG)100 NL-3xF mRNA. To determine whether that interaction 
is an artifact of the NL-3xF tag on +1 (CGG)100 NL-3xF mRNA, we repeated the 
experiment using a 3’-truncated “tagless” construct in which the NL-3xF tag had been 
deleted (leaving the FMR1 5’ UTR and minimal vector sequence intact). In two 
independent replicates, tagless (CGG)100 mRNA also co-precipitated with DDX3X, near 
or above the levels of HSPA1A mRNA as a positive control (Figure A.7B). Finally, to 
determine whether that interaction depends on the expanded CGG repeats in the 
tagless (CGG)100 construct, we repeated this experiment using a modified tagless 
construct bearing 0 CGG repeats [tagless (CGG)0]. (CGG)0 mRNAs co-precipitated with 
DDX3X at levels comparable to (CGG)100 and HSPA1A mRNA, indicating that 
expanded CGG repeats are unnecessary for this interaction. This is not surprising, 
however, as the 5’UTR of FMR1 is highly GC-rich (76%) even excluding the CGG NRE, 
and previously published work has demonstrated that DDX3X’s yeast homolog Ded1 
preferentially binds 5’ to secondary structures within 5’ UTRs59. 
To determine which features of the FMR1 5’UTR enable DDX3X to modulate 
RAN translation, we first varied the size of the CGG NRE in our reporters. Using 
plasmid-based reporters, we observed no significant effect of CGG repeat size on the 
impact of DDX3X knockdown in either the GGC (+1) frame or the GCG (+2) frame 
(Figure 2.4B-D; Figure A.4B, C). All exhibited decreased expression as measured by 
luminescence assays and western blotting. We observed similar results when we 
transfected reporters as in vitro-transcribed RNA (Figure A.4D, E). These results 
 40 
indicate that expanded CGG repeats are unnecessary for DDX3X to modulate RAN 
translation initiating within the FMR1 5’ UTR. 
One of the unique features of RAN translation is its use of non-AUG codons for 
initiation. We therefore asked whether DDX3X facilitated RAN translation by regulating 
start-codon selection. We first tested the effect of DDX3X knockdown on a modified +1 
(CGG)100 reporter, in which the major near-AUG codon (ACG) utilized for GGC (+1)-
frame RAN translation had been removed and replaced with a nearby AUG (Figure 
A.8)150. This change enhanced basal expression of the construct, but DDX3X 
knockdown still impaired AUG-(CGG)100 (+1) NL-3xF expression (Figure 2.6A). 
Similarly, insertion of an AUG codon in a strong Kozak context 5’ to the NRE in the 
GCG (+2) frame enhanced basal expression, but expression of this AUG-(CGG)100 (+2) 
NL-3xF reporter remained DDX3X-dependent. In a complementary experiment, we 
evaluated whether DDX3X knockdown affected translation of NL-3xF reporters that 
initiate with the near-cognate codons CUG, GUG, UUG, or ACG absent any NRE or 
FMR1 sequence. As expected, expression of CUG-, GUG-, UUG-, and ACG-NL-3xF 
reporter plasmids was lower than expression of AUG-NL-3xF95,169. When these 
plasmids were transfected into cells along with siRNAs, DDX3X knockdown reduced 
their expression compared to AUG-NL-3xF but significantly less than +1 (CGG)100 NL-
3xF (Figure 2.6B). In contrast, expression of in vitro-transcribed near-AUG-initiated NL-
3xF reporters were unaffected by DDX3X depletion in in vitro translation assays (Figure 
2.6C; Figure A.6C). In total, our results indicate that altered start-codon fidelity is 




























Figure 2.6: In Cultured Human Cells, Near-AUG Start Codons Are Sufficient but Not 
Necessary to Confer Dependency on DDX3X. 
A Expression of +1 and +2 (CGG)100 NL-3xF plasmid reporters with and without an AUG 
inserted 5’ to the CGG repeat, with and without DDX3X knockdown. Black asterisks refer to 
comparisons between siDDX3X- and siEGFP-treated cells; orange asterisks refer to comparisons 
between siDDX3X-treated cells expressing either +1 or +2 (CGG)100 NL-3xF and those expressing 
the respective AUG-driven variant (two-way ANOVA with Tukey’s multiple comparisons test; n=11-
12/condition). 
B Expression of NL-3xF plasmids with initiator AUG codons mutated to near-AUG codons, with 
and without DDX3X knockdown (two-way ANOVA with Dunnett’s multiple comparisons test; n=18-
24/condition). Black asterisks refer to comparisons between siEGFP-treated and siDDX3X-treated 
cells; orange asterisks refer to comparisons between siDDX3X-treated cells expressing AUG-NL-
3xF and those expressing a different reporter; white asterisks refer to comparisons between 
siDDX3X-treated cells expressing +1 (CGG)100 NL-3xF and those expressing a different reporter. 
C Expression of in vitro transcribed near-AUG reporter RNAs in in vitro translation extracts, 
collected from HeLa cells treated with siRNAs against EGFP or DDX3X (n=4/group). Results from 
independent, replicate lysates are presented in Figure A.6C. 
 
Data Information: For all panels, ns=non-significant, *** P≤0.001, **** P≤0.0001 for the specified 
statistical test. All panels depict data as means + SD, unless indicated otherwise (compiled from ≥3 
replicates). 
–––––––––––––––––––––––––––––––– 
eIF4B and eIF4H Modulate RAN Translation at CGG Repeats  
 eIF4B and eIF4H are co-stimulatory factors for the RNA helicase eIF4A, and like 
bel/DDX3X, they are required for translation of mRNAs with long or structured 5’ 
UTRs40,44-46. Previous work demonstrated that eIF4A is specifically required for RAN 
translation at both CGG repeats and at G4C2 repeats associated with ALS/FTD150,169,170. 
We were therefore interested to see whether these co-stimulatory factors might play a 
similar, specific function in RAN translation like DDX3X. In our initial Drosophila screen, 
three shRNAs against eIF4H1, one shRNA against eIF4H2, and one shRNA against 
eIF4B suppressed the rough-eye phenotype induced by (CGG)90-EGFP (Figure 2.7A, B;  
Figure A.9A, B). In addition, eIF4B overexpression exacerbated this phenotype, while 
having no effect in the absence of (CGG)90-EGFP (Figure A.9C, D). As with bel 






























Figure 2.7: eIF4B and eIF4H Modulate NRE-Elicited Toxicity in Drosophila. 
A Representative photographs of GMR-GAL4, (CGG)90-EGFP fly eyes expressing genetic 
disruptions of eIF4B and eIF4H1.  
B Quantitation of GMR-GAL4, (CGG)90-EGFP eye phenotypes with eIF4B and H1 disruptions 
(Mann-Whitney U test with Bonferroni corrections for multiple comparisons; n=26-55/genotype). 
 
Data Information: **** P≤0.0001 for the specified statistical test. All panels present data as means ± 
SD (compiled from ≥3 replicates). 
–––––––––––––––––––––––––––––––– 
overexpression decreased the lifespan of flies expressing (CGG)90-EGFP under an 
inducible Tub5 driver (Figure A.9E). These experiments suggest that, like bel/DDX3X, 
eIF4B and eIF4H are capable of modulating RAN translation. 
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In contrast to bel/DDX3X, the impact of modulating eIF4B or eIF4H expression 
was not specific to RAN translation. In cultured HeLa cells, knockdown of either EIF4B 
or EIF4H (Figure A.9F) similarly decreased expression of +1 CGG100 NL-3xF and a co-
transfected AUG-driven firefly luciferase (AUG-FF) reporter (Figure 2.8A, B), suggesting 
that we cannot separate the role of eIF4B/H in RAN translation from their functions in 
translation generally. In support of this interpretation, overexpression of EIF4B alone, 
EIF4H alone, or EIF4B and EIF4H together, significantly increased the expression of 
AUG-NL-3xF (Figure 2.8C). These data suggest that eIF4B and eIF4H both regulate 
RAN translation but do so in a manner that is not specific to transcripts that are RAN 
translated. 
 
eIF1 and eIF5 Modulate RAN Translation in Human Cells Via Start-Codon Selectivity 
 By definition, RAN translation follows a failure in start-codon fidelity. Therefore, 
we predict that eIFs that enhance start-codon fidelity suppress RAN translation, while 
eIFs that reduce start-codon fidelity enhance RAN translation. We and others have 
pursued this concept in the context of the integrated stress response169,170,202: cellular 
stressors trigger phosphorylation of eIF2α, which suppresses global protein translation 
by reducing ternary complex (eIF2α-GTP-tRNAiMet) recycling and availability. Cellular 
stressors and mutations in multiple eIF2 subunits have both been shown to enhance 
initiation at non-AUG codons in yeast and mammalian cells225,226. Consistent with this, 
we and others observed that exogenous stressors or eIF2α phosphorylation selectively 
enhance RAN translation at both CGG repeats and G4C2 repeats associated with 





























Figure 2.8: In Cultured Human Cells, EIF4B and EIF4H Modulate Both RAN and Canonical 
Translation. 
A, B Expression of plasmid-based AUG-NL-3xF and +1 (CGG)100 NL-3xF reporters (A) or the co-
transfected AUG-FF reporters (B) following knockdown of EIF4B or EIF4H. Black asterisks refer to 
comparisons between siEGFP- and siEIF4B/H-treated cells; pink and blue asterisks refer to 
comparisons between siEIF4B- (pink) or siEIF4H- (blue) treated cells expressing AUG-NL-3xF and 
those expressing +1 (CGG)100 NL-3xF (two-way ANOVA with Tukey’s multiple comparisons test, 
n=9/condition). 
C Expression of plasmid-based AUG-NL-3xF and (CGG)100 +1 NL-3xF reporters with and 
without overexpression of EIF4B, EIF4H, or both (two-way ANOVA with Dunnett’s multiple 
comparisons test; n=20/condition). Asterisks refer to comparisons between cells expressing the 
same reporter and either EGFP, EIF4B, EIF4H, or EIF4B and EIF4H. 
 
Data Information: For all panels, ns=non-significant, * P≤0.05, ** P≤0.01, **** P≤0.0001 for the 
specified statistical test. All panels present data as means + SD (compiled from ≥3 replicates).  
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 Several other eIFs are known to modulate start-codon fidelity27,206. eIF1 
maintains the fidelity of scanning 43S PICs for AUG start codons by antagonizing the 
structural reconfigurations that follow AUG recognition36,76,79-81. We therefore asked 
whether EIF1 overexpression impacts RAN translation. Overexpression of EIF1 in 
cultured human cells decreased the expression of (CGG)100 NL-3xF in the +1 and +2 
frames (Figure 2.9A). Notably, inserting an AUG codon upstream of the CGG NRE in 
the +1 frame abolished this effect, indicating that the identity of the start codon is 
essential for modulation by eIF1. This demonstrates that manipulation of the molecular 
machinery that determines start-codon fidelity can modulate RAN translation at CGG 
repeats in human cells.  
We next asked whether siRNA-mediated EIF1 knockdown would modulate RAN 
translation, and we observed that EIF1 knockdown resulted in significant inhibition of all 
transfected reporters (Figure A.10A). This finding is consistent with the known scanning-
promoting functions of eIF1 during general translation initiation36,80 and potentially 
explains the toxicity we observed with some EIF1-disrupting Drosophila lines in the 
absence of (CGG)90-EGFP (Table A.1), as well as the reduced (CGG)90-elicited toxicity 
we observed with EIF1-disrupting lines that were not, on their own, toxic. 
 We next asked whether enhancing expression of EIF5 would affect RAN 
translation. eIF5 is an eIF2γ-specific GAP227,228. Once a 43S PIC recognizes a start 
codon, eIF1 dissociates from the PIC, and eIF5 promotes the hydrolysis of eIF2γ-bound 
ATP229-232, a critical step in the dissociation of other eIFs that must precede ribosomal 
subunit joining. Furthermore, Loughran et al.85 demonstrated that higher eIF5 
































Figure 2.9: EIF1 and EIF5 Modulate RAN Translation by Determining AUG Start-Codon 
Specificity. 
A Expression of plasmid-based NL-3xF reporters in HEK293 cells with and without 
overexpression of EIF1 (two-way ANOVA with Sidak’s multiple comparisons test; n=9-12/condition). 
Black asterisks refer to comparisons between empty vector-transfected and EIF1-transfected cells; 
green asterisks refer to comparisons between EIF1-transfected cells expressing AUG-NL-3xF and 
those expressing a different reporter. 
B Expression of plasmid-based NL-3xF reporters in HEK293 cells with and without 
overexpression of EIF5 (two-way ANOVA with Sidak’s multiple comparisons test; n=9-12/condition). 
Black asterisks refer to comparisons between empty vector-transfected and EIF5-transfected cells; 
pink asterisks refer to comparisons between EIF5-transfected cells expressing AUG-NL-3xF and 
those expressing a different reporter. 
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Data Information: For all panels, *** P≤0.001, **** P≤0.0001 for the specified statistical test. All bars 
represent mean + SEM (compiled from ≥3 replicates).  
–––––––––––––––––––––––––––––––– 
results, we observed that EIF5 overexpression in cultured human cells led to higher 
expression of ACG-initiated NL-3xF and +1 and +2 (CGG)100 NL-3xF reporter plasmids, 
but not AUG-NL-3xF or AUG-initiated +1 (CGG)100 NL-3xF reporters (Figure 2.9B). 
Moreover, we confirmed by Western blot that transfection of EIF1 and EIF5 cDNA-
containing plasmids resulted in a higher level of eIF1 and eIF5 expression (Figure 
A.10B). In total, these experiments demonstrate that manipulation of factors that 
influence start-codon fidelity can up- or down-regulate RAN translation at CGG repeats. 
 
Knockdown of DDX3X Suppresses Toxicity in (CGG)100-Expressing Primary Neurons 
 The toxicity of the CGG NRE in FMR1 is driven at least in part by the products of 
RAN translation19,145,149. Having demonstrated that DDX3X regulates the abundance of 
RAN products in mammalian cells, we asked whether knockdown of DDX3X can 
mitigate the toxicity of (CGG)100 repeats in mammalian neurons. We transfected primary 
rat neurons with locked nucleic acids (LNAs) against DDX3X or non-targeting controls, 
along with plasmids containing the human FMR1 5’ UTR with 100 CGG repeats 
upstream of an EGFP reporter in the +1 frame [+1 (CGG)100 EGFP], along with an AUG-
driven mApple construct to identify transfected cells. Over the following 10 days, we 
used automated longitudinal fluorescence microscopy to track the survival of 
transfected cells (Figure 2.10A)233-235. Expression of +1 (CGG)100 EGFP markedly 
reduced survival compared to neurons expressing either EGFP (Figure A.11) or an 
EGFP reporter in which the AUG start codon has been replaced with a GGG codon 
(GGG-EGFP). Knockdown of DDX3X (Figure 2.10B) by two independent LNAs  
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Figure 2.10: Knockdown of DDX3X Mitigates (CGG)100 Toxicity in Primary Rodent Neurons. 
A Sample micrographs collected by automated longitudinal fluorescence microscopy, 
demonstrating the automated determination of cell death in cultured rat neurons. Cells outlined in 
green are alive; those outlined in red are dead or dying. 
B Anti-DDX3X western blot of B35 cells transfected with either of two independent anti-DDX3X 
locked nucleic acids (LNAs) or a control LNA. 
C EGFP fluorescence in primary rat neurons transfected with +1 (CGG)100-EGFP and either 
anti-DDX3X LNAs or a negative control LNA (one-way ANOVA with Tukey’s multiple comparisons 
test; n=2408-5689 cells/condition). Graph depicts data normalized first within the replicate. 
D, E Cumulative risk of death by automated longitudinal microscopy in rat neurons transfected 
with either GGG-EGFP control or +1 (CGG)100-EGFP, as well as non-targeting LNAs, anti-DDX3X 
LNA #1 (D), or anti-DDX3X LNA #2 (E; Cox proportional hazard analysis; n=2408-3676 
cells/condition).  
 
Data Information: For all panels, **** P≤0.0001 for the specified statistical test (compiled from ≥3 
replicates).  
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reduced the expression of FMRpolyG100-EGFP in these neurons (Figure 2.10C) and 
significantly improved the survival of (CGG)100-expressing neurons relative to 
transfection of non-targeting control LNAs (Figure 2.10D, E). We observed some 
neurotoxicity with one of the LNAs targeted DDX3X (#2) but not the other, potentially 
indicative of adverse off-target effects from LNA #2. These findings suggest that, like in 
Drosophila, knockdown of DDX3X suppresses CGG NRE-elicited toxicity by inhibiting 
RAN translation. 
 
Knockdown of DDX3X Suppresses RAN Translation of G4C2 Repeats in C9ORF72 
 The mechanism of RAN translation might differ from NRE to NRE and from 
sequence context to sequence context214. We and others have previously demonstrated 
that initiation of RAN translation of FMR1 and C9ORF72 mRNAs is dependent on the 
sequence upstream of the NRE150,169,170,203, indicating that cis features of mRNA can 
and do impact this process. Therefore, we asked whether DDX3X modulates RAN 
translation of other mRNAs, specifically, expanded G4C2 repeats in intron 1 of 
C9ORF72. In HeLa cells, knockdown of DDX3X by 5 independent siRNAs resulted in a 
dose-dependent suppression of two different transfected, plasmid-based G4C2 
reporters, both of which report on the GA RAN product: one bearing 70 G4C2 repeats in 
the native intronic sequence upstream of NL-3xF in the +0 frame (Int 1 GA70 NL-3xF; 
Figure 2.11A), and one bearing 71 G4C2 repeats embedded in non-native sequence 
upstream of the same reporter (GA71 NL-3xF; Figure 2.11B). Unlike the +1 and +2 
(CGG)n NL-3xF reporters for FMRpolyG and FMRpolyA expression, the effects of 
DDX3X knockdown on Int 1 GAn NL-3xF were repeat-dependent: GA3 and GA35  
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Figure 2.11: Knockdown of DDX3X Inhibits RAN Translation of Expanded G4C2 Repeats in 
C9ORF72. 
A, B Dose-response curves plotting the effects of siDDX3X, siEGFP, or non-targeting siRNAs 
(siNT) on the expression of C9ORF72 Intron 1 GA70 NL-3xF (A) and non-native GA71 NL-3xF (B) 
reporters [two-way ANOVA with Sidak’s multiple comparisons test (A) or Dunnett’s multiple 
comparisons test (B); n=3/condition]. Asterisks refer to comparisons between siRNAs at the 
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indicated concentration. 
C Expression of C9ORF72- and FMR1-based RAN reporters with and without DDX3X 
knockdown across a range of repeat sizes (two-way ANOVA with Tukey’s multiple comparisons test; 
n=3-13/condition compiled from ≥3 replicates). Black asterisks refer to comparisons between 
siDDX3X- and siEGFP-treated cells; orange asterisks refer to comparisons between siDDX3X-
treated cells expressing AUG-NL-3xF and those expressing a different reporter.  
D Quantitation of GMR-GAL4; (GP)28 EGFP rough-eye phenotypes with bel disruptions 
(Kruskal-Wallis test; n=35-77/genotype). 
E Anti-DDX3X western blot of C9 ALS iPSC lysates transfected with siNT or siDDX3X. 
F Abundance of endogenous GP RAN product by ELISA in C9 amyotrophic lateral sclerosis 
(ALS) patient-derived and control induced pluripotent stem cell (iPSC) lines (Student’s t test, n=3-
5/group, compiled from ≥3 replicates).  
 
Data Information: For all panels, * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001 for the specified 
statistical test. All panels depict data as mean ± SD. 
–––––––––––––––––––––––––––––––– 
reporters in the native intronic context were not significantly affected by DDX3X 
knockdown (Figure 2.11C). However, RAN translation of expanded (G4C2)70 in all 3 
sense reading frames of C9ORF72, including the GP and GR DPRs, were inhibited by 
DDX3X knockdown. 
 To determine whether bel/DDX3X knockdown might reverse (G4C2)n-elicited 
toxicity, we crossed flies expressing shRNAs against bel to mates expressing 28 G4C2 
repeats [(G4C2)28 EGFP] under a GMR-GAL4 driver. Basally, expression of (G4C2)28 
EGFP in the Drosophila eye manifests in a marked rough-eye phenotype similar to 
(CGG)100 EGFP (Todd lab; manuscript in preparation). To our surprise, bel knockdown 
significantly potentiated this phenotype (Figure 2.11D). This is the opposite of what we 
had expected based on our findings in HeLa cells, as well as the opposite of what we 
had observed in flies expressing (CGG)90-EGFP following bel knockdown. The reason 
for this discrepancy is unclear but might entail the synthesis of aggregate-prone proteins 
out-of-frame from the EGFP ORF. To resolve this discrepancy, we turned to a C9 
ALS/FTD patient-derived iPSC line, in which we can quantify the abundance of the GP 
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DPR using an ELISA163. In C9 iPSCs, DDX3X knockdown significantly reduced the 
abundance of the GP DPR (Figure 2.11E, F). This final experiment is a critical one, 
establishing that the effects of DDX3X knockdown are consistent between our reporter-




 We performed a screen of eIFs and RNA helicases to identify modifiers of FMR1-
associated RAN translation and toxicity in Drosophila and human cells, and found both 
selective (bel/DDX3X, EIF1, and EIF5) and non-selective (EIF4B and EIF4H) modifiers. 
Manipulation of these genes both reduced the expression of the RAN products 
FMRpolyG and FMRpolyA and mitigated CGG repeat-associated toxicity. This work 
both extends our understanding of RAN translation mechanisms and identifies potential 
therapeutic targets for FXTAS and other RAN translation-associated disorders. 
 RAN translation occurs in association with expanded, GC-rich, secondary 
structure-forming repeats that promote initiation in the absence of an AUG codon14,19,150. 
We originally hypothesized that disruption of RNA helicases, which resolve RNA-RNA 
secondary structures, would enhance RAN translation at CGG repeats. Our results 
demonstrated the opposite: knockdown of bel/DDX3X, EIF4B, or EIF4H inhibited FMR1 
RAN translation. How can we account for this discrepancy? DDX3X and its yeast 
homolog Ded1 are DEAD-box RNA helicases that are required for resolution of RNA-
RNA structures in long, GC-rich 5’ UTRs of particular genes46,50,58,59,61,64-68. The FMR1 
5’ UTR is GC-rich (76%) independent of the CGG repeats and is predicted to form 
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highly-stable secondary structures236-238 capable of stalling scanning 43S PICs75,111. Our 
results, in which DDX3X is required for initiation within the FMR1 5’ UTR but not for 
expression of AUG-NL-3xF, are most consistent with a model in which DDX3X interacts 
with and resolves RNA-RNA secondary structures within the FMR1 5’ UTR 5’ to and 
within the CGG repeat, which allows access of scanning PICs to sites of initiation. 
According to this model, without DDX3X, scanning 43S PICs are unable to access the 
initiation sites for RAN translation, leading to a selective decrease in their use. In 
contrast, EIF4B and EIF4H are stimulatory factors for the DEAD-box RNA helicase 
eIF4A40,44,45,239,240, which is critical for 43S PIC-mRNA binding and PIC scanning46. Our 
data, in which eIF4B and eIF4H regulate not only RAN translation but also general 
translation, is best explained by a model in which eIF4B and eIF4H facilitate 43S PIC 
attachment and basal scanning in the initial stages of RAN translation in a similar 
fashion to that for canonical translation. This model is consistent with previous 
observations that FMR1 RAN translation resembles canonical translation during these 
early stages of initiation150,169,170. 
 A key feature that distinguishes RAN translation from canonical translation is its 
use of non-AUG codons for initiation14,150,169,170. The specificity for AUG start codons is 
simultaneously central to the integrity of eukaryotic and prokaryotic proteomes and an 
essential point of regulation for determining which, when, and how much protein is 
synthesized from a given mRNA transcript98,206,241-243. RNA secondary structure-forming 
elements (including GC-rich NREs) are predicted to slow or stall PICs during scanning, 
enhancing the dwell time of codon-anticodon interactions at non-AUG codons and 
increasing the frequency of initiation events at non-AUG sites95. RAN translation might 
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initiate in a similar manner. If correct, this model predicts that increasing the abundance 
of eIFs that boost start-codon fidelity would inhibit RAN translation, while increasing 
abundance of eIFs that reduce start-codon fidelity would enhance RAN translation. 
Multiple factors and regulatory pathways converge to govern start codon selection, 
including EIF1 and EIF5. eIF1 (originally identified as Sui1) is known to increase the 
specificity of scanning 43S PICs for AUG start codons76,77, while higher availability and 
abundance of eIF5 (originally Sui5) have been shown to decrease start-codon 
fidelity83,85,86.  
 Consistent with our prediction, we observed that EIF1 overexpression decreased 
RAN translation in a start codon-dependent manner, while overexpression of EIF5 did 
the opposite. However, as factors such as EIF1 have multiple roles in translational 
initiation, suppression of their expression led to global decreases in translation that 
impacted both FMR1 RAN translation and canonical translation, which elicited intrinsic 
toxicity in Drosophila. These results align with previous work demonstrating that RAN 
translation at both CGG and G4C2 NREs and across multiple reading frames is induced 
by activation of the ISR in a start codon-dependent manner via a mechanism that 
impinges on the AUG selectivity of the 43S PIC169,202,203. This line of research supports 
a model in which RAN translation represents a failure in start codon fidelity, suggesting 
that factors that regulate start-codon fidelity also regulate this pathologic process. 
A central goal of understanding how RAN translation occurs, and how it is distinct 
from canonical translation, is to identify potential therapeutic targets. Prevention of 
FMR1 RAN translation is sufficient to suppress toxicity/neurodegeneration in human 
cells in vitro and Drosophila and mice in vivo19,145,149. Here, we demonstrate that 
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disruption of bel/DDX3X not only inhibits FMR1 RAN translation selectively in vitro and 
in vivo, but significantly mitigates repeat-induced toxicity across model systems. We 
suggest that targeting factors critical for resolving RNA secondary structures and/or 
enhancing start codon fidelity could represent viable therapeutic strategies for FXTAS 
and related neurodegenerative disorders. DDX3X in particular is currently the target of 
multiple lines of pharmacological research aimed at treating various cancers and 
viruses244-246. By targeting a proximal event in the pathophysiology of RAN translation-
associated neurodegenerative disorders, this strategy has the potential to be more 
efficacious than targeting the toxic effects of each RAN product. 
 
Materials and Methods 
Drosophila Lines 
 All fly lines used here and their sources are listed in Table A.2. 
 
Antibodies 
 For western blotting, all primary antibodies were used at 1:1,000 in 5% non-fat 
dairy milk (wt/vol), 0.02% NaN3 (wt/vol), 0.1% Tween-20 (vol/vol) in TBS. Monoclonal 
mouse anti-EGFP antibody was acquired from Sigma (clones 7.1 and 13.1, catalog 
#11814460001). Monoclonal mouse anti-β tubulin antibody, developed by Michael 
Klymkowsky, was obtained from the Developmental Studies Hybridoma Bank, created 
by the NICHD of the NIH, and maintained at The University of Iowa, Department of 
Biology, Iowa City, IA 52242. Monoclonal mouse anti-FLAG antibody was acquired from 
Sigma (clone M2, catalog #F1804). Polyclonal rabbit anti-DDX3X antibody (catalog 
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#2635), anti-eIF4B antibody (catalog #3592), anti-eIF4H antibody (catalog #2444), anti-
eIF1 antibody (catalog #12496), and anti-eIF5 antibody (catalog #13894)  
were acquired from Cell Signaling Technology. For information on the anti-DDX3X and 
isotype control antibodies used for RIP, see the relevant section below. 
 
Drosophila Phenotyping 
 All flies were raised and crossed at 25°C on SY10 food unless otherwise stated. 
For the screen, virgin female flies carrying the UAS-FMR1 (CGG)90-EGFP reporter216 
and a GMR-GAL4 driver [Bloomington Drosophila Stock Center (BDSC) 8605] were 
crossed to males carrying UAS-driven shRNA constructs against, UAS-driven 
transgenes of, or germline mutations in candidate genes. Rough-eye phenotypes in F1 
progeny were photographed and scored at 0-1 day post-eclosion according to a rubric 
adapted from Pandey et al.247. One point was given for each of the following 
morphological aberrations: supernumerary inter-ommatidial bristles, abnormal 
orientation of inter-ommatidial bristles, disorganization of the ommatidial array, 
ommatidial fusion, and total loss of the ommatidial array over 10% of the eye surface. 
Two points were given for each of the following: the presence of necrotic lesions, 
collapse of the eye’s convex surface, and shrinkage of the eye’s surface area by 25%. 
Individual flies could therefore score between 0 and 11, with higher scores indicating a 
more severe phenotype. Eye images were captured using a Leica M125 
stereomicroscope and a Leica DFC425 digital camera. 
 For longevity assays, flies carrying (CGG)90-EGFP and either a Tub5-GAL4 
GeneSwitch or ElaV-GAL4 GeneSwitch driver (both RU486-inducible)224 were placed 
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on SY10 food supplemented with 200 µM RU486 and flipped onto fresh RU486-
supplemented SY10 every 24 (Tub5) or 48 (ElaV) hours, and kept at 29°C until 
expiration. Deaths were counted and dead flies removed every 24 or 48 hours. 
 
Western Blotting and qRT-PCR of Drosophila Tissue 
For western blotting and qRT-PCR of fly tissue, <2 days post-eclosion flies 
carrying (CGG)90-EGFP and the Tub5-GAL4 GeneSwitch driver were placed on 200 µM 
RU486-supplemented SY10 for 72 hours, with fresh RU486-supplemented food 
provided every 24 hours, at 29°C. For western blotting, flies were homogenized at 4°C 
in ice-cold radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris (pH 8.0), 150 mM 
NaCl, 0.1% SDS (wt/vol), 0.5% sodium deoxycholate (wt/vol), 1% IGEPAL CA-630 
(vol/vol), and cOmplete-Mini protease inhibitor (Roche)], then briefly centrifuged at 12K 
RPM for 2 minutes at 4°C to pellet cuticle and wing debris. The supernatant was 
removed and the chromatin sheared by 10 strokes through a 28.5G syringe. Lysates 
were subsequently mixed with 6x reducing Laemmli buffer, separated by SDS-PAGE, 
and transferred to PVDF membranes (Biorad). 
For qRT-PCR assays, flies were homogenized in TRIzol (Thermo Fisher 
Scientific) and total RNA was subsequently extracted. Ten µg of RNA per sample were 
twice incubated with 2 U of TURBO DNase (Thermo Fisher Scientific) in reaction 
volumes of 50 µl at 37°C for 30 mins, per manufacturer’s instructions, then recovered 
using RNA Clean and Concentrator-25 kits (Zymo Research). Five hundred ng of 
DNase-treated RNA per sample were used to generate cDNAs using a mixture of 
oligo(dT) and random hexamer primers (iScript cDNA Synthesis Kit, Biorad). cDNA 
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abundance was measured using iQ SYBR Green Supermix (Biorad), appropriate 
primers at 300 nM (Table A.3), and an iQ5 qPCR system (Biorad). 
 
Plasmids 
 All reporter constructs used here were generated and described by Kearse et 
al.150 and/or Green et al.169. In brief, all nanoluciferase reporters were developed by site-
directed mutagenesis or digestion/ligation from pcDNA3.1(+)/AUG-NL-3xF. All 
pcDNA3.1(+)/FMR1 (CGG)n NL-3xF constructs bear the full human 5’ UTR of FMR1 
upstream of the CGG repeats. In addition, in all FMR1 (CGG)n constructs used here, the 
initiator ATG of NL-3xF has been mutated to GGG to abolish initiation at this site. The 
FF luciferase construct pGL4.13 was acquired from Promega. For in vitro transcription 
of FF luciferase RNA, the FF luciferase construct was digested and ligated into a 
pcDNA3.1(+) vector using 5’ HindIII and 3’ XbaI restriction sites (Rapid DNA Dephos 
and Ligation Kit, Sigma). All plasmids used for transfection and in vitro transcription 
were prepared from E. coli cultures using ZymoPURE Plasmid Midiprep Kits (Zymo 
Research). 
 pCMV6-XL5/EIF4B and pCMV5-XL5/EIF4H, which drive expression of human 
EIF4B and EIF4H, respectively, were acquired from OriGene. pcDNA3.1(+)/EIF1 and 
pcDNA3.1D/EIF5-V5-His, which drive expression of human EIF1 and EIF5, respectively, 
were acquired from J. Schofield. 
 
Cell Culture and Transfection 
HeLa (CCL-2, ATCC), HEK293 (CRL-1573, ATCC), HEK293T (CRL-3216, 
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ATCC), and B35 (CRL-2754, ATCC) cells were cultured and passaged at 37°C, 5% 
CO2, with HeLa cells in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% non-essential amino acids, and HEK293, 
HEK293T, and B35 cells in DMEM supplemented with 10% FBS. 
For luciferase assays, HeLa cells were plated in 96-well plates at 1.0×104 
cells/well in 100 µl media and reverse transfected with Stealth siRNAs against human 
DDX3X (DDX3XHSS102712 and DDX3XHSS176054, Thermo Fisher Scientific) or 
EGFP at 1.67 nM, unless otherwise noted, using Lipofectamine RNAiMAX (Thermo 
Fisher Scientific). Alternatively, they were transfected with ON-TARGETplus 
SMARTpool siRNAs against human EIF4B (L-020179-00, Dharmacon), EIF4H (L-
013054-00), or EIF1 (L-015804-02) or a non-targeting pool (D-001810-10). In brief, 
siRNA and RNAiMAX were diluted in Opti-MEM, combined, incubated for 10 mins at 
room temperature, then mixed with cells. For subsequent plasmid transfection, 24 hours 
after plating cells were transfected with 25 ng/well pcDNA3.1(+)/NL-3xF plasmid and 25 
ng/well pGL4.13 as transfection control using jetPRIME (Polyplus). The transfection 
media was removed and replaced 4 hours post-transfection. For RNA reporter 
transfection, 24 hours after plating cells were transfected with 25 ng/well in vitro-
transcribed nanoluciferase RNA and 25 ng/well firefly luciferase RNA using TransIT 
mRNA (Mirus Bio). Luciferase assays were performed 24 hours after plasmid 
transfection, as described by Kearse et al.150 and Green et al.169. 
For overexpression experiments, cells were plated in 96-well plates at 1.0×104 
cells/well (HeLa) or 2.0×104  cells/well (HEK293T) in 100 µl media. Twenty-four hours 
after plating, HeLa cells were transfected with 5 ng/well pcDNA3.1(+)/NL-3xF, 5 ng/well 
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pGL4.13, and 40 ng/well pCMV6-XL5/EIF4B, pCMV5-XL5/EIF4H, pEGFP N1, or a 
combination thereof, using jetPRIME (Polyplus). HEK293T cells were transfected with 
25 ng/well pcDNA3.1(+)/NL-3xF, 25 ng/well pGL4.13, and 250 ng/well 
pcDNA3.1(+)/EIF1, empty pcDNA3.1(+), pcDNA3.1D/V5-His-EIF5, or empty 
pcDNA3.1D/V5-His using FuGene HD (Promega). Luciferase assays were performed 
as above. 
For western blotting experiments, HeLa cells were plated in 12-well plates at 
1.5×105 cells/well in 1 ml media and reverse transfected, as above, with Stealth siRNAs 
against DDX3X or EGFP at 1.67 nM using Lipofectamine RNAiMAX. Alternatively, they 
were transfected with ON-TARGETplus SMARTpool siRNAs against EIF4B, EIF4H, or a 
non-targeting pool (siNT) at 15 nM. Twenty-four hours after plating cells were 
transfected with 500 ng/well pcDNA3.1(+)/NL-3xF using jetPRIME (Polyplus). The 
transfection media was removed and replaced 4 hours post-transfection. Twenty-four 
hours after plasmid transfection, cells were lysed on-plate in RIPA buffer. The lysate 
was homogenized by 10 strokes through a 28.5 G syringe (without centrifugation), 
mixed with 6x reducing Laemmli buffer, heated at 90°C for 10 mins, resolved by SDS-
PAGE, and transferred to a PVDF membrane before incubation in primary antibody. 
For qRT-PCR experiments, HeLa cells were plated in 6-well plates at 2.5×105 
cells/well in 2.5 ml media and reverse transfected with Stealth siRNAs against DDX3X 
or EGFP at 1.67 nM using Lipofectamine RNAiMAX. Twenty-four hours after plating 
cells were transfected with 625 ng/well pcDNA3.1(+)/NL-3xF and 625 ng/well pGL4.13 
using jetPRIME (Polyplus). The transfection media was removed and replaced 4 hours 
post-transfection. Twenty-four hours after plasmid transfection, cells were lysed and 
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total cellular RNA collected using Quick-RNA MiniPrep Kit (Zymo Research). Five µg of 
RNA per sample were incubated twice with 2 U of TURBO DNase (Thermo Fisher 
Scientific) for 30 minutes at 37°C to remove contaminating genomic and plasmid DNA, 
then recovered using the RNA Clean and Concentrator-25 Kit (Zymo Research). cDNA 
was generated from 500 ng of DNase-treated RNA per sample and a mixture of 
oligo(dT) and random hexamer primers (iScript cDNA Synthesis Kit, Biorad). cDNA 
abundance was measured using iQ SYBR Green Supermix (Biorad), an iQ5 qPCR 
system (Biorad), and the appropriate primers at 300 nM. cDNA abundance was 
quantified using a modified ΔΔ Ct method recommended by the manufacturer and have 
been presented as normalized to spiked-in in-vitro transcribed RNAs to account for 
differences in RT efficiency. 
 For confirmation of anti-DDX3X LNA efficacy, B35 cells were plated in 12-well 
plates at 2.0×105 cells/well in 1 ml media and reverse transfected with anti-DDX3X 
Silencer Select LNAs (s165214 and s165216, Thermo Fisher Scientific) or a non-
targeting control (4390843, Thermo Fisher Scientific) at 40 nM using Lipofectamine 
RNAiMAX. Forty-eight hours after plating, cells were lysed as above for western-blot 
analysis. 
 
Cross-linking and RNA Immunoprecipitation 
HEK293 cells were plated in poly-L-lysine-coated 10-cm plates at 3.0 ×106 
cells/plate. Forty-eight hours after plating cells were transfected with 5 µg of 
pcDNA3.1+/CGG100 (+1) NL-3xF and 5 µg of either pGL4.13 or pEGFP N1 using Viafect 
(Promega). Twenty-four hours post-transfection the media was aspirated and replaced 
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with fresh media supplemented with 6-thioguanisine248 at 100 µM and allowed to 
incubate for 12 hours. 
Cells were rinsed 3x in PBS (pH 7.4), the PBS was aspirated, and the cells were 
irradiated uncovered with 0.6 J/cm2 of 365 nm UV light using a Stratalinker 2400 
(Stratagene). Cells were then harvested using trypsin (0.25%)-EDTA and rubber 
policemen, collected by centrifugation, rinsed 2x in ice-cold PBS, flash-frozen in a dry 
ice/EtOH bath, and stored at -80°C. For processing, cell pellets were lysed in NP-40 
lysis buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM DTT, 0.5% IGEPAL CA-630 
(wt/vol)] supplemented with cOmplete Mini EDTA-free protease inhibitors (Roche), 
PhosSTOP phosphatase inhibitors (Roche), 1 U/µl recombinant RNAsin (Promega), and 
200 U/ml SuperaseIN (Thermo Fisher Scientific) for 25 mins on ice, incubated with 42 
U/ml RQ1 DNase (Promega) at 37°C for 10 mins, then centrifuged at 10K g, 4°C for 10 
mins. 
 Protein G Dynabeads (Thermo Fisher Scientific) were prepared and incubated 
with mouse anti-DDX3X (clone 2253C5a, Santa Cruz sc-81247), mouse anti-EGFP 
(clones 7.1/13.1, Sigma 11814460001), or mouse isotype control IgG (Thermo Fisher 
Scientific 10400C) as per the manufacturer’s instructions. Antibody-conjugated beads 
were rinsed 3x in NP-40 lysis buffer and incubated with the cleared lysate for 16 hours 
with inversion at 4°C. Only those cells transfected with pEGFP N1 were subjected to 
anti-EGFP RIP. The lysate was removed, and the beads were washed 3x with NP-40 
lysis buffer and 3x with 5x PBS (pH 7.4) supplemented with 0.5% IGEPAL CA-630. 
RNA was eluted by incubation with 2 mg/ml Proteinase K at 55°C for 1 hour in 50 mM 
Tris-HCl (pH 7.0), 75 mM NaCl, 6 mM EDTA, and 2% SDS (wt/vol), extracted using 
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TRIzol (Thermo Fisher Scientific) and GlycoBlue co-precipitant (Thermo Fisher 
Scientific), treated twice with 40 U/ml TURBO DNase at 37°C for 30 mins, and purified 
using the RNA Clean and Concentrator-5 Kit (Zymo Research). cDNAs were generated 
using the iScript cDNA Synthesis Kit, as described above, with each reaction spiked 
with equal amounts of in vitro-transcribed AUG-FF or EGFP RNA (depending on which 
plasmid had not been co-transfected) as a reverse-transcription control. qPCR was 
performed as described above, with cDNA abundance normalized to spiked-in FF or 
EGFP cDNA abundance. 
 
In vitro Transcription and Translation Reactions 
 pcDNA3.1(+)/NL-3xF and pcDNA3.1(+)/FF were linearized by PspOMI and XbaI 
restriction enzymes (NEB), respectively, and recovered using DNA Clean and 
Concentrator-25 kits (Zymo Research). m7G-capped and poly-adenylated RNAs were 
transcribed in vitro from these plasmids using HiScribe T7 ARCA mRNA kit (with tailing; 
NEB) as per the manufacturer’s instructions and recovered using RNA Clean and 
Concentrator-25 kits (Zymo Research). The integrity and size of all transcribed RNAs 
were confirmed by denaturing agarose gel electrophoresis with 
formaldehyde/formamide. 
 For preparation of translation-competent extracts, HeLa cells were plated in 14.5-
cm dishes at 8×106 cells/plate. Twenty-four hours later they were forward transfected 
with Stealth siRNAs against DDX3X or EGFP at 1.67 nM using RNAiMAX, as described 
above (adapted from Rakotondrafara & Heintze249). The transfection media was 
removed 5 hours post-transfection and replaced with fresh media. Two days post-
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transfection, cells were harvested using trypsin (0.25%)-EDTA, centrifuged, and rinsed 
3x with PBS (pH 7.4). Cells were allowed to swell on ice in a volume of hypotonic lysis 
buffer [10 mM HEPES-KOH (pH 7.6), 10 mM KOAc, 0.5 mM Mg2OAc, 5 mM DTT, 
supplemented with cOmplete Mini, EDTA-free protease inhibitor] equal to the cell pellet 
volume for 30 mins. Cells were mechanically disrupted at 4°C using 20 strokes in a 27G 
syringe, then allowed to incubate on ice for an additional 20 minutes. Lysis was 
confirmed visually in >95% of cells by trypan blue inclusion. The lysate was centrifuged 
at 10K g for 10 mins at 4°C. The supernatant was then collected, diluted in lysis buffer 
to 8.0 µg/µl using a modified Bradford protein quantification assay (Biorad), flash frozen 
in liquid N2, and stored at -80°C. 
 For in vitro-translation reactions, lysates were brought to final concentrations of 
20 mM HEPES-KOH (pH 7.6), 44 mM KOAc, 2.2 mM Mg2AOc, 2 mM DTT, 20 mM 
creatine phosphate (Roche), 0.1 µg/µl creatine kinase (Roche), 0.1 mM spermidine, and 
on average 0.1 mM of each amino acid (with relative amounts approximating those in 
eukaryotes250). To this, in vitro-transcribed RNAs were added to 4 nM in a final volume 
of 10 µl per reaction. After incubation at 30°C for 30 min, 25 µl room-temperature Glo 
Lysis buffer (Promega) was added to halt the reaction and allowed to incubate for 5 
mins at room-temperature. To 25 µl of this mixture was added 25 µl of NanoGlo 
substrate freshly diluted in NanoGlo buffer (Promega). This mixture was allowed to 
incubate in opaque 96-well plates on a rocking shaker in the dark for 5 minutes before 





HeLa cells were seeded in four to eight 10-cm dishes per condition. Twenty-four 
hours after plating, cells were transfected with siRNAs against DDX3X or EGFP at 1.6 
nM using RNAiMAX, as above, with the media exchanged at 5 hours post-transfection. 
When cells reached 70-90% confluency, 24-36 hours post-knockdown, they were 
treated with 100 µg/mL cycloheximide (CHX) for 5 minutes at 37° C. Cells were then 
transferred to ice and washed with 2.5 mL ice-cold PBS containing 100 µg/mL CHX, 
collected by scraping in 2.5 mL cold PBS+CHX, and pelleted at 1200 RPM and 4° C for 
5 minutes. PBS was aspirated and pellets re-suspended in polysome-profiling lysis 
buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 15 mM MgCl2, 8% (vol/vol) glycerol, 20 
U/mL SUPERase, 80 U/mL Murine RNase Inhibitor, 0.1 mg/mL heparin, 100 µg/mL 
CHX, 1 mM DTT, 1x EDTA-free protease inhibitor cocktail, 20 U/mL Turbo DNase, 1% 
Triton X-100)251. Lysates were passed through a 20G needle 10x and incubated on ice 
for 5 minutes. Cellular debris was pelleted at 14,000 g and 4° C for 5 minutes, and 
supernatant transferred to a fresh tube. Total lysate RNA was estimated by NanoDrop. 
Lysates were flash frozen in liquid N2 and stored at -80°C until fractionation. 
Sucrose gradients were prepared by successively freezing equal volumes of 
50%, 36.7%, 23.3%, and 10% sucrose (wt/vol) in 12-mL Seton tubes. Sucrose-gradient 
buffer consisted of 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 15 mM MgCl2, 10 U/mL 
SUPERase, 20 U/mL Murine RNase Inhibitor, 100 µg/mL CHX, and 1 mM DTT251. Prior 
to use, gradients were allowed to thaw and linearize overnight at 4° C252. For 
fractionation, approximately 90 (trial 1 with four 10-cm dishes), 220, and 250 µg (trials 2 
and 3, respectively, with eight 10-cm dishes each) total RNA was applied to the top of 
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the sucrose gradient. Gradients were spun at 35,000 RPM and 4° C for 3 hours using a 
Beckman Coulter Optima L-90K ultracentrifuge and SW 41 Ti swinging-bucket rotor. 
Gradients were fractionated with Brandel’s Gradient Fractionation System, 
measuring absorbance at 254 nm. The detector was base-lined with 60% sucrose 
chase solution, and its sensitivity set to 0.5 for trial 1 and 1.0 for trials 2 and 3. For 
fractionation, 60% sucrose was pumped at a rate of 1.5 mL/min. Brandel’s PeakChart 
software was used to collect data, overlay profiles, and calculate the area under the 
curve for monosome and polysome fractions. 
 
Primary Neuronal Cultures and Automated Fluorescence Microscopy 
Embryonic day (E) 19-20 Long-Evans rat (Rattus norvegicus) cortices were 
harvested and the neurons dissociated and plated in 96-well plates at 6.0×106 cells/mL 
as previously described253. On in vitro day (DIV) 4, neurons were transfected using 
Lipofectamine 2000 (Thermo Fisher Scientific)254 with 100 ng/well pGW/(CGG)100 +1 
EGFP or pGW/GGG-EGFP, 50 ng/well pGW/mApple, and LNAs to a final concentration 
of 40 nM. Following transfection, neurons were maintained in NEUMO photostable 
media (Cell Guidance Systems) for the duration of the experiment. 
Neurons were imaged using a Nikon Eclipse Ti inverted microscope with 
PerfectFocus3 and Nikon Plan Fluor 20X objective lens234. Cells were illuminated with a 
Lambda XL Xenon lamp (Sutter Instrument) and detected using an Andor iXon3 897 
EMCCD or Andor Zyla4.2 (+) sCMOS camera. Stage, filter, and shutter movements 
were controlled with scripts written in Beanshell for use in μManager. Separate 
ImageJ/Fiji macros and Python scripts were employed for automated identification of 
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transfected neurons and the drawing of regions of interest around each neuron235. Cell 
death was indicated by rounding of the cell body, deterioration of neuronal processes, 
and loss of mApple fluorescence intensity. 
 
iPSC Culturing, Transfection, and GP ELISA 
iPSCs derived from human fibroblasts that were harvested from control patients 
and C9 ALS patients were grown using standard techniques in Essential-8 media 
(Invitrogen). The day before transfection, cells were split using 50 mM EDTA with 
vigorous trituration in Essential-8 media containing RockI (Y27632, Fisher) on 
vitronectin (Fisher)-coated plates. The next day, media was replaced with mTESR 
(StemCell). For siRNA transfection, 72 pmols of each siRNA were transfected using 4.8 
µl Lipofectamine RNAiMax reagent (Invitrogen) per well of a 6-well dish. The 
transfection mixture was added to cells in 1.6 ml of media and removed 20-24 hours 
later. Cells were harvested for protein isolation 48 hours post-transfection and lysed in 
50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 5 mM EDTA, 1.0% (vol/vol) Triton X-100, 2% 
(wt/vol) SDS in the presence of phosphatase and protease inhibitors. Protein 
concentration was quantified using BCA Protein Assay Kit (Thermo Fisher Scientific) 
and the lysates analyzed by ELISA as previously described163. 
 
Data Analysis 
 Band intensity on western blots was quantified using ImageJ (NIH; anti-EGFP) or 
Odyssey Image Studio (LI-COR; anti-tubulin) software. Primary neuron survival analysis 
and determination of hazard ratios through Cox proportional hazard analysis was 
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conducted using the publicly available survival package in R. All other data were 
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A High-Throughput, Genome-Wide Screen Identifies Modifiers of C9ORF72- and 
FMR1-Associated RAN Translation3 
 
Abstract 
The G4C2 nucleotide-repeat expansion (NRE) in C9ORF72 is the most frequent 
cause of familial and sporadic amyotrophic lateral sclerosis (ALS)/frontotemporal 
dementia (FTD). One mechanism through which expanded G4C2 RNA repeats elicit 
toxicity is by inducing aberrant protein synthesis in the absence of an AUG codon, 
leading to the production of toxic dipeptide repeat (DPR)-containing proteins. This non-
canonical mode of translation, known as repeat-associated, non-AUG (RAN) translation, 
is observed in the context of several NRE-associated neurodegenerative disorders. In 
an effort to elucidate the mechanism of RAN translation and identify novel therapeutic 
targets, we conducted a high-throughput, genome-wide siRNA screen for genes that 
modulated expression of the glycine-alanine (GA) DPR RAN product using luciferase-
based reporters. Following a series of progressively discriminating screens, we 
identified 552 genes as selective modifiers of GA expression, the majority of them 
suppressors. 190 of these genes also modified the expression of RAN products 
synthesized from expanded CGG repeats in the 5’ UTR of FMR1, another disease-
associated, RAN-competent gene. Among these were the RNA-binding protein 
HNRNPA2B1 and the proteasomal subunit PSMB5. In follow-up experiments using 
independent siRNAs, we demonstrated that knockdown of HNRNPA2B1 or PSMB5 
modulated the expression of both C9ORF72 and FMR1 RAN products across reading 
frames, frequently in a repeat-dependent manner. Additional work will be required to 
narrow and prioritize this list of RAN modifiers, including elimination of putative off-target 
effects.
 
3 Tseng Y, Santoro N, and Glineburg MR contributed significantly to the work presented in this chapter. YT assisted 




ALS and FTD are progressive, fatal neurodegenerative disorders for which there 
are no effective disease-modifying therapies. Median survival after symptom onset is 
~30 months for ALS255,256 and ~8 years for FTD257-260. Despite differences in their initial 
clinical presentation, diagnostic criteria, and prognoses, ALS and FTD are linked by 
their shared disease-causing mutations, histopathological hallmarks, and some clinical 
features155-157. Major hypotheses regarding the etiology and pathogenesis of ALS/FTD 
vary widely261 and include persistent enteroviral infection262; mitochondrial 
dysfunction263; disruption of protein homeostasis264,265; DNA structural aberrations, 
double-stranded breaks, and epigenetic dysregulation161,266-269; and perturbations of 
RNA metabolism and ribonucleoprotein (RNP) phase separation270,271. In the last 
decade, extensive research has focused for multiple reasons on one ALS/FTD-
associated mutation, the NRE of G4C2 repeats in the gene C9ORF72. It is the most 
frequent genetic cause of sporadic and familial ALS/FTD151,152,272. It can be modeled 
with relative ease in a variety of in vitro and in vivo systems. And, critically, expanded 
G4C2 DNA and/or RNA elements can be plausibly linked to several of the previously 
hypothesized causes of ALS/FTD. 
Genetic screens have proved effective tools to generate novel hypotheses 
regarding the pathophysiology and treatment of NRE-associated neurodegeneration273-
278. Much of the initial study of C9ORF72-associated ALS/FTD pathogenesis was 
launched using genetic screens in a variety of model systems172,180,182,279,280. These 
were designed to identify genetic modifiers of G4C2 NRE-elicited toxicity, often broadly. 
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By design, identified modifiers could genetically interact with any of several possible 
molecular sources of G4C2 toxicity: G4C2 DNA, G4C2 and G2C4 RNA, or the aberrant 
DPR-containing protein products of G4C2 RAN translation15,17,161,173,194,281,282. In 
contrast, we are interested specifically in how RAN translation of G4C2-expanded 
C9ORF72 initiates, because 1) RAN translation appears to violate basic assumptions 
regarding protein synthesis and start-codon fidelity, and 2) a mechanistic understanding 
of RAN translation might generate novel therapeutic strategies for C9 ALS/FTD and 
other RAN translation-associated neurodegenerative disorders25. 
Identifying the proteins and pathways that modulate RAN translation will be key 
to understanding its mechanism and how it departs from canonical, AUG-initiated 
translation. To do this, we and others have previously used either hypothesis-driven 
approaches23,150,169,202,283 or limited, candidate-based screens (see Chapter 2). To 
interrogate comprehensively the mechanism of RAN translation, as well as identify 
potential therapeutic targets, we conducted a high-throughput, genome-wide screen for 
modifiers of C9ORF72-based RAN translation and an abbreviated screen for modifiers 




A Non-Biased, Genome-Wide, High-Throughput Screen Identifies Modifiers of 
C9ORF72 RAN Translation 
We plated HEK293 cells and transfected them with a genome-wide library of 
siRNAs (the human siGENOME SMARTpool library, Dharmacon), then co-transfected 
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two plasmids (Figure 3.1A): 1) a FLAG-tagged nanoluciferase reporter (NL-3xF) 
downstream of the human C9ORF72 intron 1 bearing 70 G4C2 repeats (GA70 NL-3xF), 
which is translated to produce a fusion of the GA70 RAN product and NL-3xF reporter; 
and 2) an AUG-initiated FF luciferase reporter for general translation and cell viability. 
The GA70 construct was selected from the available DPR reporters because of its high 
signal and wide dynamic range169 and because the GA product is the most abundant 
DPR protein in C9 ALS/FTD patient tissue16,17,168. Dual transfection with subsequent 
independent luminescence assays enabled the differentiation of modifiers specific to 
RAN translation (NL-3xF) from modifiers of general translation and cell viability (FF). 
Non-targeting siRNAs (siNT; Dharmacon) and siRNAs targeting the ORF of NL (siNL) 
served as negative and positive controls, respectively (Figure 3.1B). In addition, siRNAs 
against PLK1 (siPLK1) served as positive controls for loss of cell viability, as PLK1 
knockdown leads to mitotic arrest. For the purpose of identifying hits, our chief 
screening statistic was the GA70 NL-3xF luminescence normalized to AUG-FF 
luminescence (NL/FF). Across the entire C9ORF72 primary screen the average Z¢ 
score, calculated from NL/FF values of siNT- and siNL-transfected cells, was 0.681,  
–––––––––––––––––––––––––––––––– 
Figure 3.1: Design of High-Throughput siRNA Screens for Modifiers of C9ORF72 and FMR1 
RAN Translation.  
A Schematics of the NL- and FF-based reporter constructs used for C9ORF72-based RAN, 
FMR1-based RAN, and AUG-initiated translation. 
B Normalized expression of GA70 NL-3xF following transfection of siNT and nanoluciferase 
siRNA (siNL; negative and positive controls respectively; left panel), and relative expression of AUG-
FF following transfection of siNT and siPLK1 (right panel). The FF luminescence value representing 
minimally accepted cell viability [mean + 1 standard deviation (SD)] is drawn. 
C NL/FF ratios gathered from a representative assay plate, presented normalized to the mean 
of siNT-transfected cells (left y axis) and as the number of SDs from the mean of siNT-transfected 
cells (right y axis). siNL-transfected cells are included as a positive control. The lines demarcating +3 
and -3 SD from the mean siNT are drawn. 





indicating high robustness and replicability (Figure 3.1C). Each siRNA was transfected 
in triplicate, with a high correlation between replicates (Figure 3.1D). 
We determined primary hits with the algorithm detailed (Figure 3.2). We first 
excluded from further analysis any genes whose knockdown resulted in reduced cell 
viability, i.e., genes with FF signal < µPLK1+σPLK1 (Figure 3.1B, right panel). Second, we 
counted as primary hits any genes which met the following criteria. Genes were 
included as suppressors of C9ORF72 RAN translation if 1) knockdown reduced NL/FF 
values to less than the mean NL/FF of siNT-treated cells minus 3 standard deviations 
(NL/FFsiX ≤ µNT-3σNT) in at least 2 of 3 replicates; 2) knockdown reduced the mean NL 













Figure 3.2: Schematic of the Algorithm by Which RAN-Specific Suppressors and Enhancers 
of GA70 NL-3xF Were Determined During the Primary Screen.  
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and 3) knockdown did not reduce the mean FF value to below 75% of the mean FF 
value of siNT-transfected cells (FFsiX/FFsiNT ≥ 0.75). In contrast, genes were included as 
enhancers of C9ORF72 RAN translation if 1) NL/FFsiX ≥ µNT+3σNT in at least 2 of 3 
replicates; 2) NLsiX/NLsiNT ≥ 2.0; and 3) FFsiX/FFsiNT ≤ 1.25. 
Of 18,110 genes analyzed this algorithm identified 1,624 (8.97%) suppressors 
and 119 (6.57%) enhancers of C9ORF72 RAN translation (Figure 3.3A; Figure B.1; 
Table B.1; Table B.2; Table B.3; Table B.4). To increase our confidence that this set 
represents replicable, RAN-specific modifiers of translation, we performed both a 
validation screen using the same GA70 NL-3xF reporter as well as a counter screen 
using an AUG-initiated NL-3xF reporter with a short, unstructured 5’ UTR (AUG-NL-
3xF), which we have previously used as a reporter for general translation150,169. 
 In the C9ORF72 validation screen, we transfected cells with GA70 NL-3xF and 
AUG-FF reporter plasmids, as well as siRNAs targeting each primary hit. Hit criteria 
were slightly less stringent: NL/FF-suppressing siRNAs were included if NLsiX/NLsiNT ≤ 
0.75, and NL/FF-enhancing siRNAs were included if NLsiX/NLsiNT ≥ 1.5. All other criteria 
remained identical. Primary hits validated at a high rate (74.99% total), with 1,228 (6.8% 
of the whole genome) of suppressors and 79 (0.44% of the whole genome) of 
enhancers replicating as hits (Figure B.2, top panel). Primary and validation GA70 NL 
values for each gene were significantly correlated (Figure B.3A), demonstrating the high 
replicability of our assay. In addition, we find it noteworthy that this validation screen 
chiefly served to eliminate those primary hits that affected AUG-FF expression. siRNAs 
that failed to validate exhibited NL/FF ratios closer to that of siNT-transfected cells in the 




















Figure 3.3: Serial Screens Identify RAN-Specific Modifiers of C9ORF72 and FMR1 RAN 
Translation. 
A, B To-scale illustration of the numbers of genes identified as selective suppressors and 
enhancers of GA70 NL-3xF (A) and +1 (CGG)100 NL-3xF (B) following the primary and subsequent 
validation, AUG-counter, and cross-reporter validation screens, as well as the off-target filter.  
–––––––––––––––––––––––––––––––– 
C). 
In the AUG counter screen, we transfected cells with AUG-NL-3xF and AUG-FF 
plasmids, as well as siRNAs against all primary hits. C9ORF72 suppressors that also 
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suppressed AUG-NL-3xF (NLsiX/NLsiNT ≤ 0.80) and C9ORF72 enhancers that also 
enhanced AUG-NL-3xF (NLsiX/NLsiNT ≥ 1.2) were eliminated, leaving 739 (4.1% of the 
whole genome) suppressors and 14 (0.08% of the whole genome) enhancers (Figure 
B.2, middle panel). This attrition indicates that despite filtering our primary screen data 
using AUG-FF, numerous modifiers of general gene expression had escaped 
elimination. Finally, we tested each validated, RAN-specific C9ORF72 modifier with a 
reporter for RAN translation at expanded CGG repeats in the FMR1 5’ UTR: +1 
(CGG)100 NL-3xF. GA70 NL values and +1 (CGG)100 NL values were significantly 
correlated (Figure B.4A, left panel), even after we eliminated siRNAs that modified 
AUG-NL-3xF expression (Figure B.4B). Through cross-validation with the FMR1 RAN 
reporter, we identified 254 RAN translation-specific suppressors of both C9ORF72 and 
FMR1 and 3 enhancers. In brief, this set comprised genes which, following knockdown, 
reliably modified the expression of two different RAN products of two different NREs in 
two different sequence contexts. 
In reviewing the outcomes of the C9ORF72 validation and AUG counter screens, 
we noted that the frequency of validated C9ORF72 modifiers that also validated for 
FMR1 would have been higher had non-specific modulators not been eliminated from 
the datasets by the AUG counter screen. The strongest suppressors of both C9ORF72 
and FMR1 reporters also suppressed AUG-NL-3xF, resulting in their elimination (Figure 
B.4A, left panel), and the correlation between relative GA70 NL-3xF expression and 
relative AUG-NL-3xF expression among all C9ORF72-validated siRNAs, including those 
the counter screen would eliminate, was significant (Figure B.4A, right panel). Our 
screen design nevertheless permitted identification of siRNAs that modified both 
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C9ORF72 and FMR1 reporters without affecting AUG-NL-3xF; there remained a 
significant correlation between GA70 NL and +1 CGG100 NL expression for each siRNA, 
even after elimination of siRNAs that impacted AUG-NL expression (Figure B.4B). This 
perspective supports our decision to construct and conduct these screens in the manner 
we did. 
 
Analogous Screens Identify Modifiers of FMR1 RAN Translation 
In parallel, we conducted a series of screens to identify specific modifiers of 
FMR1 RAN translation. For these we replaced the GA70 NL-3xF reporter of the 
C9ORF72 screens with +1 (CGG)100 NL-3xF, translation of which yields the polyglycine 
RAN product FMRpolyG150. In the primary FMR1 screen we screened only the Drug 
Target and Druggable Genome subsets of the siGENOME siRNA library (Dharmacon). 
These enrich for identified and characterized targets of pharmacologic agents as well as 
kinases, phosphatases, proteases, ion channels, and others which are potentially 
amenable to pharmacological inhibition. FMR1 screens followed the same high-
throughput format, hit-detection algorithm, and validation/counter-screen design 
described above for C9ORF72 screens (Figure 3.2). 
Of 7,811 siRNAs tested, we identified 359 (4.60%) primary suppressors and 26 
(0.33%) primary enhancers of FMR1 RAN translation (Figure 3.3B; Figure B.5; Table 
B.5; Table B.6; Table B.7). In the subsequent validation screen 216 (2.77% of the 
primary siRNA library) suppressors and 20 (0.26%) enhancers validated (Figure B.6). 
Of these, 100 (1.28% of the siRNA library) suppressors and 0 enhancers remained 
following the AUG counter screen. Finally, 88 (1.13%) so-validated FMR1-suppressing 
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siRNAs cross-validated against the GA70 NL-3xF reporter. While this number is lower 
than the number of validated, AUG-cleared C9ORF72 modifiers, it actually represents a 
larger fraction of the primary +1 (CGG)100 NL-3xF suppressors (88/359, 24.51%) than 
does the fraction of primary GA70 suppressors that validated, cleared the AUG counter 
screen, and cross-validated against +1 (CGG)100 NL-3xF (286/1,624, 17.61%). As in the 
C9ORF72-modifier set, primary and validation +1 (CGG)100 NL values were significantly 
correlated (data not shown). 
 
There is Significant Overlap Between C9ORF72 and FMR1 RAN-Translation Modifiers 
 The frequency of siRNAs that dual-validated for C9ORF72 and FMR1 hint that 
there is significant overlap in the biological pathways that regulate RAN translation at 
these loci. Comparison of the primary C9ORF72 and FMR1 modifiers revealed that 198 
of the C9ORF72 (198/647, 28.6%) and FMR1 hits (198/359, 51.4%) in the Drug-Target 
and Druggable-Genome library either suppressed or enhanced both RAN translation 
reporters (Figure 3.4A, B). Overlap was reduced following validation and AUG counter 
screens [to 58 of the C9ORF72 (58/380, 15.1%) and FMR1 hits (58/100, 58%)], but 
remained significant (Figure 3.4C, D). With analysis restrained to the Drug-
Target/Druggable-Genome C9ORF72 primary hits, siRNAs that likewise modified FMR1 
validated against GA70 NL-3xF and cleared the AUG counter screen with significantly 
less frequency than siRNAs that did not modify FMR1 (Figure 3.4E). In contrast, among 
primary FMR1 modifiers, siRNAs that likewise modified C9ORF72 validated against +1 
(CGG)100 NL-3xF with significantly more frequency than siRNAs that did not modify 





Figure 3.4: Identification of a Subset of Genes that Modifies Both C9ORF72 and FMR1 RAN 
Translation.  
A To-scale illustration of the number of siRNAs identified in the primary screens for C9ORF72 
and FMR1 modifiers, including common hits (c2 test). 
B Scatterplot of Log2 NL/FF ratios by siRNA across the C9ORF72 vs. FMR1 primary screens 
of the Drug-Target/Druggable Genome siRNA library. siRNAs have been categorized based on 
identification as a hit in either/both primary screens. 
C To-scale illustration of the number of siRNAs identified in the primary screens for C9ORF72 
and FMR1 modifiers that validated and were RAN-specific, including common hits (c2 test). 
D Scatterplot of Log2 NL/FF ratios by siRNA across the C9ORF72 vs. FMR1 primary screens 
of the Drug-Target/Druggable Genome siRNA libraries, categorized based on identification as a hit 
following primary, validation, and AUG counter screens. 
E Percentage of primary C9ORF72 (left panel) and FMR1 (right panel) hits that validated and 
cleared the AUG counter screen, based on whether siRNAs modified both C9ORF72 and FMR1 or 
either alone (c2 test; * P≤0.05, *** P≤0.001). 
–––––––––––––––––––––––––––––––– 
suppressors of C9ORF72 and FMR1 (data not shown). This suggests that our 
C9ORF72 primary screen was more selective for RAN-specific modifiers than was our 
FMR1 primary screen. 
 
Eliminating Genes with Low Expression in HEK293 Cells Reduces False Positives Due 
to Off-Target Effects of siRNAs 
Given the high expected frequency of false positives in all siRNA screens due to 
off-target effects284-286, we conducted a pilot experiment to estimate this frequency in 
our sets of candidate RAN modifiers. Of 156 independent-library (Dharmacon ON-
TARGETplus) siRNA pools targeting our siGENOME-validated modifiers of C9ORF72 
and/or FMR1, only 100 (64%) cleared an AUG counter screen, of which only 30 (19%) 
had the same effects as siGENOME siRNAs on GA70 NL-3xF or +1 (CGG)100 NL-3xF 
(Table 3.1). The 156 genes so tested included 41 dual-primary and dual-validated RAN 
modifiers, which validated at approximately the same frequency (8/41, 20%) as the 


























Table 3.1: Validation of RAN-Translation Modifiers Using the ON-TARGETplus siRNA Library.  
Data Information: * All percentages reflect fractions of the indicated candidate set that were 
submitted to ON-TARGETplus testing. ** These candidates were independently identified during 
both primary screens and subsequently validated against both GA70 and FMRpolyG100 reporters 
using siGENOME siRNAs. 
–––––––––––––––––––––––––––––––– 
frequency: 1) off-target effects in the original, siGENOME library generated false 
positives against C9ORF72-/FMR1-RAN expression in the primary and validation 
screens; 2) ON-TARGETplus siRNAs are less efficacious, generating false negatives 
against C9ORF72/FMR1 reporters in this pilot experiment; or 3) off-target effects or 
greater efficacy of knockdown in the second, ON-TARGETplus library impacted AUG-
NL-3xF expression, leading to erroneous elimination of true positives. We favor the first 
explanation, since more candidates failed to validate against the C9ORF72-/FMR1-RAN 
reporters than were eliminated in the ON-TARGETplus AUG-counter screen, and we 
(admittedly anecdotally) have not observed failure of siRNA-mediated knockdown with 
the ON-TARGETplus library in other experiments. 
We therefore sought to reduce the frequency of false positives by identifying and 
eliminating those genes that are unexpressed or minimally expressed in HEK293 
cells—if gene X is not expressed in HEK293 cells, any effects of anti-X siRNAs likely 
reflect off-target interaction(s)287. We therefore selected 4 publicly available RNA 
sequencing (RNA-Seq) libraries collected from HEK293 cells with minimal genetic or 
pharmacological manipulation—essentially, control sets for their respective 
experiments288-291. Each set exhibited a multimodal distribution of mRNA expression 
across genes [transcripts per million (TPM)], with one mode near 0 TPM, corresponding 
to no or minimal expression. Within each set, we identified the TPM value at the inter-






Table 3.2: RNA Sequencing (RNA-Seq) Libraries Used to Construct the Off-Target Filter. 
–––––––––––––––––––––––––––––––– 
method eliminated 31-53% of genes of each individual RNA-Seq set (Table 3.2). We 
then compared the four RNA-Seq libraries (Table B.8), and those genes which were 
beneath threshold in ≥3 libraries were eliminated from our sets of C9ORF72 (163/739 
removed, 23%) and FMR1 RAN-translation modifiers (25/100 removed, 25%), as 
delineated in Table 3.3. As crude proof of concept, application of this filter to the list of 
156 candidates tested using ON-TARGETplus siRNAs resulted in preferential filtration 
of candidates that failed to validate: whereas 33/126 (26%) of those candidates that 
failed ON-TARGETplus validation were eliminated by this off-target filter, significantly 
fewer—only 3/30 (10%)—of candidates that successfully validated were eliminated 
(Table 3.3). Our pilot results imply that this filter reduced the number of false positives 
due to off-target siRNA-mediated knockdown, thus further refining our list of modifiers of 
C9ORF72, FMR1, or both (Table B.9; Table B.10; Table B.11; Table B.12; Table B.13). 
 
Gene Ontology Analysis Reveals Biological Processes That Modulate RAN Product 
Abundance 
–––––––––––––––––––––––––––––––– 
Table 3.3: Off-Target Filtration of Candidate Modifiers by Modifier Class.  
Data Information: * All submitted genes in this column passed the ON-TARGETplus AUG-counter 
screen and validated against either C9ORF72 or FMR1. ** These candidates were independently 
identified during both primary screens and subsequently validated against both GA70 and 


























Next, we sought to identify biological pathways and molecular functions common 
to modifiers of RAN translation of C9ORF72, FMR1, or both using gene ontology (GO) 
analysis. The 585 genes remaining after off-target filtration were analyzed using Advaita 
Bio’s iPathwayGuide in collaboration with the Bioinformatics Core at the University of 
Michigan. This software analysis tool implements the Impact Analysis approach that 
takes into consideration the direction and type of all signals on a pathway, as well as the 
position, role, and type of every gene292-295. This analysis identified biological processes 
and molecular functions enriched among suppressors of C9ORF72 (Figure B.7A, B) 
and FMR1 (Figure B.8A, B) RAN translation. Among C9ORF72 RAN suppressors, GO 
terms of notable interest included proteasome-mediated protein degradation (“SCF-
dependent proteasomal ubiquitin-dependent protein catabolic process,” P=4.60E-5; and 
“Proteasome-activating ATPase activity,” P=1.26E-2), NFkB/TNF signaling (“NIK/NF-kB 
signaling,” P=1.50E-4; and “TNF-mediated signaling pathway,” P=5.80E-4), “mRNA 
methyltransferase” (P=1.73E-2), “C-terminal protein methylation” (P=8.9E.4), “Golgi-to-
lysosome transport” (P=1.32E-3), and “Positive regulation of canonical Wnt signaling 
pathway” (P=3.60E-4). In parallel, GO terms of interest among FMR1 RAN suppressors 
included “IRES-dependent viral translational initiation” (P=8.5E-4) and “Chaperone-
binding” (P=7.50E-3). Each of these terms has been linked to either neurodegeneration 
in general, autosomal dominantly inherited variants of ALS296, non-canonical modes of 
mRNA translation initiation, or functions of known modifiers of RAN translation (see 
Discussion). 
To our surprise, despite the significant overlap between our sets of C9ORF72 
and FMR1 RAN translation modifiers (Figure 3.4C, D), the 10 most statistically 
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significant GO terms for each set were typically not enriched in the other. Among 
biological processes only “IRES-dependent viral translational initiation” and “Vagina 
development” were common to both sets; among molecular functions only “ATP-
binding” and “Protein serine/threonine kinase activity” were common to both sets. This 
distinction might be attributed to “true” biological deviation in mechanism, differences in 
NL-3xF reporter design (the FMR1 reporter had a PEST tag to optimize its linear range, 
whereas the C9ORF72 reporter did not), or the difference in genes screened.  
 
Depletion of hnRNPA2/B1 Suppresses C9ORF72 and FMR1 RAN Reporters 
hnRNPA2/B1 is an RNA-binding protein that, in humans and mice, regulates pre-
mRNA splicing and polyadenylation190,297,298. In addition, hnRNPA2/B1 is linked to 
neurological disease: the D290V mutation is associated with multisystem proteinopathy 
(related to ALS/FTD)140, hnRNPA2/B1 binds expanded CGG repeats in FMR1137-139 and 
recombinant GR50 and PR50195, and overexpression of human HNRNPA2B1 or its 
Drosophila orthologs suppresses (CGG)n toxicity in flies141. Therefore, we were intrigued 
to find that knockdown of HNRNPA2B1 suppressed the expression of both C9ORF72 
and FMR1 RAN products in our screens. In follow-up luciferase assays and western 
blots, HNRNPA2B1 knockdown using individual and pooled siRNAs significantly and 
selectively reduced the expression of +1 (CGG)100 NL-3xF and GA70 NL-3xF in HEK293 
cells (Figure 3.5A, B). In contrast, AUG-NL-3xF was not suppressed by HNRNPA2B1 
knockdown. In the inverse experiment, overexpression of HNRNPA2B1 in HeLa cells 
had the opposite effects, selectively enhancing the expression of +1 (CGG)100 NL-3xF 























Figure 3.5: Knockdown of HNRNPA2B1 Selectively Inhibits RAN Translation of G4C2-
Expanded C9ORF72 and CGG-Expanded FMR1, Part 1.  
A, B Expression of transfected, plasmid-based NL-3xF reporters by luminescence assay (A) and 
western blot (B) in HEK293 cells following transfection of siNT or pooled and individual siRNAs 
against HNRNPA2B1 (two-way ANOVA with Tukey’s multiple comparisons test; n=6/condition). 
Black asterisks indicate comparisons between siNT- and siHNRNPA2B1-transfected cells 
expressing the same reporter; colored asterisks indicate comparisons between siHNRNPA2B1-
transfected cells expressing AUG-NL-3xF and those expressing either GA70 NL-3xF or +1 (CGG)100 
NL-3xF.  
C Expression of transfected, plasmid-based NL-3xF reporters by luminescence assay in HeLa 
cells following overexpression of HNRNPA2B1 or empty vector (two-way ANOVA with Tukey’s 
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multiple comparisons test; n=9/condition). Black asterisks indicate comparisons between empty 
vector- and HNRNPA2B1-transfected cells expressing the same reporter; green asterisks indicate 
comparisons between HNRNPA2B1-transfected cells expressing AUG-NL-3xF and those expressing 
either GA70 NL-3xF or +1 (CGG)100 NL-3xF. 
 
Data Information: All panels depict data as mean ± SD (compiled from ≥2 replicates). ** P≤0.01, *** 
P≤0.001, **** P≤0.0001. 
–––––––––––––––––––––––––––––––– 
expression of the C9ORF72 glycine-proline (GP70 NL-3xF) and glycine-arginine (GR70 
NL-3xF) DPR RAN products, as well as the FMR1 alanine RAN product [+2 (CGG)100 
NL-3xF] (Figure 3.6A), demonstrating that the effects of HNRNPA2B1 knockdown are 
not limited to single reading frames and suggesting that our use of single-reading-frame 
RAN reporter constructs does not hinder extrapolation of our results to other reading 
frames. Finally, the effects of HNRNPA2B1 knockdown on +1 (CGG)n NL-3xF and GAn 
NL-3xF reporters were repeat-dependent, whereas the effects of knockdown on +2 
(CGG)n NL-3xF reporters were not (Figure 3.6B-D). The reason for this discrepancy is 
unclear, but it might represent differences in the site of translation initiation relative to 
the NRE19,150. In total, our results suggest that hnRNPA2/B1 is a specific regulator of 
RAN-product expression. 
We next asked whether hnRNPA2/B1 acts peri-transcriptionally or peri-
translationally, since hnRNPA2/B1 has described functions in both pre-mRNA 
processing190 and translational regulation299-302. We first replaced our plasmid-based 
reporters with in vitro-transcribed RNA reporters for RAN translation. To our surprise, 
HNRNPA2B1 knockdown significantly increased the expression of both GA70 NL-3xF 
and +1 (CGG)100 NL-3xF RNA reporters (Figure 3.6E) without impacting the expression 
of AUG-FF RNA reporters. We next asked whether HNRNPA2B1 knockdown impacted 
the abundance of mRNAs transcribed from GA70 NL-3xF or +1 (CGG)100 NL-3xF  
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Figure 3.6: Knockdown of HNRNPA2B1 Selectively Inhibits RAN Translation of G4C2-
Expanded C9ORF72 and CGG-Expanded FMR1, Part 2.  
A Expression of transfected, plasmid-based AUG-NL-3xF and multiple RAN reporters with 
varied sequence contexts and reading frames. Following transfection of siNT or pooled siRNAs 
against HNRNPA2B1, expression was quantified by luminescence assay in HEK293 cells (two-way 
ANOVA with Tukey’s multiple comparisons test; n=6/condition). Black asterisks indicate 
comparisons between siNT- and siHNRNPA2B1-transfected cells expressing the same reporter; 
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green asterisks indicate comparisons between siHNRNPA2B1-transfected cells expressing AUG-
NL-3xF and those expressing another NL-3xF reporter.  
B-D Expression of transfected, plasmid based +1 (CGG)n NL-3xF (B), +2 (CGG)n NL-3xF (C), 
and (GA)n NL-3xF (D) reporters in HEK293 cells with a range of repeat sizes following HNRNPA2B1 
knockdown (two-way ANOVA with Tukey’s multiple comparisons test; n=3-9/condition). 
E Expression of transfected, RNA-based NL-3xF reporters by luminescence assay in HEK293 
cells following HNRNPA1B1 knockdown (two-way ANOVA with Sidak’s multiple comparisons test; 
n=5-6/condition). 
F Abundance of NL-3xF reporter mRNAs by qRT-PCR following HNRNPA2B1 knockdown 
(two-way ANOVA with Sidak’s multiple comparisons test; n=5-6/condition). 
 
Data Information: All panels depict data as mean ± SD (compiled from ≥2 replicates). * P≤0.05, ** 
P≤0.01, *** P≤0.001, **** P≤0.0001. 
–––––––––––––––––––––––––––––––– 
plasmids. Again bucking our expectations, qRT-PCR revealed that HNRNPA2B1 
knockdown significantly increased the abundance of AUG-NL-3xF and +1 (CGG)100 NL-
3xF mRNAs and slightly increased (non-significantly) GA70 NL-3xF mRNA abundance 
(Figure 3.6F). This increase in mRNA abundance, coupled with the lower abundance of 
plasmid-encoded RAN products following HNRNPA2B1 knockdown, implied that 
hnRNPA2/B1 depletion was preventing RAN-competent mRNAs (when transcribed in the 
nucleus) from engaging the translational machinery. To assess whether HNRNPA2B1 
knockdown alters the cellular distribution of RAN-competent mRNAs, we performed 
hybridization chain reaction (HCR) to fluorescently label and localize +1 (CGG)100 NL-
3xF mRNAs in HEK293 cells, with and without HNRNPA2B1 knockdown. This revealed 
that +1 (CGG)100 NL-3xF mRNAs cluster throughout both the nucleus and cytoplasm 
(Figure 3.7). Following HNRNPA2B1 knockdown, +1 (CGG)100 NL-3xF mRNA signal 
increased in both cellular compartments, consistent with the increased abundance of 
these mRNAs we observed by qRT-PCR. But we observed no gross difference in the 
distribution of these mRNAs following knockdown. Therefore, the relationship between 













Figure 3.7: Knockdown of HNRNPA2B1 Does Not Change the Subcellular Localization of +1 
(CGG)100 NL-3xF mRNA. 
Hybridization chain reaction (HCR) against +1 (CGG)100 NL-3xF mRNA and immunocytochemistry 
(ICC) against hnRNPA2B1 protein following knockdown of HNRNPA2B1 in HEK293 cells. Scale bar 
= 50 µm. 
–––––––––––––––––––––––––––––––– 
depletion suppresses RAN translation of these reporters, remains unclear. 
 
hnRNPA2/B1 and its Drosophila Homologs Modulate NRE-elicited toxicity, but Not Via 
RAN Translation 
 In parallel, we investigated the effects of modulating expression of HNRNPA2B1 
and its homologs in Drosophila on NRE-induced toxicity. Sofola et al.139 demonstrated 
that overexpression of human HNRNPA2B1 or its fly homologs HRB87F and HRB98DE 
mitigated the toxicity of expanded CGG repeats in FMR1, while knockdown of HRB87F 
or HRB98DE potentiated toxicity. We replicated these results using flies that expressed 










Figure 3.8: Modulation of HNRNPA2B1 and its Homologs Bidirectionally Modifies (CGG)90 
Toxicity in Drosophila. 
A Quantification of rough-eye phenotypes in flies expressing +1 (CGG)90-EGFP under the 
GMR-GAL4 driver, along with various disruptions of HNRNPA2B1’s fly homologs (one-way ANOVA 
with Dunnett’s multiple comparisons test; n=20-47/genotype). 
B Quantification of rough-eye phenotypes in flies expressing various disruptions of 
HNRNPA2B1’s fly homologs under the GMR-GAL4 driver alone. 
 
Data Information: Data are presented as mean ± SD (compiled from ≥3 replicates). **** P≤0.0001.  
–––––––––––––––––––––––––––––––– 
HNRNPA2B1 or HRB87F nor knockdown of HRB87F or HRB98DE affected eye 
phenotype in flies carrying the GMR-GAL4 driver alone (Figure 3.8B). Given the 
possibility that HNRNPA2B1 modulates expression of RAN products, we next asked 
whether these genetic disruptions modulated expression of the FMRpolyG-EGFP RAN 
product in +1 (CGG)90-EGFP-expressing flies. Western blotting revealed, however, that 
neither overexpression nor knockdown of HNRNPA2B1, HRB87F, and HRB98DE had 
consistent effects on FMRpolyG-EGFP (Figure 3.9A, B; Figure 3.10A, B). These data 
–––––––––––––––––––––––––––––––– 
Figure 3.9: Modulation of HNRNPA2B1 and Its Homologs Has Inconsistent Effects on 
FMRpolyG Expression in Drosophila, Part 1. 
A-B Western blots of the FMRpolyG-EGFP RAN product and tubulin in flies expressing +1 
(CGG)90-EGFP and either shRNAs against firefly luciferase (shFF) or UAS-driven HRB87F (A) or 
UAS-driven human HNRNPA2B1 (B) under the inducible Tub5-GS driver, with quantification. 
Colored asterisks above westerns indicate which samples were loaded at ½ and ¼ volume to 
determine the linear range suitable for quantification (Student’s t test; n=4-6 bands/genotype).  
 




















































Figure 3.10: Modulation of HNRNPA2B1 and Its Homologs Has Inconsistent Effects on 
FMRpolyG Expression in Drosophila, Part 2. 
A-B Western blots of the FMRpolyG-EGFP RAN product and tubulin in flies expressing +1 
(CGG)90 EGFP and either shFF or shRNAs against HRB87F (A) or against HRB98DE (B) under the 
inducible Tub5-GS driver, with quantification. Colored asterisks above westerns indicate which 
samples were loaded at ½ and ¼ volume to determine the linear range suitable for quantification 
(Student’s t test; n=6 bands/genotype).  
 
Data Information: Data are presented as mean ± SD. ns=non-significant, * P≤0.05. 
–––––––––––––––––––––––––––––––– 
suggest that HNRNPA2B1 and its fly homologs modulate the toxicity of CGG repeats 
via a different mechanism than RAN translation. 
 In an attempt to resolve the discrepancies between our Drosophila and HEK293 
findings, we utilized an ELISA to detect the endogenous GP RAN product in a C9 ALS 
patient-derived iPSC line163 following HNRNPA2B1 knockdown (Figure 3.11A). As 
expected, GP was more abundant in C9 iPSCs compared to a control line. However, we 
could detect no difference in GP abundance following hnRNPA2/B1 depletion (Figure 
3.11B). 
 
Depletion of PSMB5 Suppresses C9ORF72 and FMR1 RAN Reporters 
Our screens identified multiple subunits of the proteasome, knockdown of which 
suppressed expression of C9ORF72 reporters (Figure B.9, Table B.3, Table B.4, Table 
B.7). Among these was the proteolytic subunit PSMB5. In parallel, other investigators 
have discovered that a polymorphism in PSMB5 that decreases its expression was 
protective against FXTAS in individuals carrying FMR1 CGG repeats in the premutation 
range (P. Jin, personal communication). To confirm the effects of PSMB5 knockdown 
we observed in our screen, we first tested an independent pool of anti-PSMB5 siRNAs 


















Figure 3.11: Knockdown of HNRNPA2B1 in C9 iPSCs Does Not Affect GP Expression. 
A Anti-hnRNPA2/B1 and anti-tubulin western blots of lysates of iPSCs derived from a C9 ALS 
patient. iPSCs were transfected with siNT or siRNAs against HNRNPA2B1. 
B Abundance of the GP RAN product by ELISA in C9 ALS iPSCs or controls, following 
transfection of siNT or siRNAs against HNRNPA2B1 (Student’s t test; n=5/condition). Abundance of 
the GP RAN product in a control iPSC line is shown for comparison.  
 
Data Information: Data are presented as mean ± SD (compiled from 3 replicates). ns=non-
significant. 
–––––––––––––––––––––––––––––––– 
In our initial studies with this independent siRNA pool, its transfection led to widespread 
loss of cell viability and a global reduction in reporter expression (Figure 3.12A). To 
reconcile these results, we tested the effects of the individual ON-TARGETplus siRNAs 
on AUG-NL-3xF, +1 (CGG)100 NL-3xF, and GA70 NL-3xF (Figure 3.12B) while 
monitoring PSMB5 knockdown by western blot (Figure 3.12C). Transfection of siPSMB5 



























Figure 3.12: PSMB5 Knockdown with Pooled and Individual siRNAs Have Differential Effects 
on Expression of C9ORF72 RAN Products, FMR1 RAN Products, and PSMB5. 
A, B Expression of transfected, plasmid-based NL-3xF reporters by luminescence assay in 
HEK293 cells following transfection of siNT and pooled (A) or individual (B) siRNAs against PSMB5 
(siPSMB5). 
C Anti-FLAG, anti-PSMB5, and anti-tubulin western blot of lysates from HEK293 cells 
transfected with siRNAs against PSMB5 and either +1 (CGG)100 or GA70 NL-3xF. 
 
Data Information: In all panels data are presented as mean ± SD (compiled from ≥2 replicates). 
–––––––––––––––––––––––––––––––– 
the loss of cell viability and global reduction in reporter expression, but also did not 
reduce PSMB5 expression; #3 specifically inhibited expression of +1 (CGG)100 NL-3xF 
and GA70 NL-3xF while slightly reducing PSMB5 expression; and #4, which exhibited 
the strongest PSMB5 knockdown, manifested in a global reduction in reporter 
expression but with more pronounced effects on +1 (CGG)100 NL-3xF and GA70 NL-3xF. 
The effects of siPSMB5 #3 and #4, therefore, are most consistent with our screen 
results. The RAN-selective nature of their effects are best illustrated following 
normalization of +1 (CGG)100 NL-3xF and GA70 NL-3xF expression to either total protein 
loaded (western blot; Figure 3.12C) or expression of a co-transfected AUG-FF reporter 
(luminescence assay; Figure 3.13A): their effects persit.  
We next tested whether the effects of siPSMB5 #3 and #4 on C9ORF72 and 
FMR1 RAN translation were frame- or repeat-dependent. Transfection with siPSMB5 #3 
reduced the expression of expanded-repeat FMR1 [+1 and +2 (CGG)100 NL-3xF] and 
C9ORF72 constructs (GA70, GP70, and GR70 NL-3xF), but had no effect on AUG-NL-
3xF, +1 CGG0 NL-3xF, or GA3 NL-3xF (Figure 3.13B). In addition, the effects of 
siPSMB5 #4 were significantly stronger on +1 and +2 (CGG)100 NL-3xF and GA70, GP70, 
and GR70 NL-3xF than AUG-NL-3xF, but AUG-NL-3xF, +1 CGG0 NL-3xF, and GA3 NL-


























Figure 3.13: Knockdown of PSMB5 Selectively Suppresses Expression of C9ORF72 and 
FMR1 RAN Products at Expanded Repeat Sizes. 
A Expression of +1 (CGG)100 or GA70 NL-3xF, normalized to a co-transfected AUG-FF reporter, 
in HEK293 cells transfected with siNT or siPSMB5. Colored asterisks indicate comparisons between 
siPSMB5-transfected cells expressing AUG-NL-3xF and those expressing a different NL-3xF 
reporter. 
B, C Expression of NL-3xF reporters in HEK293 cells following transfection with siNT or siPSMB5 
(two-way ANOVA with Sidak’s multiple comparisons test; n=6/condition). Black asterisks indicate 
comparisons between siNT- and siPSB5-transfected cells expressing the same reporter. 
 
Data Information: In all panels data are presented as mean ± SD (compiled from ≥2 replicates). **** 
P≤0.0001. 
–––––––––––––––––––––––––––––––– 
that depletion of PSMB5 results in a repeat-dependent inhibition of RAN-product 
expression regardless of frame, repeat, or sequence context. 
 Previous studies have suggested that FMRpolyG is degraded by the proteasome 
in Drosophila and HeLa cells19,147. If so, one would expect that depletion of PSMB5, a 
key proteasome component, would lead to higher, not lower, abundance of RAN 
products. We observed the opposite. To investigate this discrepancy, we tested whether 
pharmacological inhibition of the proteasome with the PSMB5-targeting proteasome 
inhibitor bortezomib303,304 has the same effect as siRNAs on RAN product abundance. 
In HEK293 cells transfected with +1 (CGG)100 NL-3xF reporter plasmids 24 hours prior, 
treatment with 100 nM bortezomib resulted in higher reporter expression relative to a 
vehicle control. We did not observe the same effect on an AUG-NL-3xF reporter (Figure 
3.14A, B). These results are consistent with the field’s general consensus, suggesting 
that FMRpolyG is degraded by the proteasome. We next asked whether proteasome 
impairment might affect the rate of FMRpolyG synthesis in addition to its degradation. 
To test this, we treated cells with 100 nM bortezomib, transfected plasmid-based 
reporters, then monitored reporter expression at multiple time points afterwards. The 
rate of neither AUG-NL-3xF nor +1 (CGG)100 NL-3xF synthesis varied significantly 
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Figure 3.14: Inhibition of PSMB5 by Bortezomib Increases the Expression of FMRpolyG 
Reporters. 
A Expression of AUG-NL-3xF (left) or +1 (CGG)100 NL-3xF (right) in the presence of 100 nM 
bortezomib or vehicle. Bortezomib was added 24 hours post-transfection (two-way ANOVA with 
Sidak’s multiple comparisons test; n=6/condition). Asterisks indicate comparisons between 
bortezomib- and vehicle-treated cells. 
B Expression of AUG-NL-3xF and +1 (CGG)100 NL-3xF with bortezomib normalized to vehicle. 
Asterisks indicate comparisons between cells expressing AUG-NL-3xF and those expressing +1 
(CGG)100 NL-3xF (two-way ANOVA with Sidak’s multiple comparisons test; n=6/condition). 
C Expression of AUG-NL-3xF and +1 (CGG)100 NL-3xF with bortezomib or vehicle, with 
bortezomib added 2 hr before reporter transfection. 
 
Data Information: In all panels data are presented as mean ± SD (compiled from ≥2 replicates). ** 
P≤0.01, *** P≤0.001, **** P≤0.0001. 
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following bortezomib administration over most of the experiment (Figure 3.14C). These 
results support the conclusion that knockdown of PSMB5 exerts its effects through 




 We conducted a high-throughput, non-biased screen of the full human genome to 
identify modifiers of RAN translation of G4C2-expanded C9ORF72. The five DPRs 
synthesized via C9ORF72 RAN translation are hypothesized to elicit toxicity through a 
variety of interactions with endogenous, physiological proteins and RNAs305,306. 
Previous screens for modifiers of (G4C2)n-elicited toxicity focused, by design, on these 
interactions171,172,180,181,195,280. In contrast, this screen targeted modifiers of DPR 
abundance directly. Furthermore, we have validated each candidate modifier using both 
C9ORF72 and FMR1 reporters, allowing us to delineate a set of candidates that 
modulate RAN translation across NREs and local sequence context. We sought to 
better understand the mechanism of RAN translation through recognition of the genetic 
factors and pathways that can inflect it. This knowledge might be applied to devise new, 
effective therapeutic interventions that target RAN translation, a proximal pathogenic 
event shared by the five DPRs. 
We so identified 585 RAN-selective modifiers of the GA DPR, the most abundant 
RAN product of G4C2-expanded C9ORF7216,17,168-170, and/or FMRpolyG, a RAN product 
of expanded (CGG)n in FMR1. We have already launched studies of two promising 
candidates, the RNA-binding protein hnRNPA2/B1 and the catalytic proteasomal subunit 
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PSMB5. In addition, by using GO analysis we have identified multiple biological 
pathways enriched among C9ORF72 and FMR1 RAN suppressors, hinting at future 
lines of research into the mechanism of RAN translation. 
 hnRNPA2/B1 is an RNA-binding protein that interacts with the FMR1 5’ UTR, 
likely through the UTR’s CGG repeats137-139. Overexpressing HNRNPA2B1 or its 
Drosophila homologs suppresses the toxicity of expanded CGG repeats, and the 
suppressing effects of both TARDBP and CUGBP1 overexpression on CGG repeats are 
mediated by hnRNPA2/B1139,141. Mutations in the LCD of HNRNPA2B1, though rare, 
have been linked to ALS/FTD140. Finally, there is some evidence to suggest that 
hnRNPA2/B1 can tune the translation of mRNAs bearing expanded CGG repeats307. 
Thus, there are multiple lines of evidence that situate hnRNPA2/B1 at the intersection of 
RNA metabolism and neurodegeneration. We demonstrated here that, in HEK293 cells, 
HNRNPA2B1 knockdown suppressed the expression of C9ORF72 and FMR1 RAN 
products regardless of frame and (generally) in a repeat size-dependent manner. 
However, in Drosophila, altering the expression of HNRNPA2B1 or its homologs did not 
consistently affect the abundance of the FMRpolyG-EGFP RAN product, despite bi-
directionally modulating the toxicity of (CGG)90 repeats. The cause of this discrepancy is 
unclear. Our Drosophila data not only contradict our findings in HEK293 cells, but also 
imply that changes in RAN translation do not underlie the phenotypic effects of 
HNRNPA2B1 modulation that we and others have observed139. A major concern here is 
the possibility that the effect of HNRNPA2B1 knockdown in HEK293 cells is an artifact 
of our transfected, plasmid-based reporters. This concern is compounded by our 
observation that knockdown of HNRNPA2B1 had no effect on the abundance of the GP 
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RAN product in expanded G4C2-expressing iPSCs. At least, this discrepancy should 
give pause to future investigators utilizing these tools—it points to the need for 
validation in model systems expressing RAN products in an endogenous context. 
Nevertheless, we were intrigued that, in HEK293 cells, HNRNPA2B1 knockdown 
also increased the abundance of +1 (CGG)100 reporter mRNAs, despite decreasing the 
abundance of proteins synthesized from these transcripts. This implies that hnRNPA2/B1 
might act at two distinct stages of gene expression—one impacting mRNA abundance, 
one impacting mRNA translation—in opposing directions. Alternatively, an 
overabundance of +1 (CGG)100 reporter mRNAs might overwhelm some peri-
translational rate-limiting step in RAN-product expression—more mRNAs leading 
directly to less protein. Based on our HCR results, nuclear export does not appear to be 
this limiting step. Given our concerns with heterologous expression in HEK293 cells, the 
effects of HNRNPA2B1 knockdown must first be validated in an alternate system, 
preferably one with physiological C9ORF72 expression. Still, we find it tempting to 
speculate that changes in the abundance or processing of (CGG)n or (G4C2)n-containing 
mRNAs might underlie the phenotypic rescue we observed in Drosophila.  
 PSMB5 is a catalytic subunit of the proteasome, possessing “chymotrypsin-like” 
activity308. Previous work has demonstrated that C9ORF72 and FMR1 RAN products 
interact with and are regulated by the proteasome19,147,167,178,179,309,310. We were 
therefore surprised to find that knockdown of PSMB5 and other proteasomal subunits 
suppressed GA70 NL-3xF expression in our screen. The mechanism of this effect is 
unclear, but it might involve substitution of PSMB5 with PSMB8, a closely related 
component of the immunoproteasome with higher catalytic efficiency311-316. This would 
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explain why PSMB5 knockdown suppressed GA70 and +1 (CGG)100 NL-3xF while 
bortezomib, a PSMB5-binding proteasome inhibitor, enhanced +1 (CGG)100 NL-3xF 
expression: bortezomib inhibits both PSMB5 and PSMB8304,317-320. 
The effects of PSMB5 knockdown on AUG-, +1 (CGG)100-, and GA70 NL-3xF 
expression were siRNA-dependent: though several siRNAs suppressed C9ORF72 and 
FMR1 RAN reporters, two (#2 and #4) also had effects on AUG-NL-3xF (though the 
effects of siPSMB5 #4 were significantly stronger on +1 (CGG)100 and GA70 NL-3xF). 
We had not observed any effects of PSMB5 knockdown on AUG-NL-3xF in our screen, 
in which we used a different siRNA library. The effects of siPSMB5 #4 on AUG-NL-3xF 
might be explained by its stronger depletion of PSMB5 relative to the others. In contrast, 
siPSMB5 #2 exhibited the strongest effect on global reporter expression by luciferase 
assay, most likely as a side-effect of loss of cell viability, while having no effect on the 
abundance of mature or immature PSMB5 levels. This exemplifies a common issue with 
siRNA screens: how to eliminate off-target effects of siRNAs without introducing new 
ones284-286. In the ideal scenario, investigators can validate hits using a second, 
independent siRNA library. Acquiring additional siRNAs on a large scale can prove 
financially prohibitive, however, depending on institutional resources and the number of 
hits to be validated. Furthermore, as happened here, these new siRNAs can introduce 
their own unanticipated effects, whether based on off-target recognition or differences in 
the efficiency of knockdown. 
Besides HNRNPA2B1 and PSMB5, 583 genes—candidate modifiers of either 
C9ORF72, FMR1, or both—remain. We based our dual C9ORF72 and FMR1 screen 
design on the conjecture that RAN translation might differ mechanistically based on the 
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sequences of NREs and surrounding contexts169, as NRE-adjacent sequences often 
harbor stop codons and near-AUG initiation sites150,169,170, and RNA-binding proteins 
with high consensus-sequence specificity (MBNL, for example23) might affect RAN 
translation in a transcript-specific manner. As our screens identified 372 modifiers 
specific to either C9ORF72 (362) or FMR1 (10), this work provides some support for 
this hypothesis. The disparity between the number of C9ORF72-specific and FMR1-
specific modifiers is intriguing, however. It can be attributed somewhat to the size of the 
siRNA libraries screened: 1,052/1,742 (60.4%) of C9ORF72 primary modifiers were not 
tested in the FMR1 primary screen because they were not included in the Drug-
Target/Druggable siRNA library. However, assuming 1) equal hit frequency between 
C9ORF72 and FMR1 primary screens and 2) similar distribution of hits between Drug-
Target/Druggable and whole-genome libraries, we would have expected to identify 
~60% fewer FMR1-specific than C9ORF72-specific modifiers, not 97% (352/362) fewer. 
One of these assumptions must be wrong. We can offer no explanation why FMR1 
modifiers are less likely to be receptors, kinases, phosphatases, proteases, or ion 
channels than C9ORF72 modifiers are. But slight variations in the structures of 
C9ORF72 and FMR1 reporter could generate different hit frequency. In order to 
maintain expression of the FMR1 reporter within the linear range of the luminescence 
assay, we tagged this reporter with a C-terminal PEST tag, which decreases reporter 
abundance by destabilizing the protein product and rapidly targeting it for degradation. 
This PEST tag might explain why knockdown of multiple proteasomal subunits 
suppressed the expression of GA70 NL-3xF but had no effect on our +1 CGG100 NL-3xF-
PEST reporters, for example (despite reducing the expression of non-PEST-tagged +1 
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CGG100 NL-3xF reporters in subsequent experiments). If this interpretation is correct 
and multiple “C9ORF72-specific” siRNAs failed to affect +1 CGG100 NL-3xF-PEST in our 
screen because of differences in reporter-protein stability, those genes whose 
knockdown did impact both C9ORF72 and FMR1 reporter expression might be more 
likely to modulate RAN-product synthesis than their degradation. These are therefore 
prime candidates for follow-up—in brief, a narrow, translation-specific set came at the 
cost of a comprehensive list of FMR1 modifiers. 
 GO analysis revealed significant enrichment of GO terms with high a priori 
relevance to RAN translation and RAN-product metabolism, including “IRES-dependent 
viral translational initiation” (C9ORF72 and FMR1), “positive regulation of canonical Wnt 
signaling pathway,” proteasome-mediated protein catabolism, mRNA/DNA 
methyltransferase activity, “transcription factor-binding,” “C-terminal protein 
methylation,” and “Golgi-to-lysosome transport” (all C9ORF72 alone), as well as the 
unanticipated GO term “NIK/NFkB signaling” (C9ORF72 alone). Besides these, 
“chaperone-binding” was significantly enriched within the FMR1 set, but the 
corresponding genes—BIRC5, BAX, and LRP2—have been more thoroughly described 
in contexts other than unfolded proteins and proteotoxic stress321,322. The question of 
whether RAN translation initiates via an IRES-like mechanism has been interrogated, 
discussed, and debated on its empiric merits and mechanistic implications 
elsewhere150,169,170,202,214,323-325; suffice it to say that there is evidence from heterologous 
expression systems both in favor of and against IRES-mediated initiation for both 
C9ORF72 and FMR1. (Notable, however, are the two genes associated with this GO 
term: PTB preferentially binds expanded (G4C2)n RNA in vitro281, undergoes phase 
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separation187, interacts with GR50 and PR50 DPRs in HEK293 cells, and modulates 
PR50-elicited toxicity in Drosophila195; and eIF3F, though a canonical eIF, appears to 
also modulate RAN translation of SCA8283.) In addition, DDX3X is a Wnt-dependent 
regulator of casein kinase 1326, besides its more extensively explored functions in 
translation initiation. 
The ubiquitin-proteasome system is a central determinant of cellular toxicity 
secondary to either misfolded or intrinsically disordered proteins, both with regard to 
neurodegeneration in general327-330 and to RAN-associated disease in particular (see 
discussion of PSMB5 above). That we identified several proteasomal subunits and 
proteasome regulators as RAN modifiers is therefore intriguing. But in addition to its role 
in general proteome turnover, the proteasome promotes NFkB signaling by degrading 
IkBa, thus disinhibiting NFkB proteins from entering the nucleus and regulating gene 
expression331. Multiple ligands, receptors, signal-transduction components, and 
regulators of the NFkB/TNF pathway were also identified by GO analysis of our 
C9ORF72 RAN modifiers, including TNF receptor superfamily 9, RhoA, MAP3K14, IkB 
kinase b, Fbxw11, ectodysplasin A, and ectodysplasin A receptor. The mechanism by 
which inhibition of NFkB activity might suppress RAN translation is unclear, but there is 
evidence in support of mutual up-regulation of NFkB activity and the ISR332-334. Though 
ours is not the first screen of C9ORF72 RAN modifiers to identify multiple subunits of 
the proteasome171,280, it is the first (at least among those published) to potentially relate 
proteasomal function to NFkB/TNF signaling in the context of RAN translation. 
 mRNA methyltransferases and demethylases (such as the METTL3-METTL14-
WTAP complex and ALKBH5, respectively) regulate translation efficiency, the 
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translational response to cellular stress, phase separation of mRNAs, and the 
requirement of various eIFs in translation335-339 through introduction and removal of N6-
methyladenosine (m6A) and other mRNA modifications. Here, knockdown of the mRNA 
methyltransferase METTL16 suppressed C9ORF72 RAN translation. Little is known of 
METTL16 other than it is predominantly cytoplasmic, mediates m6A modification at a 
UACAGAGAA consensus site (found in neither genomic nor transcriptomic C9ORF72 
sequences), and regulates transcript-selective intron retention340-343. In addition, 
knockdown of METTL7A—a presumed nucleic-acid methyltransferase (based on 
homology) that is known to regulate replication of Hepatitis C virus (an RNA virus, 
translation of which also requires DDX3X60) on the surface of lipid-rich, membraneless 
organelles344—also suppressed C9ORF72. Oddly, knockdown of several RNA 
demethylases likewise suppressed RAN product expression. ALKBH5 knockdown 
suppressed both C9ORF2 and FMR1 RAN translation, while knockdown of FTO and 
ALKBH2 (by either siGENOME or ON-TARGETplus siRNAs) selectively suppressed 
C9ORF72 RAN translation. Fto is a highly CNS-expressed protein that mediates mRNA 
demethylation and thereby regulates mRNA stability and abundance in a transcript-
specific manner338,340,345-348. ALKBH2 might regulate RAN translation in similar fashion, 
though evidence to date suggests that it exhibits preferential demethylation of DNA 
substrates349. Our screens also identified as a C9ORF72 modifier ADAR1, an RNA-
editing enzyme that mediates A-to-I deamination and thereby regulates RNA-RNA 
secondary structure and mRNA stability350,351. Alternatively, methylation and/or 
demethylation of DNA NREs or flanking regions by these enzymes might be the critical 
regulatory step: multiple lines of evidence implicate dysregulation of DNA methylation in 
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C9 ALS/FTD268,269, including the observation that patients with C9 ALS and those with 
non-C9 ALS exhibit similar patterns of DNA methylation in post-mortem brain352. We 
here and others previously180,195 have implicated XRCC proteins in C9 ALS/FTD (and 
here, FMR1 RAN translation); these proteins are key mediators of repair of DNA 
double-stranded breaks induced by, among other stressors, alkylation353. 
 Boeynaems et al.180 screened for modifiers of eye toxicity in Drosophila 
expressing an AUG-initiated, codon-optimized PR25 transgene and demonstrated that 
depletion of 4 different arginine (R) methyltransferases enhanced PR25 toxicity: FBXO11 
(either FBXO11 or FBXO10 in human), Art1/PRMT1, Art6, and Art7/PRMT7. They went 
on to demonstrate that PRMT1 colocalized with both PR and GR in heterologous DPR-
overexpressing cultured cells and GR was methylated in C9 ALS/FTD post-mortem 
brain. That our screen—interrogating non-AUG initiation of the native-sequence GA 
DPR and FMRpolyG in a totally orthologous experimental system—identified the same 
category of genetic modifiers is tremendous: PRMT2 (C9ORF72 and FMR1), PRMT7 
(FMR1), FBXO11 (C9ORF72 and FMR1), as well as related leucine and cysteine 
methyltransferases LCMT1 and ICMT (both C9ORF72). Knockdown of these 
suppressed RAN translation. We also point out that PRMT1 knockdown strongly 
reduced expression of both C9ORF72 and FMR1 RAN products, but narrowly failed to 
meet inclusion criteria during the primary screens. How might these methyltransferases 
regulate RAN translation? The ALS/FTD-associated protein FUS might be an 
informative example. The subcellular localization of multiple predominantly nuclear 
RNA-binding proteins (FUS, EWS, TAF15) is dependent on the methylation of R 
residues adjacent to their nuclear localization signals (NLSs), which is mediated by, 
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among other enzymes, PRMT1354,355—R-dimethylated FUS is predominantly 
cytoplasmic, and PRMT1 inhibition appears to promote cytoplasmic-to-nuclear transport 
of WT FUS and ALS-associated FUS mutants355,356. But in addition, non-methylated WT 
FUS exhibits liquid-liquid phase separation at lower concentrations than R-dimethylated 
FUS in vitro, reduced intra-droplet diffusion, increased incorporation into stress granules 
in cultured heterologous cells, and increased resistance to proteasomal degradation in 
Drosophila357,358. This literature implies that R methyltransferases exert neuroprotective 
effects in the setting of FUS mutation by mitigating FUS phase separation and the 
subsequent dysregulation of membraneless organelles (stress granules, P bodies, 
nucleoli, and others), consistent with the observed potentiation of PR50- and mutant 
FUS-elicited toxicity by PRMT1 knockdown180,356. One might speculate that depletion of 
R methyltransferases could therefore inhibit RAN translation of non-R products by 
leading to the triage and sequestration of RAN-competent mRNAs (though it remains 
unclear how to reconcile that hypothesis with the facilitation of RAN translation following 
ISR activation169,202) or by disrupting the activity of PRMT1 targets such as Rap55/Scd6, 
which binds eIF4G, recruits PICs to stress granules, and mediates general translational 
repression in the setting of ISR activation and in an R dimethylation-dependent 
manner359-362. In our hands, Rap55 depletion, like that of several PRMTs, selectively 
suppressed C9ORF72 RAN translation. Alternatively, perhaps R-dimethylated RAN 
products exhibit different molecular characteristics than FUS. Overall, GO analysis 
serves two purposes: it is a catalyst for new hypotheses as to how RAN translation is 
regulated, as well as a map, specifying which genes of interest are most ripe for follow-
up mechanistic experiments when testing those hypotheses. 
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 Besides HNRNPA2B1 and PSMB5, 211 promising candidate genes remain: 
replicable, RAN-selective modifiers with some effect on both C9ORF72 and FMR1 RAN 
translation, with minimization of off-target false positives. With this smaller, higher-
confidence set, determining therapeutic potential and the phenotypic effects of gene 
disruption (using Drosophila disease models), physiological relevance (using patient-
derived iPSCs), and possibly on-target validity (using individual siRNAs rather than 
siRNA pools) is more feasible. Our experience validating HNRNPA2B1 and PSMB5 has 
been informative—these candidates hint at some of the stimulating biology our screen 
reveals, while highlighting which experiments must be performed in order to validate 
other candidates with confidence. We eagerly anticipate our next steps. 
 
Materials and Methods 
 
Plasmids 
 pcDNA3.1(+)/C9ORF72 GA70 NL-3xF and pGL4.13 (AUG-FF) have been 
described previously169. pcDNA3.1(+)/AUG-NL-3xF-PEST was generated from 
pcDNA3.1(+)/AUG-NL-3xF150 using Q5 Site-Directed Mutagenesis (New England 
BioLabs) and the primers detailed in Table B.14. pcDNA3.1(+)/FMR1 +1 (CGG)100 NL-
3xF-PEST was generated from pcDNA3.1(+)/FMR1 +1 (CGG)100 NL-3xF150 using the 
same method. All plasmids used throughout the screen were purified from E. coli 
cultures using the Maxiprep Plasmid DNA Purification Kit (Qiagen). 
 
C9ORF72 and FMR1 High-Throughput Screens 
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HEK293 cells (ATCC, CRL-1573) were maintained and passaged at 37° C, 5% 
CO2 in DMEM supplemented with 10% (vol/vol) FBS. Use of the Human siGENOME 
SMARTpool siRNA Library (Dharmacon) with full-genome coverage was acquired 
through the Center for Chemical Genomics at the University of Michigan, Ann Arbor. 
siRNAs were reconstituted in 1x siRNA Buffer (Dharmacon), sealed, and stored under 
RNase-free conditions in 384-well stock plates (Thermo Fisher Scientific, AB-0781) at -
20° C. 
 siGENOME siRNAs were moved to 4° C and allowed to thaw for 24 hours. Using 
a Biomek FXP (Beckman-Coulter), siRNAs were transferred to white 384-well assay 
plates (Greiner Bio-One, cat. # 781080) in triplicate, diluted to 13.17 nM in OptiMEM 
Reduced Serum Medium (Thermo Fisher Scientific) containing 450 nl/well of 
Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific; final volume 
of 10.4 µl/well), briefly centrifuged, and incubated at room temperature for 30 minutes. 
siNT, siNL, and siPLK1 were added to each assay plate and handled identically. Using 
a MultiDrop Dispenser (Thermo Fisher Scientific), dissociated HEK293 cells in DMEM 
were added at 6,000 cells (20 µl)/well, with final concentrations of 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin (Thermo Fisher Scientific), and 39.5 nM siRNA. 
 Forty-eight hours later, cells were transfected with 15 ng/well firefly luciferase 
plasmid (pGL4.13) and 15 ng/well either pcDNA3.1(+)/C9ORF72 GA70 NL-3xF plasmid 
or pcDNA3.1(+)/FMR1 +1 CGG100 NL-3xF-PEST plasmid using Viafect (Promega). 
Twenty-four hours after plasmid transfection, excess media was aspirated using a 405 
Select Microplate Washer (BioTek) to leave 10 µl media/well. The Nano-Glo Dual 
Luciferase Reporter Assay System (Promega) and Envision 2104 Multilabel Reader 
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(Perkin-Elmer) were used per manufacturer’s instructions to quantify expression of GA70 
NL-3xF (or +1 CGG100 NL-3xF-PEST) and AUG-FF reporters independently. 
 
Low-Throughput Luminescence Assays 
 All cell plating, siRNA transfections, plasmid transfections, and luminescence 
assays in low-throughput format were performed as described previously (Chapter 2). 
 
Western Blotting 
 Western blotting was performed as described previously (Chapter 2). All 
antibodies used for blotting were diluted in 5% non-fat dairy milk (wt/vol), 0.02% NaN3 
(wt/vol), 0.1% Tween-20 (vol/vol) in TBS. Mouse anti-hnRNPA2/B1 antibody (Dp3B3; 
Santa Cruz, sc32316) was used at 1:1,000 dilution. Monoclonal mouse anti-EGFP 
antibody was acquired from Sigma (clones 7.1 and 13.1, catalog #11814460001). 
Monoclonal mouse anti-β tubulin antibody, developed by Michael Klymkowsky, was 
obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of 
the NIH, and maintained at The University of Iowa, Department of Biology, Iowa City, IA 
52242. Monoclonal mouse anti-FLAG antibody was acquired from Sigma (clone M2, 




 All qRT-PCR experiments were performed as described previously (Chapter 2). 
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Drosophila melanogaster Phenotyping and Western Blotting 
 All fly lines used in this study and their sources are listed (Table B.15). Eye 
phenotypes were quantified and Drosophila tissue prepared for western blotting as 
previously described (Chapter 2). For western blot quantification, prepared lysates were 
loaded onto two duplicate gels and transferred, blotted, developed, and quantified 
identically using ImageJ (NIH). The mean band density was used for subsequent 
statistical analysis.  
 
Hybridization Chain Reaction (HCR) 
HCR version II was done following Molecular Instruments “Mammalian cells on 
slide” protocol363 with the following modifications. HEK293 cells were transfected in 8-
well slides and fixed for 10 minutes in 4% PFA, washed 3x in PBS, and permeabilized in 
70% ethanol overnight at 4° C. Cells were washed 3x in PBS, treated with DNase (10 
U/well Turbo DNase; Invitrogen) in 1X Turbo DNase buffer at 37° C for 30 minutes. 
Cells were washed 3x in PBS and prehybridized in 50% formamide hybridization buffer 
(Molecular Instruments) for 30 minutes at 45° C, followed by hybridization with 1 pmol 
(CCG)8 probe/well overnight at 45° C. Cells were washed 4x with probe wash buffer 
(Molecular Instruments), 2x with 5X SSCT, and incubated for 30 minutes at room 
temperature in amplification buffer (Molecular Instruments). Cells were incubated with 
3.75 pmols of snap-cooled Alexa Fluor 647-labeled B1H1 and B1H2 hairpin probes 
(Molecular Instruments) per well in amplification buffer at room temperature overnight. 
Cells were washed 5x with 5X SSCT and mounted with ProLong Gold Antifade Mount 
with DAPI. Fifty transfected cells/condition at minimum were imaged at 40x with oil on a 
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confocal microscope. Representative images are shown. 
 
iPSC Culturing, Transfection, and GP ELISA 
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Conclusions and Future Directions 
 
 
Summary and Significance 
 
Candidate-Based and Non-Biased Screens Identified Modifiers of RAN Translation 
The objective of this thesis work was to identify proteins and regulatory pathways 
that modulate RAN translation. This objective is significant for two reasons. First, RAN-
translation products are sufficient and in some contexts necessary to elicit toxicity in 
overexpression models of FXTAS and C9 ALS/FTD15,19,173, suggesting they are directly 
involved in pathogenesis. Understanding how RAN translation occurs and how it might 
be blocked, therefore, carries significant clinical implications for neurodegenerative 
disorders associated with RAN translation25. Second, by initiating at non-AUG codons, 
RAN translation violates a fundamental assumption of protein synthesis that underlies 
how we understand and define eukaryotic proteomes. Though it has been known for 
decades that PICs can and do initiate at non-AUG codons92,95, it is only recently that 
investigators have begun to appreciate the biological significance of these 
events100,206,207. Therefore, RAN translation represents a new, important, and clinically 
meaningful mechanism by which mRNAs are translated and protein synthesis regulated 
that likely has implications beyond a relatively rare set of neurodegenerative 
disorders205.
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 To meet this objective, we conducted two screens for modifiers of RAN 
translation: one a candidate-based, phenotype-modifier screen in a Drosophila 
melanogaster model of FXTAS, and the other a genome-wide, high-throughput screen 
for modifiers of C9ORF72 RAN-product expression in HEK293 cells. Our Drosophila 
screen closely resembles previous modifier screens that have been used to identify 
genetic suppressors and enhancers of toxicity elicited by other NREs273-278, using a 
degenerative, “rough-eye” phenotype as a visible proxy for FMRpolyG expression. In 
contrast, our HEK293 screen provided >100,000 direct measurements of RAN-product 
(GA70- and FMRpolyG100-NL) and canonical-translation (AUG-FF) reporters, enabling us 
to identify selective modifiers of RAN translation (explaining why EIF4B and EIF4H were 
identified as hits in Drosophila but not HEK293 cells, for example). This high-throughput 
screen is among the first of its kind to directly identify genes that specifically impact 
RAN-product expression, rather than those that modulate RAN product-elicited 
toxicity171,180,279,280. In combination, these screens identified three proteins—bel/DDX3X, 
hnRNPA2/B1, and PSMB5—as novel modifiers of RAN-product expression across gene 
contexts and reading frame, along with others (eIF4B, eIF4H, eIF1, and eIF5) that 
influence RAN translation through mechanisms that also impact translation globally. 
 
Bel/DDX3X Facilitates RAN Translation, and its Disruption Mitigates NRE Toxicity 
 We demonstrated that knockdown of bel/DDX3X both reduces the expression of 
FMRpolyG and FMRpolyA in Drosophila, cultured HeLa cells, and primary rodent 
neurons, as well as mitigates the toxicity of expanded CGG repeats in Drosophila and 
cultured neurons. We then demonstrated that DDX3X acts co-translationally, consistent 
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with its described interactions with eIFs and function in promoting 43S PIC scanning58-
61,64-68,364. Finally, we demonstrated that DDX3X knockdown reduced the expression of 
multiple C9ORF72 RAN products, including GA70 reporters in HeLa cells and 
endogenous GP in patient-derived iPSCs. This line of research is the first in-depth, 
mechanistic investigation of a RAN-modulating factor, drawing on experiments 
performed in Drosophila in vivo, HeLa cells, cultured rodent neurons, and patient-
derived iPSCs. Though other researchers have previously identified factors such as 
MBNL and eIF3F that impact the abundance of RAN products23,283, they did not 
demonstrate co-translational activity of these factors nor modification of NRE-elicited 
toxicity in vivo following their manipulation. Besides building a strong, multi-tiered 
argument that DDX3X modulates RAN translation, this course of experiments 
delineates a strategy to validate candidate modifiers of RAN translation on the basis of 
efficacy, mechanism, reduction in toxicity, and physiological relevance. 
 
Highly Coincident Sets of Genes Modify C9ORF72 and FMR1 RAN Translation 
Our high-throughput screens tested the 7,811 genes of Dharmacon’s Drug-
Target and Druggable Genome libraries for modifiers of GA70 and FMRpolyG100 
independently. In addition, we tested those siRNAs that modified GA70 from across the 
human genome for congruent effects on FMRpolyG100. Both schemes revealed 
significant, but not complete, overlap between modifiers of C9ORF72 and FMR1 RAN 
translation. Moreover, knockdown of at least one modifier (PSMB5) inhibited expression 
of all tested C9ORF72 and FMR1 RAN products despite meeting hit criteria only for 
C9ORF72, implying that our design actually underestimates C9ORF72/FMR1-modifier 
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congruency. This work is the first of its kind to systematically compare modifiers of RAN 
translation of different NREs within different genetic contexts. In light of the significant 
congruency of RAN modifiers observed, it is both reasonable to conclude that RAN 
translation exhibits some mechanistic commonalities despite sequence disparities, as 
well as tempting to speculate that these commonalities are amenable to therapeutic 




How Does DDX3X Modulate RAN Translation? 
This thesis work establishes that bel/DDX3X modulates RAN translation. It does 
not directly address how it does so. DDX3X and its homologs in yeast and Drosophila 
are RNA helicases51,53,55,65,66 involved in multiple aspects of mRNA 
metabolism58,61,68,73,365-367. On the basis of our RIP assay results, we cannot conclude 
that the RAN-specific effects of bel/DDX3X knockdown reflect transcript-specific 
binding. (Our results are consistent with previous work, in which Ded1 did not 
demonstrate sequence-specific binding across or within 5’ UTRs59.) And because the 
effects of DDX3X knockdown are not dependent on the size of the CGG repeat 
(following transfection of plasmid reporters, at least), but rather on the 5’ UTR of FMR1 
itself, we cannot conclude that DDX3X’s activity is mediated by molecular interaction 
with the NRE. 
Because knockdown of DDX3X suppressed RAN translation of +1 (CGG)0 and 
(CGG)100 NL-3xF comparably, we hypothesize that DDX3X interacts with the FMR1 5’ 
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UTR itself. The FMR1 5’ UTR is highly GC-rich (80%, excluding the repeat), and is 
therefore predicted to form stable secondary structures. (Intron 1 of C9ORF72 is 
likewise highly GC-rich.) Such structures are capable of impeding scanning 43S 
PICs91,111 and preventing them from accessing downstream initiation sites, leading to a 
decrease in protein synthesis. Bel/DDX3X might act to resolve these structures, 
facilitating 43S PIC scanning and permitting them access to the downstream initiation 
sites for RAN translation19,150. Testing this hypothesis will require in vivo probing of the 
structure of the FMR1 5’ UTR in the presence and absence of DDX3X. Such 
techniques, including variations on DMS-Seq and SHAPE-Seq, exist and have been 
used successfully368-372. These tools would enable investigators to understand the 
structure (or structures) of the FMR1 5’ UTR on a molecule-by-molecule basis. Based 
on our hypothesis, we would predict that DDX3X knockdown would result in a greater 
degree of secondary-structure stability 5’ to the start sites for RAN translation. 
 
How Does PSMB5 Modulate the Expression of RAN Products? 
Depletion of a conspicuous number of proteasomal subunits, including the 
catalytic subunits PSMB1 and PSMB5308, suppressed the expression of the GA 
C9ORF72 RAN product. Despite not suppressing FMR1 RAN translation in our high-
throughput screen, follow-up experiments demonstrated that knockdown of PSMB5 did, 
in fact, comparably suppress the RAN products of C9ORF72 and FMR1 across reading 
frames and in a repeat-dependent manner. This was unexpected, as the FMRpolyG 
RAN product is a substrate of the proteasome147, and pharmacological inhibition of 
PSMB5 resulted in an increase in FMR1 +1 (CGG)100 NL-3xF reporter expression, both 
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overall and relative to an AUG-initiated reporter. Clearly, knockdown of PSMB5 does 
not have the same effect as pharmacological proteasome inhibition. How can we 
account for this difference? 
Three non-constitutive proteasomal subunits—PSMB8, PSMB9, and PSMB10—
are induced by interferon g and, in response to interferon g, substitute for the catalytic 
subunits PSMB5, PSMB1, and PSMB2, respectively373,374. This interferon g-induced, re-
constituted proteasome, known as the immunoproteasome375, exhibits accelerated 
protein degradation, potentially to facilitate antigen presentation in anticipation of viral 
infection311-313,315,316. Intriguingly, researchers have also observed neuronal induction of 
immunoproteasomal subunits in patient tissue and animal models of Huntington’s 
disease, Parkinson’s disease, and ALS376-378. Could knockdown of PSMB5 induce 
incorporation of the more catalytically-active PSMB8, leading to a higher rate of RAN 
product degradation? This could explain the divergent results of PSMB5 knockdown 
versus bortezomib administration, since bortezomib targets both constitutive and 
immuno-proteasomes. This hypothesis is readily testable using traditional methods of 
PSMB8 detection (western blotting and qRT-PCR) and genetic and pharmacological 
inhibitors379,380 of the immunoproteasome in cultured HEK293 cells, patient-derived 
iPSCs, and primary rodent neurons. 
 
Do RAN-Translation Modifiers That Act Via Different Mechanisms Converge to 
Suppress NRE-Elicited Toxicity? 
 The work presented here makes a strong argument that disruption of bel/DDX3X 
mitigates NRE-elicited toxicity by inhibiting RAN translation per se. In parallel, others 
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have demonstrated that knockdown of multiple proteasomal subunits mitigates toxicity 
elicited by exogenous, recombinant PR20 and GR20280, reflecting effective modulation of 
toxicity after these DPRs have been synthesized. This prompts the question: might the 
combination of therapeutic interventions that impact different events in RAN products’ 
lifespans lead to an additive reduction in NRE-elicited toxicity? In that regard, further 
understanding of the relation between hnRNPA2/B1 and NRE-elicited toxicity could 
prove useful. Though we demonstrated that disrupting HNRNPA2B1’s homologs results 
in bi-directional modulation of NRE-elicited toxicity in Drosophila, we could not point 
conclusively to its mechanism of action: overexpression and knockdown of 
HNRNPA2B1 or its fly homologs did not yield consistent effects on FMRpolyG 
expression. It is possible that hnRNPA2/B1 exerts its protective effects via modulation of 
RNA-mediated toxicity, invoking the previously dominant RNA-mediated gain-of-function 
hypothesis of FXTAS pathogenesis, in which expanded (CGG)n sequester essential 
RNA-binding proteins10,132. Indeed, the C9 ALS/FTD field has long recognized that 
G4C2-containing RNAs likely have their own downstream toxicities381. Further 
comparison of known modifiers of RAN translation (from ours and others’ genome-wide 
screens325,382) to known modifiers of NRE-elicited toxicity in model 
systems171,172,180,182,279,280,383-388 and genotype-phenotype correlations in patients could 
shed more light on the respective contributions of RAN products and NRE-containing 
RNAs to NRE-associated neurodegeneration, in turn highlighting potential combination 
therapeutic strategies. 
 
How to Minimize False Positives Due to Off-Target siRNA Interactions? 
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 Our high-throughput screens identified an ample set of putative RAN translation-
specific modifiers: 544 C9ORF72 RAN-suppressing and 8 RAN-enhancing siRNA pools 
(of which 188 suppressors and 2 enhancers had analogous effects on FMR1 RAN 
translation), as well as 75 independently identified FMR1-suppressing siRNA pools (of 
which 65 had analogous effects on C9ORF72). Based on previous investigations of off-
target siRNA interactions284-286 and our own pilot data, this set is not without false 
positives due to off-target effects, however. These present a significant but not 
insurmountable challenge. Of course, those 30 genes already validated using the 
alternative, ON-TARGETplus siRNA library have already cleared this hurdle and await 
further study. Using the ON-TARGETplus library does effectively eliminate off-target 
candidates, but it does so with significant financial burden relative to the number of 
candidates that validate. In addition, it risks attrition of true positives due to off-target 
effects of ON-TARGETplus siRNAs. (PSMB5, a promising candidate, is a key example.) 
For the 465 remaining candidates not yet tested with ON-TARGETplus siRNAs, we 
favor a different approach: increasing the stringency of the off-target filter generated 
from HEK293 RNA-Seq sets. That this filter preferentially eliminated ON-TARGETplus 
non-validating candidates supports its continued use. It is high-yield, low-cost, and 
adjustable—we can exploit the ON-TARGETplus pilot data to generate a receiver-
operator characteristic curve and “tune” the exclusion criteria to maximize elimination of 
false positives and minimize attrition of true positives. One could even consider testing 
additional ON-TARGETplus siRNAs to increase statistical confidence in this method. 
Alternatively, one could consider constructing a custom single-guide RNA (sgRNA) 
library of modifiers and leveraging CRISPR-mediated disruption to further eliminate off-
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target effects. Advantages of this method include an orthogonal disruption strategy, as 
well as the availability of computational tools to identify and minimize off-target effects 
with non-pooled disruption reagents280,287. 
 
How to Determine Which Candidate Modifiers are Most Promising? 
 Prioritizing candidates based first on dual activity against GA and FMRpolyG and 
second on the results of GO analysis is perhaps our best option to identify the modifiers 
most ripe for further study. With mechanistic investigation of the proteasome already 
launched with our experiments on PSMB5, elucidating the potential roles of NFkB/TNF 
signaling, RNA methyltransferases/demethylases, and R methyltransferases would 
likely have the highest yield. (In fact, it is through modulation of NFkB that proteasomal 
perturbation might impact RAN translation331.) NFkB/TNF signaling and 
pharmacological inhibitors thereof have been extensively studied in the context of 
immunology, rheumatological disease, and multiple cancers389. Its implication in RAN 
translation, if verified, should immediately spark novel therapeutic hypotheses with 
small-molecule and recombinant therapies borrowed from these fields (with 
caution390,391). With regard to covalent nucleic-acid modifications, modulating the 
enzymes that mediate such changes has the potential to mitigate neurotoxicity via 
effects on C9ORF72 transcription392, mRNA translation per se335-339, or more global 
dysregulation of gene expression268,269. 
 Once identified, how best to proceed with investigation of likely high-yield RAN 
modifiers? Further study must prioritize reversal of NRE-elicited toxicity (in Drosophila, 
potentially rodent neurons), validation of RAN-product expression effects in endogenous 
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systems (in patient-derived iPSCs, quantified by ELISA or CRISPR-inserted tagging), 
mechanistic novelty, and therapeutic potential. In that regard, we stand to benefit from 
the number of (G4C2)n- and DPR-elicited phenotype-modifier screens published in the 
last 5 years171,172,180,182,279,280,383-388. As a first step, our candidate genes of particular 
interest should be cross-referenced with published lists of C9ORF72 modifiers. 
Modifiers for which suppression of RAN translation in our hands correlates with reversal 
of NRE- or DPR-elicited toxicity (as for bel/DDX3X, eIF4B, eIF4H, and possibly PSMB5) 
might avoid some of the mechanistic confusion we encountered with HNRNPA2B1. In 
addition, if consistent phenotypic effects have been confirmed elsewhere previously, it is 
prudent to proceed to other high-priority tests rather than essentially repeat these 
experiments. If such effects have not been confirmed, doing so using Drosophila 
disease models is the fastest, most cost-effective method (provided the cross scheme is 
not onerous) to arrive at a set of genes with high technical confidence, cross-model 
validity, and demonstrated therapeutic potential. Alternatively, if a time- and labor-
intensive series of crosses is required to generate the experimental genotype, testing 
should emphasize early validation of RAN-product expression effects in endogenous 
systems (iPSCs). At that point, mechanistic studies should proceed. Here again, cross-
referencing with lists of previously identified DPR-binding proteins, (G4C2)n-binding 
proteins, or components of membraneless organelles187,195,196,281,388,393 might enable 
prioritization of modifiers, as well as imply whether coprecipitation or colocalization 
experiments are appropriate next steps. So contextualizing our screens’ modifiers within 










































Figure A.1: Supplement to Figure 2.2. 
A Representative photographs of fly eyes expressing GMR-GAL4, (CGG)90-EGFP with 
additional bel disruptions.  
B Quantitation of GMR-GAL4, (CGG)90-EGFP eye phenotypes with additional bel disruptions 
(Mann-Whitney U test with Bonferonni corrections for multiple comparisons; n=42-98/genotype). 
C Representative photographs of fly eyes expressing an AUG-initiated EGFP along with bel 
shRNAs under a GMR-GAL4 driver. 
D Quantitation of GMR-GAL4, EGFP eye phenotypes with bel shRNAs (n=20-64/genotype). 
 






Figure A.2: NL-3xF and FF Reporter Constructs Used in This Study. 
The tag (e.g., NL-3xF, FF, tagless), 5’ leader sequence (e.g., β Actin or β Globin 5’ UTR), start 


























Figure A.3: Supplement to Figure 2.4. 
Asterisks indicate comparisons between relative AUG-NL-3xF and +1 (CGG)100 NL-3xF expression 
(two-way ANOVA with Sidak’s multiple comparisons test; n=9-21/condition).  
 
Data Information: *** P≤0.001, **** P≤0.0001 for the specified statistical test at the indicated siRNA 







Figure A.4: Supplement to Figures 2.4 and 2.5.  
A Expression in HeLa cells of transfected AUG-NL-3xF and +1 (CGG)100 NL-3xF reporter 
plasmids, with and without DDX3X knockdown, compared to the expression of AUG-initiated NL-3xF 
reporters bearing the short, minimally-structured 5’ UTRs of human β actin and β globin (two-way 
ANOVA with Tukey’s multiple comparisons test; n=15-39/condition). Black asterisks refer to 
comparisons between siEGFP-treated and siDDX3X-treated cells; white asterisks refer to 
comparisons between siDDX3X-treated cells expressing +1 (CGG)100 NL-3xF and those expressing 
a different reporter. 
B, C (CGG)n +1 and (CGG)n +2 NL-3xF expression with and without DDX3X knockdown across a 
range of CGG repeat sizes (two-way ANOVA with Tukey’s multiple comparisons test; n=12-
18/condition). Black asterisks refer to comparisons between siDDX3X- and siEGFP-treated cells; 
blue asterisks refer to comparisons between siDDX3X-treated cells expressing AUG-NL-3xF and 
those expressing a different reporter. 
D, E Expression of in vitro-transcribed (CGG)n +1 and (CGG)n +2 NL-3xF reporter RNAs with and 
without DDX3X knockdown across a range of CGG repeat sizes (two-way ANOVA with Tukey’s 
multiple comparisons test; n=12-24/condition). Orange and blue asterisks refer to comparisons 
between siDDX3X- and siEGFP-treated cells. 
 
Data Information: For all panels, ns=non-significant, ** P≤0.01, *** P≤0.001, **** P≤0.0001 for the 




































Figure A.5: Knockdown of DDX3X Does Not Inhibit Global Translation.  
A Representative polysome-fractionation profiles of HeLa cell lysates transfected with siDDX3X 
#1 or siEGFP. The areas-under-the-curve (AuC) for monosomes and polysomes are shaded blue 
and pink, respectively. 
B Mean ratios of the AuCs of monosomes to polysomes across three replicates (Student’s 
paired t-test, n=3/condition). ns=non-significant. 
C Anti-DDX3X western blot of HeLa lysates processed for polysome fractionation. The DDX3X 




Figure A.6: Reporter Expression in In Vitro Translation Assays is Consistent Across 
Independently Prepared, Replicate Extracts. 
A, B Expression of in vitro-transcribed AUG-NL-3xF (A) and +1 (CGG)100 NL-3xF RNAs (B) in in 
vitro translation assays, collected from HeLa cells treated with siRNAs against EGFP or DDX3X. 
Four replicate lysates (“A-D”) were generated per siRNA (n=4/lysate). 
C Expression of in vitro-transcribed near-AUG reporter RNAs in in vitro translation extracts, 
collected from HeLa cells treated with siRNAs against EGFP or DDX3X. Reporter RNAs were tested 
in duplicate lysates (2 lysates per siRNA; n=4/lysate). 
Data Information: All panels depict pooled data (means + SD) gathered across two replicates. 
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Figure A.7: Anti-DDX3X RIP Co-Precipitates +1 (CGG)100 NL-3xF RNA Independently of the NL-
3xF Tag or NRE Size. 
A Enrichment of +1 (CGG)100 NL-3xF and MALAT RNA following anti-DDX3X and anti-EGFP 
RIP, relative to incubation with isotype control IgG (Student’s t test, n=3). In addition, +1 (CGG)100 
NL-3xF mRNA is not enriched following anti-EGFP RIP from cells expressing EGFP (Student’s t test, 
n=3). This experiment is a replicate of that presented in Figure 2.5D. 
B Enrichment of (CGG)100, (CGG)0, and HSPA1A, but not MALAT RNA, following anti-DDX3X 
RIP in two independent replicates. In contrast with panel A and Figure 2.5D, the (CGG)100 and 
(CGG)0 constructs here do not have a NL-3xF tag. 
Data Information: **** P≤0.0001. All panels depict technical triplicates (means + SD) within the given 
experiment. 
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Figure A.8: Sequence Maps of the +1 and +2 (CGG)100 NL-3xF Reporter Constructs, With and 




































Figure A.9: Supplement to Figures 2.7 and 2.8. 
A Representative photographs of fly eyes expressing GMR-GAL4, (CGG)90-EGFP with 
additional eIF4H1 and eIF4H2 shRNAs. 
B Quantitation of GMR-GAL4, (CGG)90-EGFP eye phenotypes with additional eIF4H1 and 
eIF4H2 shRNAs (Mann-Whitney U test with Bonferonni corrections for multiple comparisons; n=21-
55/genotype). 
C Representative photographs of fly eyes expressing eIF4H1 and eIF4H2 shRNAs alone under 
a GMR-GAL4 driver. 
D Quantitation of eye phenotypes of eIF4B, eIF4H1, and eIF4H2 shRNAs expressed under a 
GMR-GAL4 driver (n=12-33/genotype). 
E Longevity assays of (CGG)90-EGFP; Tub5-GS flies with knockdown and overexpression of 
eIF4B (Log-rank Mantel-Cox test with Bonferroni corrections for multiple comparisons; n=26-
32/genotype). 
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F Anti-eIF4B and anti-eIF4H western blot of HeLa cells transfected with siRNAs against EIF4B 
or EIF4H. 
 
Data Information: For all panels, ns=non-significant, *** P≤0.001, **** P≤0.0001 for the specified 




































Figure A.10: Supplement to Figure 2.9. 
A Expression of plasmid-based NL-3xF reporters in HEK293 cells with and without knockdown 
of EIF1 (two-way ANOVA with Sidak’s multiple comparisons test; n=12/condition). Black asterisks 
refer to comparisons between siNT-transfected and siEIF1-transfected cells; green asterisks refer to 
comparisons between siEIF1-transfected cells expressing AUG-NL-3xF and those expressing a 
different reporter. Graph depicts data as means + SD (compiled from ≥3 replicates). **** P≤0.0001. 
B Anti-eIF1 and -eIF5 western blot demonstrating overexpression of eIF1 and eIF5 after 































Figure A.11: Supplement to Figure 2.10. 
Transfection of +1 (CGG)100 EGFP plasmid-based reporters increased the cumulative risk of death in 
primary rodent neurons, relative to transfection of EGFP reporters (Cox proportional hazard analysis; 
















































Table A.1: Summary of the Candidate-Based Screen for Modifiers of (CGG)90-Elicited Toxicity. 
Candidate modifier genes for RAN translation were crossed to flies carrying either GMR-GAL4, 
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(CGG)90-EGFP or GMR-GAL4 alone and their eye phenotypes were assessed. Blue indicates 
suppression of the rough-eye phenotype. Red indicates exacerbation or induction of a rough-eye 
phenotype. Each candidate modifier was screened against both GMR-GAL4, (CGG)90-EGFP flies 





Table A.2: Fly Stocks Used in This Study and Their Sources.  
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Table A.3: Primers Used in This Study for qRT-PCR.
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Appendix B 





































Figure B.1: Primary Screen Identifies Candidate Suppressors and Enhancers of C9ORF72 
RAN Translation. 
Scatterplot of Log2 GA70 NL vs. Log2 AUG-FF values, each relative to siNT-transfected cells, 
gathered across the entire C9ORF72 primary screen. siRNAs are colored based on whether they 
suppressed, enhanced, or had no effect on GA70 NL-3xF. Data points corresponding to HNRNPA2 


















































Figure B.2: Serial Validation and Refinement of RAN-Specific C9ORF72 Candidate Modifiers. 
Scatterplot of Log2 GA70 NL vs. Log2 AUG-FF values gathered during the C9ORF72-validation 
screen (top panel), Log2 AUG NL vs. Log2 AUG-FF values gathered during the AUG counter screen 
(middle panel), and Log2 CGG100 NL vs. Log2 AUG-FF values gathered during the FMR1 validation 
screen (bottom panel). Data points are colored based on whether the corresponding siRNAs 


















































Figure B.3: The Failure of Some Candidate C9ORF72 Modifiers to Validate Was Driven by 
Inconsistencies in Effects on AUG-FF Expression, not GA70 NL-3xF Expression. 
A Scatterplot of Log2 GA70 NL/FF values in the primary vs. the C9ORF72 validation screen. All 
primary hits are graphed. Each is colored depending on whether it validated against the C9ORF72 
reporter (Pearson’s correlation; n=1,734; P<1E-6). 
B Scatterplot of Log2 GA70 NL values in the primary vs. the C9ORF72 validation screen. All 
primary hits are graphed. Each is colored depending on whether it validated against the C9ORF72 
reporter (Pearson’s correlation; n=1,734; P<1E-6).  
C Scatterplot of Log2 AUG-FF values in the primary vs. the C9ORF72 validation screen. All 
primary hits are graphed. Each is colored depending on whether it validated against the C9ORF72 








































Figure B.4: The AUG Counter Screen Eliminates Several Hits That Modified Both C9ORF72 
and FMR1 Reporters.  
A Scatterplots of validation Log2 GA70 NL values vs. validation Log2 CGG100 NL values (left 
panel; Pearson’s correlation; n=1,307; P<1E-6) and validation Log2 GA70 NL data vs. Log2 AUG-NL 
data (right panel; Pearson’s correlation; n=1,307; P<1E-6). Each point represents a primary hit that 
successfully validated against the C9ORF72 reporter. These have been categorized and colored 
based on whether they were eliminated during the AUG counter screen. 
B Scatterplot of validation Log2 GA70 NL data vs. validation Log2 CGG100 NL values, plotting 
only C9ORF72-validated and RAN-specific siRNAs. siRNAs have been categorized ad colored 
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Figure B.5: An Independent Primary Screen Identifies Candidate Suppressors and Enhancers 
of FMR1 RAN Translation. 
Scatterplot of Log2 CGG100 NL vs. Log2 AUG-FF values, each relative to siNT-transfected cells, 
gathered across the FMR1 primary screen of Drug-Target/Druggable Genome siRNA library. siRNAs 
are colored based on whether they suppressed, enhanced, or had no effect on +1 CGG100 NL-3xF. 


















































Figure B.6: Serial Validation and Refinement of RAN-Specific FMR1 Candidate Modifiers.  
Scatterplot of Log2 CGG100 NL vs. Log2 AUG-FF values gathered during the validation screen (top 
panel), Log2 AUG NL vs. Log2 AUG-FF values gathered during the AUG counter screen (middle 
panel), and Log2 GA70 NL vs. Log2 AUG-FF values gathered during the C9ORF72 validation screen 
(bottom panel). Data points are colored based on whether the corresponding siRNAs progressed to 


















































Figure B.7: Gene Ontology (GO) Analysis of Validated, RAN-Specific Modifiers of C9ORF72.  
A, B Top 10 GO terms (biological process, A; or molecular function, B) by descending statistical 
significance among validated, RAN-specific C9ORF72 suppressors that passed the off-target filter 
(red). Representation and statistical significance of these terms among validated, RAN-specific, 
filtered FMR1 suppressors, if significant, is illustrated by teal bars. P=0.05 is demarcated by the 
dashed vertical line. Some biological process terms have been excluded due to complete overlap of 
their corresponding genes to those of the term “SCF-dependent proteasomal ubiquitin-dependent 
protein catabolism;” these include “hematopoietic stem cell differentiation,” “ubiquitin-protein ligase 
activity involved in mitotic cell cycle,” “regulation of G2/M transition of mitotic cell cycle,” and “antigen 


















































Figure B.8: GO Analysis of Validated, RAN-Specific Modifiers of FMR1.  
A, B Top 10 GO terms (biological process, A; or molecular function, B) by descending statistical 
significance among validated, RAN-specific FMR1 suppressors that passed the off-target filter (teal). 
Representation and statistical significance of these terms among validated, RAN-specific, filtered 





Figure B.9: The Relationship Between Multiple Modifiers of C9ORF72 RAN Translation, All 
Related to the Proteasome. 
The candidates depicted were identified and validated against the GA70 NL-3xF and AUG-NL-3xF 
reporters, were not eliminated by the off-target filter, and are associated with the GO term “SCF-





Table B.1: Modulation of GA70 NL-3xF by Knockdown of eIFs, Part I. 
siRNAs from the whole-genome library that target genes annotated with the GO terms “Translation 
initiation factor activity,” “Translation pre-initiation complex,” and “eIF4F complex” are listed above. 
Pink shading indicates that siRNA validated as a suppressor in the indicated screen; green shading 








Table B.3: Modulation of GA70 NL-3xF by Components of the Proteasome, Part I. 
siRNAs from the whole-genome library that target genes annotated with the GO terms “Proteasome 
core complex,” “Proteasome regulatory particle,” “Proteasome-activating ATPase activity,” 
“Proteasome accessory complex,” and “Proteasome assembly” are listed above. Pink shading 
indicates that siRNA validated as a suppressor in the indicated screen; green shading indicates that 










Table B.5: Modulation of +1 CGG100 NL-3xF by Knockdown of eIFs, Part I. 
siRNAs from the Drug-Target and Druggable Genome libraries that target genes annotated with the 
GO terms “Translation initiation factor activity,” “Translation pre-initiation complex,” and “eIF4F 
complex” are listed above. Pink shading indicates that siRNA validated as a suppressor in the 









Table B.7: Modulation of +1 CGG100 NL-3xF by Components of the Proteasome. 
siRNAs from the Drug-Target and Druggable Genome libraries that target genes annotated with the 
GO terms “Proteasome core complex,” “Proteasome regulatory particle,” “Proteasome-activating 
ATPase activity,” “Proteasome accessory complex,” and “Proteasome assembly” are listed above. 
Pink shading indicates that siRNA validated as a suppressor in the indicated screen; green shading 










Table B.9: Most Efficacious C9ORF72-Validated, RAN-Specific Suppressors. 
siRNAs are ranked by their mean NLsiX/siNT value between the primary and validation C9ORF72 
screens in ascending order. siRNAs shaded pink in the final column also validated as suppressors of 
FMR1.  
 




Table B.10: Most Efficacious C9ORF72-Validated, RAN-Specific Enhancers. 
siRNAs are ranked by their mean NLsiX/siNT value between the primary and validation C9ORF72 
screens in descending order. siRNAs shaded green in in the final column also validated as 
enhancers of FMR1. 
 





Table B.11: Most Efficacious C9ORF72-Validated, RAN-Specific, FMR1-Validated 
Suppressors. 
siRNAs are ranked by their mean NLsiX/siNT value between the C9ORF72 primary, C9ORF72 
validation, and FMR1 validation screens in ascending order.  
 




Table B.12: Most Efficacious C9ORF72-Validated, RAN-Specific, FMR1-Validated Enhancers. 
siRNAs are ranked by their mean NLsiX/siNT value between the C9ORF72 primary, C9ORF72 
validation, and FMR1 validation screens in descending order.  
 





Table B.13: Most Efficacious FMR1-Validated, RAN-Specific Suppressors. 
siRNAs are ranked by their mean NLsiX/siNT value between the primary and validation FMR1 screens 
in ascending order. siRNAs shaded pink in the final column also validated as suppressors of 
C9ORF72. 
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